AUDITED FINANCIAL STATEMENTS, SUPPLEMENTARY INFORMATION, AND REPORTS AND SCHEDULES REQUIRED BY THE UNIFORM GUIDANCE

Baylor College of Medicine Years Ended June 30, 2024 and 2023 With Reports of Independent Auditors



Audited Financial Statements, Supplementary Information, and Reports and Schedules Required by the Uniform Guidance

Years Ended June 30, 2024 and 2023

Contents

Report of Independent Auditors	1
Audited Financial Statements	
Canastidated Dalamas Charts	1
Consolidated Balance Sheets	
Consolidated Statements of Activities	
Consolidated Statements of Cash Flows	
Notes to Consolidated Financial Statements	8
Reports and Schedules Required by the Uniform Guidance Report of Independent Auditors on Internal Control Over Financial Reporting and	
on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With <i>Government Auditing Standards</i>	49
Report of Independent Auditors on Compliance for Each Major Federal and State	
Program and Report on Internal Control Over Compliance Required by the Uniform	
Guidance and Texas Grant Management Standards	51
Schedule of Expenditures of Federal Awards	56
Schedule of Expenditures of State Awards	99
Notes to Schedule of Expenditures of Federal and State Awards	109
Schedule of Findings and Questioned Costs	111



Ernst & Young LLP 1401 McKinney Street Suite 2400 Houston, TX 77010 Tel: +1 713 750 1500 Fax: +1 713 750 1501 ev com

Report of Independent Auditors

Management and The Board of Trustees Baylor College of Medicine

Report on the Audit of the Financial Statements

Opinion

We have audited the consolidated financial statements of Baylor College of Medicine (the College), which comprise the consolidated balance sheets as of June 30, 2024 and 2023, and the related consolidated statements of activities and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of Baylor College of Medicine at June 30, 2024 and 2023, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (Government Auditing Standards). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the College and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

2503-11117-CS 1



In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the College's ability to continue as a going concern for one year after the date that the financial statements are issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free of material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and Government Auditing Standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the College's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the College's ability to continue as a going concern for a reasonable period of time.

2503-11117-CS 2



We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplementary Information

Our audits were conducted for the purpose of forming an opinion on the financial statements as a whole. The accompanying Schedule of Expenditures of Federal Awards, and Schedule of Expenditures of State Awards as required by Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards and State Awards of Texas Singular Audit Circular. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with GAAS. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated November 25, 2024 on our consideration of Baylor College of Medicine's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of Baylor College of Medicine's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Baylor College of Medicine's internal control over financial reporting and compliance.

Ernst & Young LLP

November 25, 2024, except for our report on the Schedule of Expenditures of Federal and State Awards, for which the date is March 31, 2025

2503-11117-CS 3

Consolidated Balance Sheets

	June 30			0
		2024		2023
	(In Thousands)			nds)
Assets				
Cash and cash equivalents	\$	158,169	\$	89,109
Accounts receivable, net:				
Patient		34,267		30,393
Affiliates		181,013		152,278
Grants and contracts, and others		158,409		144,461
Pledges receivable, net		66,151		82,656
Notes receivable		17,856		16,585
Investments, including securities loaned of \$83,427				
and \$80,610 for 2024 and 2023, respectively		1,494,798		1,488,492
Equity investments in unconsolidated affiliates		263,555		278,352
Security lending collateral		88,257		84,259
Property and equipment, net		451,144		385,348
Leased right-of-use assets – operating		62,544		25,951
Other assets		32,137		29,995
Total assets	\$	3,008,300	\$	2,807,879
Liabilities and net assets Liabilities: Accounts payable and other liabilities Short-term line of credit Interest rate swap liability, net Lease liability – operating Self-insurance reserves Deferred revenue Bonds and notes payable Assets held on behalf of others Payable under security lending agreements Total liabilities	\$	263,511 154,780 28,869 66,172 53,571 137,389 662,246 49,249 88,257 1,504,044	\$	235,808 107,500 37,172 27,624 53,238 116,049 569,829 49,081 84,259 1,280,560
Net assets:				
Without donor restrictions		346,819		408,443
With donor restrictions		1,157,437		1,118,876
Total net assets		1,504,256		1,527,319
Total liabilities and net assets	\$	3,008,300	\$	2,807,879

See accompanying notes.

Consolidated Statements of Activities

	Year Ended June 30, 2024			Year Ended June 30, 2023		0, 2023
	Without	With	<u> </u>	Without	With	
	Donor	Donor		Donor	Donor	
	Restrictions	Restrictions	Total		Restrictions	Total
			(In The	ousands)		
Operating revenues						
Tuition and fees, net	\$ 23,819	\$ -	\$ 23,819	\$ 23,866	\$ -	\$ 23,866
Medical services, net	384,954	_	384,954	355,332	=	355,332
Affiliated hospital contracts	1,435,424	_	1,435,424	1,298,579	=	1,298,579
Government grants and contracts:						
Direct	423,929	_	423,929	421,184	=	421,184
Indirect	122,206	_	122,206	111,108	_	111,108
Private grants and contracts:						
Direct	90,920	_	90,920	91,558	_	91,558
Indirect	13,907	_	13,907	13,225	=	13,225
Gifts and pledges	1,600	_	1,600	2,611	_	2,611
State appropriations	37,714	_	37,714	32,439	_	32,439
Investment income, net of expenses	81,240	_	81,240	65,954	_	65,954
Equity in loss of unconsolidated						
affiliates – operating	(15,578)	_	(15,578)	(24,135)	_	(24,135)
Net assets released from restrictions	39,193	_	39,193	36,182	_	36,182
Other	82,019	_	82,019	96,357	_	96,357
Total operating revenues	2,721,347	_	2,721,347	2,524,260	-	2,524,260
Operating expenses						
Salaries, wages, and benefits	2,176,133	_	2,176,133	1,985,560	_	1,985,560
Services, supplies, and other	492,140	_	492,140	497,274	_	497,274
Depreciation Depreciation	58,147	_	58,147	57,366	_	57,366
Interest	29,938	_	29,938	25,840	_	25,840
Total operating expenses	2,756,358	_	2,756,358	2,566,040	_	2,566,040
Operating expenses in excess of revenues	(35,011)	_	(35,011)	(41,780)	_	(41,780)
Nonoperating activities						
Gifts and pledges	_	70,633	70,633	368	44,651	45,019
Investment income (loss), net of		,	,		,	,
distribution and expenses	(34,489)	7,121	(27,368)	3	25,407	25,410
Unrealized gain on interest rate swaps	8,303	´ _	8,303	11,304	_	11,304
Net assets released from restrictions	_	(39,193)	(39,193)	,	(36,182)	(36,182)
Equity in gain (loss) of unconsolidated		(,,	(,,		(,)	(,)
affiliates – nonoperating	781	_	781	1,388	_	1,388
Other nonoperating activities	(1,208)	_	(1,208)	(90)	_	(90)
Change in net assets from nonoperating	(=,===)		(-,)	(3 0)		(2 0)
activities	(26,613)	38,561	11,948	12,973	33,876	46,849
Change in not assets	(61.634)	20 574	(22.0(2)	(20.007)	22.076	F 0/0
Change in net assets	(61,624)	38,561	(23,063)	(28,807)	33,876	5,069
Net assets, beginning of year	408,443	1,118,876	1,527,319	437,250	1,085,000	1,522,250
Net assets, end of year	\$ 346,819	\$1,157,437	\$1,504,256	\$ 408,443	\$1,118,876	\$1,527,319

See accompanying notes.

Consolidated Statements of Cash Flows

	Year Ended June 30 2024 2023		
		(In Thousan	ds)
Operating activities	•	(22.062) \$	<i>5</i> 060
Change in net assets	\$	(23,063) \$	5,069
Adjustments to reconcile change in net assets to net cash used in			
operating activities:		(1.40)	50.026
Depreciation and loss on disposal of property and equipment and other		61,406	58,936
Loss on extinguishment of debt		283	20.746
Equity in losses of unconsolidated affiliates, net		14,797	22,746
Equipment acquired through grants and contracts		(10,134)	(14,427)
Reinvested income		(4,511)	(4,277)
Change in interest rate swap liability		(8,303)	(11,304)
Net realized and unrealized gains on investments		(48,165)	(96,380)
Decrease (increase) in bond premium/discount and original issue costs		8,122	(548)
Change in pledges receivable, net		16,505	9,111
Change in accounts receivable, net		(46,557)	(22,465)
Gifts and pledges with donor restrictions and other		(19,052)	(13,988)
Change in other assets		(2,142)	(6,607)
Change in assets held on behalf of others		168	329
Change in accounts payable and other liabilities		28,037	(9,762)
Change in deferred revenue		21,340	17,419
Net cash used in operating activities		(11,269)	(66,148)
Investing activities			
Purchases of investments		(136,590)	(200,672)
Proceeds from sales of investments		148,728	396,920
Purchases of property and equipment		(115,113)	(50,809)
Investment income		4,511	4,277
Issuances of notes receivable		(3,627)	(3,152)
Repayment of notes receivable		2,356	2,275
Net cash (used in) provided by investing activities		(99,735)	148,839
Financing activities			
Proceeds from line of credit, net		47,280	57,000
Repayment of bonds payable		(89,880)	(14,385)
Issuance costs on bonds		(1,107)	(= 1,1= 1-) -
Proceeds from issuance of bonds		175,000	_
Gifts and pledges with donor restrictions and other		19,052	13,988
Cash flows from financing leases			(464)
Net cash provided by financing activities		150,345	56,139
Net easil provided by infaheing activities	-	130,343	30,139
Net change in cash, cash equivalents, restricted cash, and restricted		20.241	120.020
cash equivalents		39,341	138,830
Cash, cash equivalents, restricted cash, and restricted cash equivalents at beginning of year		252,845	114,015
Cash, cash equivalents, restricted cash, and restricted cash equivalents			
at end of year	\$	292,186 \$	252,845

Consolidated Statements of Cash Flows (continued)

	Year Ended June 30			ne 30
		2024		2023
	· <u> </u>	(In Th	ousan	ds)
Reconciliation of cash, cash equivalents, restricted cash, and restricted cash equivalents				
Cash and cash equivalents	\$	158,169	\$	89,109
Restricted cash and cash equivalents included in investments		134,017		163,736
Cash, cash equivalents, restricted cash, and restricted cash equivalents	\$	292,186	\$	252,845
Supplemental disclosures				
Net interest paid on debt	\$	33,377	\$	28,723
Right-of-use assets obtained in exchange for lease liabilities	\$	48,669	\$	2,867
Noncash investing and financing activities				
Increase in security lending collateral	\$	3,998	\$	8,371
Increase in payable under security lending agreement	\$	3,998	\$	8,371

See accompanying notes.

2408-4588520 7

Notes to Consolidated Financial Statements

June 30, 2024

1. Organization

Baylor College of Medicine (the College or Baylor) is one of the leading health science universities and biomedical research institutions in the United States. Founded in 1900, Baylor owns and operates educational, research, and patient care facilities. The College is an institution comprising four separate colleges, including a medical school, a graduate school of biomedical sciences, a health professions school, and a national school of tropical medicine. Baylor trains more than 3,500 medical, graduate, nurse anesthesia, physician assistant, orthotics and prosthetics, and genetics counseling students, as well as residents and postdoctoral fellows, each year. The College ranks among the nation's top biomedical research institutions and the country's top medical schools. Finally, the College provides extensive patient care services through its wholly owned Baylor Medicine Clinic and through faculty physician service agreements primarily with eight independently owned and operated affiliated hospitals, including Baylor St. Luke's Medical Center; see description below.

Baylor's main campus is located in the Texas Medical Center, a 700-acre complex of approximately 50 independent institutions and state instrumentalities in Houston, Texas. The College is the only private medical school in the southwestern United States.

Effective January 1, 2014, St. Luke's Health System Corporation (n/k/a CHI St. Luke's Health), a Texas nonprofit corporation exempt from federal income tax under Section 501(a) of the Internal Revenue Code of 1986, as amended (the Code), as an organization described in Section 501(c)(3) of the Code, conveyed to the College a 35% membership interest in St. Luke's Medical Center (n/k/a CHI St. Luke's Health Baylor College of Medicine Medical Center), a Texas nonprofit corporation exempt from federal income tax under Section 501(a) of the Code, as an organization described in Section 501(c)(3) of the Code. CHI St. Luke's Health retained a 65% membership interest in CHI St. Luke's Health Baylor College of Medicine Medical Center (BSLMC), which owns and operates a quaternary care hospital in the Texas Medical Center; other land and improvements in and near the Texas Medical Center; and ambulatory clinics located in the Texas Medical Center area, Tanglewood, and Pearland. As consideration, the College contributed to BSLMC cash, certain real property, and improvements, including a portion of the real property generally known as the McNair Campus; the hospital/clinic building located on the McNair Campus (except for a portion of the top five floors to be used for the College's clinical operations and a conference center on the first floor); and, effective February 16, 2015, the ambulatory surgery center located in the Lee and Joe Jamail Specialty Care Center. BSLMC sold the O'Quinn Medical Tower in 2016. The College and CHI St. Luke's Health share governance of BSLMC: each member appoints, and has the unilateral ability to remove, six voting board members and one

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

1. Organization (continued)

nonvoting board member. Doing business under the name Baylor St. Luke's Medical Center, the hospital serves as the home of most of the College's medical doctors dedicated to caring for private adult inpatients.

Effective February 2, 2015, the College formed a joint venture with H.U. Group (HUG, formerly Miraca Holdings, Inc.), a company based in Tokyo, Japan, and traded on the Tokyo Stock Exchange. HUG is dedicated to in vitro diagnostic, clinical laboratory testing, and other health-care-related businesses through its subsidiaries, such as Fujirebio Inc., one of the major Japanese domestic in vitro diagnostic reagent manufacturers, and SRL, Inc., the largest clinical laboratory testing company in Japan. Under the agreement, the College contributed its clinical genetics diagnostic laboratories business (including leases, equipment, receivables, other contracts, and certain employees) into a subsidiary company and conveyed a 60% membership interest in the subsidiary to a HUG affiliate for \$135.9 million in cash. The College retained a 40% membership interest. The College and the HUG affiliate share governance of the joint venture, called Baylor Miraca Genetics Laboratories, LLC (Baylor Genetics), a Texas limited liability company, and the College retained certain approval rights over aspects of Baylor Genetics that relate to the College's mission.

2. Summary of Significant Accounting Policies

Basis of Accounting and Reporting

The accompanying consolidated financial statements of Baylor have been prepared in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP). The accompanying consolidated financial statements include the accounts of all entities in which Baylor has a significant financial interest and over which Baylor has control. All intercompany accounts and transactions have been eliminated upon consolidation. Baylor Medical Foundation (the Foundation) is consolidated in the College's consolidated financial statements. The Foundation is a Texas nonprofit corporation organized exclusively to aid, support, and maintain the College through contributions received from third-party donors. Baylor's membership interests in BSLMC and Baylor Genetics are included in the College's consolidated financial statements as equity method investments.

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

2. Summary of Significant Accounting Policies (continued)

Based on the existence or absence of donor-imposed restrictions, Baylor classifies resources into two categories: net assets without donor restrictions and net assets with donor restrictions.

Net assets without donor restrictions are free of donor-imposed restrictions. All revenues, gains, and losses that are not restricted by donors are included in this classification. All expenditures are reported in the without donor restrictions category since the use of restricted gifts and pledges in accordance with donors' stipulations results in the release of the restriction. Net assets without donor restrictions may be designated for specific purposes by the College's Board of Trustees.

Net assets with donor restrictions are subject to donor-imposed restrictions. Some donor-imposed restrictions expire with the passage of time or can be satisfied by action of the College. Other donor-imposed restrictions are perpetual in nature. These net assets may include unconditional pledges, interests in trusts held by others, accumulated appreciation on donor-restricted endowments that have not yet been appropriated by the Board of Trustees for distribution, and donor-restricted endowments (at historical value). Generally, the donors of these assets permit the College to use a portion of the income earned on related investments for specific purposes.

Expirations of donor-imposed restrictions on net assets (i.e., the passage of time, along with the annual board approval of the endowment spending rate and/or fulfilling donor-imposed stipulations) are reported as net assets released from restrictions between the applicable classes of net assets on the consolidated statements of activities. Net assets with donor-imposed restrictions related to the purchase or construction of property and equipment are released when the property or equipment is placed in service, unless donor stipulations limit the use of the assets for a period of time or for a particular purpose.

Net assets with donor restrictions as of June 30, 2024 and 2023 are principally restricted for research, education, and facilities for these purposes.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses during the reporting period, as well as the disclosure of contingent assets and liabilities. Actual results ultimately could differ from management's estimates and assumptions.

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

2. Summary of Significant Accounting Policies (continued)

Cash Equivalents

Cash and cash equivalents are liquid assets with minimal interest rate risk and original maturities of three months or less when purchased. Such assets, reported at fair value, primarily consist of depository account balances, money market funds, and short-term U.S. treasury securities.

Restricted cash and cash equivalents represent amounts set aside for long-term investments or posted as collateral as required by interest rate swap agreements. These amounts are included in investments, including securities loaned and interest rate swap liability, net on the consolidated balance sheets.

Patient Receivables

Patient receivables are reported at the amount that reflects the consideration to which the College expects to be entitled in exchange for providing physician health care services. Patient receivables include discounts for contractual, implicit price concession and charity adjustments and are recorded on an accrual basis at net realizable value on the consolidated balance sheets. The estimates of implicit price concessions for patient receivables are based primarily on the College's historical collection and write-off experience (see Note 4).

Affiliate Receivables

Affiliate receivables consist of amounts owed by various affiliated hospitals to which the College provides medical, professional, and supervisory staff to deliver patient care, teaching, and staff leadership services. These receivables are recorded on an accrual basis at net realizable value on the consolidated balance sheets.

Grants and Contracts, and Other Receivable

Grants and contracts, and other receivable primarily represent unreimbursed grant and contract expenditures from the federal government, principally the National Institutes of Health, and other nonfederal sources for payment for research provided by the College. These amounts are recorded on an accrual basis at net realizable value on the consolidated balance sheets.

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

2. Summary of Significant Accounting Policies (continued)

Pledges Receivable

Unconditional promises to give that are expected to be collected within one year are recorded at net realizable value. Unconditional promises to give that are expected to be collected in future years are recorded at fair value, which is measured as the present value of their future cash flows. The discounts on those amounts are computed using risk-adjusted interest rates applicable to the years in which the promises are received. Amortization of the discounts is included in gifts and pledges revenue.

An allowance is made for uncollectible pledges receivable based upon the College's analysis of past collection experience and other judgmental factors.

Investments

The College's investments in marketable equity and fixed-income securities are recorded at fair value. Non-marketable securities are securities for which no public market exists; substantially all of these securities are accounted for at fair value using the practical expedient of net asset value per share or the equivalent. These non-marketable securities include investments in private equity limited liability corporations or partnerships. Other investments are stated at cost or fair value at the date of the acquisition or donation.

Realized gains and losses arising from the sale or other disposition of investments have been accounted for as changes in net assets without donor restrictions unless restrictions have been imposed by the donor. Certain investments are pooled with each fund subscribing to or disposing of units on the basis of the market value per unit, which is computed monthly. Realized gains and losses arising from the sale of securities are determined on an average cost basis.

The College's intent is to maintain a long-term investment portfolio to support research, education, and other activities. Accordingly, the total investment return is reported on the consolidated statements of activities in two categories. The investment return allocated to operating activities is determined by a formula, which involves allocating 5% of a trailing 28-quarter average market value of the endowment assets. Management believes this return is approximately equal to the real return the College expects to earn on its investments over the long term. The Board of Trustees may, in its discretion, designate additional funds to be used for operating purposes. The unallocated investment return, included in nonoperating activities on the consolidated statements of activities, represents the difference between the total investment return and the amount allocated to operating activities, net of investment costs.

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

2. Summary of Significant Accounting Policies (continued)

Securities Lending

The College participates in securities lending transactions, whereby a portion of its investments are loaned through its agent under respective borrowing agreements to various parties. In return, the parties provide collateral for the securities loaned, usually on a short-term basis. The collateral consists of eligible securities that meet credit quality criteria and diversification limits in accordance with noncash collateral guidelines selected by the College. The College's claim on the collateral is limited to the market value of the loaned securities. Market values of the securities on loan and the collateral are monitored each business day by the agent to ensure the collateral is maintained at levels of at least 100% of the fair value of the securities on loan. Upon termination of a borrowing agreement or as deemed necessary by the agent, the agent is to deliver identical collateral or a portion of it to satisfy the College's obligations with the borrower. The collateral and the obligation of the College to return the collateral is reported as an asset and a liability, respectively, on the consolidated balance sheets at the fair value of the underlying securities. The fees received for these transactions are recorded as investment income.

Property and Equipment

Purchased property, plant, and equipment are recorded at cost, including, where appropriate, capitalized interest and software costs. Donated assets are recorded at fair value at the date of donation. Repairs and maintenance costs are expensed as incurred. Depreciation is calculated using the straight-line method to allocate the cost of various classes of assets over their estimated useful lives. Property, plant, and equipment are removed from the accounting records at the time of disposal.

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment charge is recognized when the fair value of the asset or group of assets is less than the carrying value.

Deferred Revenue

Deferred revenue consists of amounts received from grant and contract sponsors, affiliated hospitals, and others for which the College has not yet fulfilled its obligations. These amounts will be recognized in future periods to support the College's medical, education, and research missions once the obligations have been satisfied.

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

2. Summary of Significant Accounting Policies (continued)

Assets Held on Behalf of Others

The College holds assets received from others and agrees to use those assets on behalf of or transfer the assets, return on investment of the assets, or both to a specified beneficiary. For the years ended June 30, 2024 and 2023, pooled investments in the amount of \$38.0 million and \$38.4 million, respectively, were held on behalf of the state of Texas (see Note 6). The College also held funds associated with a cooperative agreement with the federal government in the amount of \$11.2 million and \$10.6 million for the years ended June 30, 2024 and 2023, respectively. These funds are appropriated for the use of a federal government facility.

Fair Value Measurements

Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, Fair Value Measurement, defines fair value, requires expanded disclosures about fair value measurements, and establishes a three-level hierarchy for fair value measurements based on the observable inputs to the valuation of an asset or a liability at the measurement date. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (exit price) in an orderly transaction between market participants at the measurement date. ASC 820 prioritizes the inputs to the valuation techniques used to measure fair value by giving the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements).

Furthermore, ASC 820 applies to certain investment funds that do not have readily determinable fair values, including private investments, hedge funds, real estate, and other funds. ASC 820 allows for the estimation of the fair value of investments in investment companies for which the investment does not have a readily determinable fair value using net asset value per share or its equivalent. See Note 12 for further discussion of fair value measurements.

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

2. Summary of Significant Accounting Policies (continued)

Debt Portfolio Financial Instruments

Long-term debt is reported at carrying value. The College employs derivatives in the form of fixed payor swaps, primarily interest rate exchange agreements, to help manage interest rate risks associated with variable rate debt. Derivative financial instruments are reported at fair value with any resulting gain or loss recognized as a nonoperating item on the consolidated statements of activities. Periodic net cash settlement amounts with counterparties are accounted for as adjustments to interest expense on the related debt.

Parties to interest rate exchange agreements are subject to risk for changes in interest rates, as well as risk of credit loss in the event of nonperformance by the counterparty. Baylor deals only with high-quality counterparties that meet rating criteria for financial stability and creditworthiness. Additionally, certain agreements require the posting of collateral when amounts subject to credit risk under the contracts exceed specified levels. Collateral levels are tied to the College's credit rating. The College records its interest rate swap liability net of collateral posted.

Operating Results

Operating results are broadly defined as changes in net assets without donor restrictions from operating activities and are reported as operating expenses in excess of revenues on the consolidated statements of activities. Net assets without donor restrictions are also affected by nonoperating activities, which include gains on formation of joint ventures; equity in earnings or losses that are not integral to operations; investment income/loss and other, net of distributions; change in the fair value of interest rate swap agreements; gifts and pledges for plant facilities; and certain other nonrecurring items.

Charity Care

The College is committed to providing assistance to financially indigent patients in the community who require care and services at reduced or no cost, as determined by its affiliated hospitals. Records are maintained to identify and monitor the level of charity care the College provides. These records include the amount of charges forgone and estimated costs for services and supplies furnished under its charity care policy. Costs incurred are estimated based on a Medicare cost factor applied to total gross charges for indigent patients after reducing costs for any payments received. The level of charity care provided, based on estimated costs, during fiscal years 2024 and 2023 was \$69.6 million and \$60.2 million, respectively.

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

2. Summary of Significant Accounting Policies (continued)

Endowment Investments and Income Distribution

The College's investments are managed to achieve the maximum long-term return. Operating investment income distribution and other consists of amounts distributed from the College's endowment funds and from income on operating investments. The amount distributed from the endowment funds to support current operations is determined by the Board of Trustees and is based on a 5% distribution rate applied to a trailing 28-quarter average market value of the endowment portfolio. The Board of Trustees may, in its discretion, designate additional funds to be used for operating purposes. The primary objective of the 5% endowment distribution methodology is to reduce the impact of capital market fluctuations on operational programs. Nonoperating investment income (loss) consists of dividends, interest, and realized and unrealized gains and losses on endowed investments, net of distribution to operations and investment expenses.

Leases

The College recognizes right-of-use (ROU) assets and related lease liabilities in accordance with Accounting Standards Update (ASU) No. 2016-02, *Leases (Topic 842)*.

The College leases various equipment and facilities, including office space. Operating and financing leases with an initial term greater than 12 months are recognized as ROU assets and lease liabilities on the consolidated balance sheets. Financing ROU assets and liabilities are reported as part of property and equipment, net and accounts payable and other liabilities, respectively. ROU assets and related liabilities are recognized on the commencement date on the consolidated balance sheets based on future lease payments, and discounted based on the applicable risk-free interest rate, as permitted under the standard for nonpublic business entities.

Lease payments under certain agreements may escalate over the lease term either by a fixed percentage or a fixed dollar amount. Certain leases may provide for variable lease payments in the form of payments based on index-based (e.g., the U.S. Consumer Price Index) adjustments to lease payments. Baylor's lease terms may include options to extend or terminate the lease. Such options are included in the measurement of the ROU asset and liability, provided the existence of reasonable assurance that the College will exercise the option. The College has no leases that contain residual value guarantees provided by the College as a lessee.

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

2. Summary of Significant Accounting Policies (continued)

Income Taxes

The College is a tax-exempt organization as described in Section 501(c)(3) of the Code and is generally exempt from federal income taxes on related income pursuant to Section 501(a) of the Code. Baylor is, however, subject to federal and state income tax on unrelated business income and files unrelated business income tax and other information returns as required by government authorities. Management annually reviews its tax positions and has determined that there are no material uncertain tax positions that require recognition on the accompanying consolidated balance sheets as of June 30, 2024 or 2023. As of and for the year ended June 30, 2024, the College has followed regulations and made reasonable estimates of the provision for income taxes; the compensation excise tax; and the effects, if any, on existing deferred tax balances based on accounting guidance included in ASC 740, *Income Taxes*.

Reclassifications

Certain reclassifications have been made to the fiscal year 2023 consolidated financial statements to conform with classifications used in fiscal year 2024. Certain amounts have been reclassified between accounts payable and other liabilities to grants and contracts, and others on the consolidated balance sheets. Additionally, equipment acquired through grants and contracts revenue has been reclassified to direct government grants and contracts on the consolidated statements of activities. Reclassifications had no significant effect on total assets, total liabilities, or operating results.

Subsequent Events

The College evaluated events and transactions occurring subsequent to June 30, 2024 through November 25, 2024, the date the accompanying consolidated financial statements were issued. During this period, there were no subsequent events that required recognition in the accompanying consolidated financial statements.

In November 2024, the College signed an integration agreement with The Texas Heart Institute to form a premier cardiovascular health and research center to be known as The Texas Heart Institute at Baylor College of Medicine. Over the next five years, this phased consolidation will create a comprehensive cardiovascular center that will be fully integrated within Baylor's academic and clinical programs.

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

3. Equity Investments in Unconsolidated Affiliates

The College has a 35% membership interest in BSLMC, which operates as a tax-exempt entity described in Section 501(c)(3) of the Code. The College's investment in BSLMC, which is accounted for under the equity method, was \$210.1 million and \$225.7 million at June 30, 2024 and 2023, respectively. The College recorded a loss from its investment in BSLMC in the amount of \$15.5 million and \$24.1 million for the fiscal years 2024 and 2023, respectively. The difference between the carrying value of the College's investment in BSLMC and its interest in BSLMC's net asset value is \$63.4 million of total distributions received in prior years, \$26.9 million recorded by the College to report its initial investment at fair value, and changes to BSLMC's net assets in excess of net income (loss). A summary of BSLMC's reported total assets, liabilities, and net assets at June 30 is as follows (in thousands):

	 2024	2023
Total assets	\$ 1,311,905	\$ 1,265,450
Total liabilities Total net assets	\$ 594,984 716,921	\$ 509,486 755,964
Total liabilities and net assets	\$ 1,311,905	\$ 1,265,450

A summary of BSLMC's reported revenues, expenses, and net loss for the years ended June 30 is as follows (in thousands):

	2024	2023
Revenue	\$ 1,295,608	\$ 1,151,242
Expenses	(1,340,949)	(1,220,379)
Operating loss	(45,341)	(69,137)
Nonoperating income	980	334
Deficit of revenues over expenses	\$ (44,361)	\$ (68,803)

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

3. Equity Investments in Unconsolidated Affiliates (continued)

The College has a 40% membership interest in Baylor Genetics, which operates as a Texas limited liability company. The College's investment in Baylor Genetics, which is accounted for under the equity method, was \$51.5 million and \$50.8 million at June 30, 2024 and 2023, respectively. The College recorded earnings of \$0.8 million and \$1.4 million from its investment in Baylor Genetics in fiscal years 2024 and 2023, respectively. The difference in the carrying value of the College's investment in Baylor Genetics and its interest in Baylor Genetics shareholder's deficit is \$12.4 million of members' net capital contributions recorded in Baylor Genetics shareholder's deficit, \$70.6 million recorded by the College to report its initial investment in Baylor Genetics at fair value, and the College's additional contribution of \$2.3 million. A summary of Baylor Genetics' reported total assets, liabilities, and shareholder's deficit at June 30 is as follows (in thousands):

	 2024	2023
Total assets	\$ 42,795 \$	35,428
Total liabilities Total shareholder's deficit	\$ 55,186 \$ (12,391)	52,269 (16,841)
Total liabilities and shareholder's deficit	\$ 42,795 \$	35,428

A summary of Baylor Genetics' reported revenues, expenses, and net income for the years ended June 30 is as follows (in thousands):

	 2024	2023
Revenues Expenses	\$ 104,675 \$ (102,723)	79,315 (75,844)
Net income	\$ 1,952 \$	3,471

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

4. Revenue Recognition

Revenue is recognized when control of the promised services is transferred to the customers (students, patients, affiliated hospitals, and governmental entities) in an amount that reflects the consideration the College is entitled to receive in exchange for those services.

The timing of revenue recognition, billings, and cash collections results in accounts receivable and deferred revenue on the consolidated balance sheets. Receivables are recognized only to the extent that it is probable that the College will collect substantially all of the consideration to which the College is entitled in exchange for the services that will be transferred to the customer.

Tuition and Fees, Net

The performance obligation for tuition and fees, net relates to the training or educating of undergraduate medical, research graduate, and health profession students. Revenue is recognized ratably as services are rendered during the academic semester using the input method based on time elapsed over the academic semester.

The transaction price is the price of tuition net of scholarships, applicable discounts, and refunds.

The College's academic year is consistent with its fiscal year in which students are billed at the beginning of each semester within the fiscal period and payment is due before the semester ends, also within the fiscal period. The College does not receive advance payments from students prior to the start of the fiscal period. No accounts receivable or deferred liabilities related to tuition and fees were recorded within the accompanying consolidated balance sheets as of June 30, 2024 or 2023.

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

4. Revenue Recognition (continued)

Medical Services, Net

Medical services, net consist of physician health care services in health care facilities, which include inpatient, outpatient, and ambulatory care facilities; physician practices; and other sites. Performance obligations include individual medical services provided to patients in both an inpatient and outpatient setting. Inpatient services are satisfied over time from patient admission to the point when services are no longer required, which is generally at the time of discharge. The inpatient medical services are recognized utilizing the input method of measuring progress, which is based on actual charges incurred. Outpatient services are satisfied at a point in time and revenue is recognized when control of services is transferred. The College believes this method provides a fair depiction of the transfer of services over the term of performance obligations based on the inputs needed to satisfy the obligations. These services are considered to be a single performance obligation.

Because all of its performance obligations relate to contracts with a duration of less than one year, the College has elected to apply the optional exemption provided in Topic 606, *Revenue From Contracts With Customers*, and, therefore, is not required to disclose the aggregate amount of transaction price allocated to medical services performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

The College uses a portfolio approach to account for categories of patient contracts as a collective group rather than recognizing revenue on an individual contract basis. The portfolios consist of major payor classes. Based on the historical collection trends and other analyses, the College believes that revenue recognized by utilizing the portfolio approach approximates the revenue that would have been recognized if an individual contract approach were used.

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

4. Revenue Recognition (continued)

The College determines the transaction price of medical services revenue, which involves significant estimates and judgment, based on standard charges for goods and services provided, reduced by explicit and implicit price concessions, including contractual adjustments provided to commercial insurance carriers, health care maintenance organizations, and preferred provider organizations; discounts provided to uninsured and underinsured patients in accordance with policy; and/or implicit price concessions based on the historical collection experience of patient accounts. The majority of what historically was classified as provision for doubtful accounts is now treated as an implicit price concession factored into net medical service revenues.

In addition, the College determines the transaction price associated with services provided to patients who have third-party payor coverage with Medicare and Medicaid based on reimbursement terms per contractual agreements, discount policies, and historical experience.

Laws and regulations governing Medicare and Medicaid programs are complex and subject to interpretation. The College believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no such regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medicaid programs. Changes in the Medicare and Medicaid programs could have a material adverse or positive impact on prospective medical services revenues.

Management has determined that the nature, amount, timing, and uncertainty of revenue and cash flows are affected by the payors. The composition of medical service revenue, by payor, was as follows (in thousands):

	 2024	2023
Managed care	\$ 198,235 \$	175,344
Medicare	124,940	118,333
Medicaid	37,311	40,920
Self-pay	12,580	11,156
Other	11,888	9,579
	\$ 384,954 \$	355,332

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

4. Revenue Recognition (continued)

The composition of patient receivables (net of contractual allowance and implicit price concession) by payor at June 30 was as follows:

	Patient Receivables		
	2024	2023	
Managed care	67.0%	64.3%	
Medicare	19.4	17.1	
Medicaid	10.7	15.1	
Self-pay	1.3	1.9	
Other	1.6	1.6	
	100.0%	100.0%	

Affiliated Hospital Contracts

The College has affiliation agreements with hospitals, including, but not limited to, Texas Children's, Harris Health (formerly Harris County Hospital District), Baylor St. Luke's Medical Center, Michael E. DeBakey Veterans Affairs Medical Center, The Methodist Hospital, The Menninger Clinic, MD Anderson Cancer Center, Christus Children's, and The Institute for Rehabilitation and Research. Under the terms of these agreements, the College conducts administrative, research, and educational activities on behalf of these hospitals.

The College provides residents to the affiliated institutions; the residents in turn, provide patient care services as part of their medical training. The College satisfies this performance obligation over time as the hospitals receive the benefit of professional services. Affiliated hospital contract revenue is recognized as time elapses for actual personnel and operating costs incurred less collections that are received by the College from patient payors.

Amounts are billed periodically in accordance with agreed-upon contractual terms. The timing of revenue recognition, billings, and cash collections results in billed and unbilled receivables and customer advances and deposits on the consolidated balance sheets. These assets and liabilities are reported on the consolidated balance sheets on a contract-by-contract basis at the end of each reporting period. Affiliate receivables in the amount of \$181.0 million and \$152.3 million were recorded as of June 30, 2024 and 2023, respectively. Affiliate deferred revenue in the amount of \$18.6 million and \$23.7 million is included within deferred revenue on the accompanying consolidated balance sheets as of June 30, 2024 and 2023, respectively.

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

4. Revenue Recognition (continued)

Following were the affiliates that accounted for greater than 10% of total affiliated contract revenue for the years ended June 30:

	2024	2023
Harris Health	17.2%	17.5%
BSLMC	19.8	20.8
Texas Children's	52.9	50.5

Following were the affiliates that accounted for greater than 10% of total affiliated contract receivables as of June 30:

	2024	2023
Harris Health	22.4%	24.1%
BSLMC	27.0	22.2
Texas Children's	37.2	39.8

Other

Other revenue primarily consists of several other exchange contracts, including academic program fees from the College's affiliates, royalties on certain licenses of intellectual property and the Baylor College of Medicine brand, and various other types of income. Depending on the program, revenue is recognized at a point in time or over time as obligations are met.

State Appropriations

The College received funding in the form of appropriations from the State of Texas Higher Education Coordinating Board (the Coordinating Board) for the purpose of training or educating Texas resident undergraduate medical students and graduate medical residents in the amount of \$37.7 million and \$32.4 million in 2024 and 2023, respectively. The College expended \$258.9 million and \$257.8 million for fiscal years 2024 and 2023, respectively, to train and educate undergraduate medical students and graduate medical residents. Expenditures used to satisfy these appropriations are reflected on the schedule of functional expenses (see Note 13) as instruction expenditures and certain amounts related to the instruction of graduate medical residents that are included in affiliated hospital programs expenditures.

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

4. Revenue Recognition (continued)

For the State's fiscal year beginning September 1, 2023, the Coordinating Board transferred an approved amount of the College's undergraduate medical funding to the Texas Health and Human Services Commission. The intergovernmental transfer allows the College to provide health care services to patients enrolled in Medicaid managed care programs and receive federal funding under the Texas Incentives Physicians and Professional Services (TIPPS), a directed payment program approved by the Centers for Medicare & Medicaid Services (CMS). The College recognized \$12.4 and \$11.4 million of TIPPS payments as medical services, net, for services provided at Baylor clinics during the fiscal years ended June 30, 2024 and 2023, respectively.

The College provided services under TIPPS to patients of the Harris Health System and Christus Children's Hospital. In accordance with affiliation hospital agreements, the College pays the affiliated hospitals a share of the TIPPS payments received and recognized its share of the payments. The College recognized \$23.4 million and \$26.0 million of TIPPS payments as affiliated hospital contracts under these arrangements during the fiscal years ended June 30, 2024 and 2023, respectively.

Government and Private Grants and Contracts

Government and private grants and contracts represent revenue from grants and contracts with federal, state, and local governments; private foundations; and corporate sponsors primarily for research and education activities conducted by the College. Direct recoveries are recognized when allowable direct expenditures for salaries and supplies are incurred under the terms of each sponsor's agreement. Indirect recoveries represent reimbursement of the costs of facilities and administrative (F&A) overhead associated with government and private grants and contracts. Indirect recoveries are recognized as revenue as the corresponding allowable direct grant and contract expenses are incurred under the terms of each sponsor's agreement. Baylor's federal F&A costs recovery rate for on-campus research was 60.0% in both fiscal years 2024 and 2023. Baylor's federal F&A costs recovery rate for off-campus research was 26.0% in both fiscal years 2024 and 2023.

2408-4588520 25

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

4. Revenue Recognition (continued)

Gifts and Pledges

As pledges are made to the College, the intent of the donor, circumstances regarding the pledge, and any action taken by the College in response to the pledge are considered in determining whether the pledge is an unconditional promise to give or a conditional promise. Unconditional promises to give (pledges) are recognized as revenue without donor restrictions when the donor's commitment is received. Gifts and pledges with donor-imposed restrictions are recorded as revenue without donor restrictions if those restrictions are met in the same reporting period. Otherwise, gifts and pledges with donor-imposed restrictions are recorded as increases in net assets with donor restrictions.

Conditional promises (primarily bequest intentions) are not recorded until donor conditions are substantially met.

Gifts and pledges recorded as donor-restricted net assets are released from restrictions and recognized as net assets without restrictions after any donor stipulations are met. Gifts and pledges for equipment are released from restrictions and recognized as an operating item only after resources are expended for the applicable equipment. Gifts and pledges for buildings are released from restrictions and recognized as an operating item over time only after the building is brought into service.

5. Pledges Receivable

Pledges receivable as of June 30 are expected to be realized as follows (in thousands):

	 2024	2023
In one year or less	\$ 40,628 \$	42,435
Between one year and five years	23,438	36,562
More than five years	4,900	7,230
Less present value discount	(2,815)	(3,571)
Total	\$ 66,151 \$	82,656

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

6. Investments

Investments (including amounts for self-insurance) held by the College at June 30 are as follows (in thousands):

	2024	2023
Pooled investments:		_
U.S. equities	\$ 389,787	\$ 352,221
Fixed income	52,091	77,092
Cash and cash equivalents	134,017	163,736
International equities	361,100	323,181
Private equity securities	 541,864	556,537
Total pooled investments	1,478,859	1,472,767
Other stocks	1,669	1,957
Real estate, at cost	2,656	2,656
Assets held in trust and other	 11,614	11,112
Total investments	\$ 1,494,798	\$ 1,488,492

In fiscal year 2000, the College received \$25.0 million to establish a fund for investing a portion of receipts paid to the state of Texas under a judgment rendered in the tobacco settlement (the tobacco funds). The College is responsible for the administration of the tobacco funds, which are invested along with the College's pooled investments; however, the College does not have title to the assets. As of June 30, 2024 and 2023, the value of the tobacco funds is included in pooled investments and a corresponding liability has been recorded in assets held on behalf of others to reflect that the College does not currently have an ownership interest.

The earnings of the tobacco funds are required to be remitted to the state of Texas, which, in turn, appropriates the earnings to the College to benefit programs in medical research, health education, and treatment. The distributions totaling \$3.3 million in the years ended June 30, 2024 and 2023 are included in state appropriations on the consolidated statements of activities.

The U.S. and international financial markets have experienced significant volatility that has resulted in substantial fluctuations in equity markets in which the College invests. Market volatility can affect the value the College receives for its investments in future periods.

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

6. Investments (continued)

Investment performance for the years ended June 30 is summarized as follows (in thousands):

	2024						
	0	perating	Nor	operating	With Donor Restrictions	To	tal
Distribution of endowment							
earnings and other	\$	9,814	\$	– §	5 2	\$	9,816
Investment income		_		12,723	15,468		28,191
Net realized gains		_		47,722	709		48,431
Net unrealized losses		_		(13,793)	(9,093)	((22,886)
Total investment return		9,814		46,652	7,086		63,552
Investment return, designated							
for current operations		64,534		(64,569)	35		_
Investment management fees		(4,328)		(5,352)	_		(9,680)
Redemption proceeds		11,220		(11,220)	_		_
Total investment return, net of		•		_			
distributions and expenses	\$	81,240	\$	(34,489) \$	7,121	\$	53,872

During the 2024 fiscal year, the College appropriated \$11.2 million of investment returns from board-designated endowed funds that were redeemed in the 2023 fiscal year. The funds were used for the construction of research and education facilities.

	2023							
	0	perating	No	noperating		Donor rictions		Total
Distribution of endowment								
earnings and other	\$	6,691	\$	_	\$	10	\$	6,701
Investment income				19,227				19,227
Net realized (losses) gains		(1)		58,785		3,480		62,264
Net unrealized losses				(9,344)		21,709		12,365
Total investment return		6,690		68,668		25,199		100,557
Investment return, designated								
for current operations		63,796		(64,004)		208		_
Investment management fees		(4,532)		(4,661)		_		(9,193)
Total investment return, net of								
distributions and expenses	\$	65,954	\$	3	\$	25,407	\$	91,364

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

7. Endowment Funds

The College's endowment consists of approximately 900 individual funds established for a variety of purposes. Its endowment includes both donor-restricted endowment funds and funds designated by the College to function as endowments. As required by U.S. GAAP, net assets associated with endowment funds, including funds designated by the College to function as endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

ASC 958-205-45-28, Not-for-Profit Entities – Presentation of Financial Statements – Other Presentation Matters – Classification of Donor-Restricted Endowment Funds Subject to UPMIFA, provides guidance on the net asset classification of donor-restricted endowment funds for a not-for-profit organization that is subject to an enacted version of the Uniform Prudent Management of Institutional Funds Act of 2006 (UPMIFA) and improves disclosures about an organization's endowment funds (both donor-restricted and College-designated endowment funds).

Interpretation of relevant law – The College has established a policy consistent with UPMIFA as adopted by the state of Texas. The College seeks to preserve the fair value of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. Accordingly, the College classified as net assets with donor restrictions: (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor agreement at the time the accumulation is added to the fund. The remaining portion of the donor-restricted endowment fund that is not classified as permanent endowment is available for appropriation for expenditure by the College in a manner consistent with the standard of prudence prescribed by UPMIFA.

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

7. Endowment Funds (continued)

In accordance with UPMIFA, the College considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds:

- (1) The duration and preservation of the fund
- (2) The purposes of the College and the donor-restricted endowment fund
- (3) General economic conditions
- (4) The possible effects of inflation and deflation
- (5) The expected total return from income and the appreciation of investments
- (6) Other resources of the College
- (7) The investment policies of the College

The College's endowment consists of the following net asset types at June 30 (in thousands):

	Without Donor Restrictions		R	With Donor Restrictions		Total
2024						
Donor-restricted endowment funds	\$	_	\$	929,467	\$	929,467
Board-designated endowment funds		542,237		_		542,237
Total endowments at June 30, 2024	\$	542,237	\$	929,467	\$	1,471,704
		Without Donor estrictions	R	With Donor estrictions		Total
2023						
Donor-restricted endowment funds	\$	_	\$	872,823	\$	872,823
Board-designated endowment funds		572,690		20,883	_	593,573
Total endowments at June 30, 2023	\$	572,690	\$	893,706	\$	1,466,396

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

7. Endowment Funds (continued)

Funds with deficiencies – From time to time, the fair value of the assets associated with the individual donor-restricted endowment funds may fall below the level that the donor or UPMIFA requires the College to retain as a fund of perpetual duration. As of June 30, 2024, the College had deficiencies of this nature in 36 donor-restricted endowment funds, which together have an original gift value of \$22.8 million, a current fair value of \$21.1 million, and a deficiency of \$1.7 million. As of June 30, 2023, the College had deficiencies of this nature in 28 donor-restricted endowment funds, which together have an original gift value of \$18.5 million, a current fair value of \$17.5 million, and a deficiency of \$1.0 million. The College maintains policies that permit spending from underwater endowment funds depending on the degree to which the fund is underwater, unless otherwise precluded by donor intent or relevant laws and regulations.

Return objectives and risk parameters — The College recognizes that the goals of endowment management are preserving the purchasing power of the assets and providing stable support for current programs. The primary focus of the College's endowment investment policy is structuring both the endowment's investment portfolio and its annual spending in order to balance the needs of current and future generations of scholars, scientists, patients, and teachers. Current annual spending from the endowment plus inflation combines to create a minimum target total return for the portfolio. The College expects its endowment funds, over time, to provide an average rate of return at least equal to the spending policy requirements plus the rate of inflation. Actual rates of return in any given year may vary from this amount.

Strategies employed for achieving objectives – The College employs strategies of investing in equity assets and some illiquid assets, broadly diversifying, and investing in assets that are out of favor. The College believes that these strategies will help achieve the total return target over the long term.

Spending policy and how the investment objectives relate to spending policy – The College's board-approved endowment earnings distribution policy, as permitted by UPMIFA, is based on a 5% distribution applied to a trailing 28-quarter average market value of the endowment assets for both fiscal years. In establishing this spending policy, the College considered the long-term expected return on its endowment assets and expects the current spending policy to preserve the real purchasing power of the endowment assets, while helping to maintain intergenerational value of the assets, as well as to provide additional real growth through new gifts and pledges and investment return. The Board of Trustees may, in its discretion, designate additional funds to be used for operating purposes.

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

7. Endowment Funds (continued)

The following endowment-related activities occurred during the years ended June 30 (in thousands):

	 hout Donor estrictions	ith Donor estrictions	Total	
Endowment net assets at June 30, 2023	\$ 572,690	\$ 893,706 \$	1,466,396	6
Investment income, net of expense	7,191	15,883	23,074	4
Gifts and pledges	_	22,163	22,163	3
Realized and unrealized gains (losses), net Appropriation of endowment assets	27,983	(2,285)	25,698	8
for expenditure	(65,627)	_	(65,627	7)
Endowment net assets at June 30, 2024	\$ 542,237	\$ 929,467 \$	1,471,704	4

During the 2024 fiscal year, the College appropriated \$11.2 million of investment returns from board-designated endowment funds that were redeemed in the 2023 fiscal year. The funds were used for the construction of research and education facilities.

		hout Donor estrictions		th Donor strictions		Total
Endowment not agests at June 20, 2022	\$	615 224	\$	051 066	C	1 467 200
Endowment net assets at June 30, 2022 Investment income, net of expense	Ф	615,334 19,417	Ф	851,866 1,095	Ф	1,467,200 20,512
Gifts and pledges		19,417		13,247		13,257
Realized and unrealized gains, net		49,852		23,994		73,846
Appropriation of endowment assets		,		,		,
for expenditure		(64,669)		_		(64,669)
Other changes:						
Transfer to/from board-designated endowments						
within net assets without donor restrictions		(47,254)		3,504		(43,750)
Endowment net assets at June 30, 2023	\$	572,690	\$	893,706	\$	1,466,396

During the 2023 fiscal year, the College redeemed \$48.4 million of board-designated endowment units for the pending construction of research and education facilities.

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

8. Financial Assets and Liquidity Resources

The table below represents financial assets and liquidity resources available for general expenditures within one year (in thousands). The College defines general expenditures as the normal expenditures related to operations, excluding capital expenditures.

	 2024	2023	
Financial assets:			
Cash and cash equivalents	\$ 158,169	\$ 89,1	09
Accounts receivable	373,689	327,1	32
Pledges receivable	66,151	82,6	56
Notes receivable	17,856	16,5	85
Investments, including securities loaned of \$83,427	,	ŕ	
and \$80,610 for 2024 and 2023, respectively	1,494,798	1,488,4	92
Total financial assets	2,110,663	2,003,9	
Liquidity resource:			
Unused bank line of credit	95,000	142,5	00
Less those unavailable for general expenditures within			
one year due to:			
Contractual or donor-imposed restrictions	(929,467)	(893,7	
Investments with liquidity restrictions	(3,083)	(2,9)	
Investments held in trust	(11,614)	(11,1)	
Pledges receivable	(25,523)	(40,2)	21)
Notes receivable	(17,856)	(16,5	85)
Assets held on behalf of others	 (49,249)	(49,0	81)
Financial assets not available for use within one year	(1,036,792)	(1,013,6	39)
Financial assets and liquidity resources available for			
general expenditures within one year	\$ 1,168,871	\$ 1,132,8	35

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

8. Financial Assets and Liquidity Resources (continued)

The College's endowment funds consist of donor-restricted endowments and funds designated by the board as endowment. Income from endowments is restricted for specific purposes. The College has a spending policy and \$69.2 million of appropriation from the endowments will be available in the next 12 months. As part of a liquidity management plan, the College has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. Cash in excess of daily requirements is invested in short-term investments. In the event of an unanticipated liquidity need, the College maintains a four-year, \$150.0 million line of credit available for working capital purposes that is scheduled to expire on June 29, 2025. During fiscal year 2023, the College secured a supplemental line of credit of \$100.0 million that expires on June 30, 2026 (see Note 10).

9. Property and Equipment

Property and equipment consist of the following at June 30 (in thousands):

	Useful Life (Years)	2024	2023
Land	_	\$ 5,269	\$ 5,269
Buildings	16–28	764,621	754,466
Land improvements	15–20	17,499	17,499
Leasehold improvements	5–15	106,508	104,414
Furniture and equipment	5–10	371,413	376,283
Computer software	3–5	150,389	110,012
		1,415,699	1,367,943
Less accumulated depreciation		(1,071,146)	(1,040,803)
		344,553	327,140
Construction-in-progress		106,591	57,790
Leased right-of-use assets –			
financing			418
		\$ 451,144	\$ 385,348

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

9. Property and Equipment (continued)

In accordance with ASC 360, *Property, Plant, and Equipment*, when events or changes in circumstances indicate the carrying amount of property and equipment, and intangible or other long-lived assets, related to specifically acquired assets may not be recoverable, an evaluation of the recoverability of currently recorded costs is performed. When an evaluation is performed, the estimated value of undiscounted future net cash flows associated with the asset is compared with the asset's carrying value to determine whether a write-down to fair value is required. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. No impairments were recognized for the years ended June 30, 2024 or 2023.

10. Bonds and Notes Payable

A summary of bonds and notes payable at June 30 is as follows (in thousands):

	2024	2023
2012 Bond Series		
In September 2012, the College issued \$109.1 million of taxable		
fixed rate bonds. The interest rate is 5.26%, payable		
semiannually. Mandatory annual redemption before maturity		
is required between November 15, 2038 and 2045, with final		
maturity on November 15, 2046.	\$ 109,121	\$ 109,121
2016 Bond Series		
In May 2016, the Harris County Cultural Education Facilities		
Finance Corp. issued for the College \$142.7 million of tax-		
exempt fixed rate bonds with multiple maturities. The interest		
rates range from 3.00% to 5.00%, payable semiannually.		
Beginning in November 2018, principal installments are due		
annually with final maturity at November 15, 2032. A		
majority of the outstanding bonds are callable beginning in		
May 2026.	98,425	106,510
Way 2020.	90,423	100,510

2408-4588520

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

10. Bonds and Notes Payable (continued)

	2024	2023
2019A Bond Series		
In May 2019, the College retired \$75.0 million of tax-exempt		
floating rate notes with the Harris County Cultural Education		
Facilities Finance Corp. The Harris County Cultural		
Education Facilities Finance Corp. simultaneously issued		
\$75.0 million of tax-exempt floating rate notes. The interest		
rate reset monthly at a spread of 0.65% over the Secured		
Overnight Financing Rate (SOFR) plus 0.11448% during		
FY24. These bonds were scheduled to mature on		
November 15, 2046, but had an initial mandatory repurchase		
in July 2024. In February 2024, these bonds were refunded		
and extinguished in advance of their maturity date in 2046		
with proceeds from the 2024B Bond Series.	\$ _	\$ 75,000
2020 Bond Series		
In November 2020, the Harris County Cultural Education		
Facilities Finance Corp. issued for the College the Taxable		
Medical Facilities Mortgage Revenue Refunding Bonds for		
\$208.02 million. The interest rates, payable semiannually,		
range from 1.4% to 3.9%. Principal installments are due		
annually beginning in 2022 and through 2030, with additional		
maturities due in 2037 and 2046. The proceeds from this		
issuance were used to advance refund the Bonds Series		
2012A.	194,550	201,345
2022A Bond Series		
In January 2022, the Harris County Cultural Education		
Facilities Finance Corp. issued for the College \$75.0 million		
of tax-exempt floating rate notes. The proceeds from this		
issuance were used to advance refund the Bonds Series		
2019B. The interest rate resets weekly at a spread of 0.52%		
over the Securities Industry and Financial Markets		
Association (SIFMA) rate. The interest rate at June 30, 2024		
was 4.4%. These bonds mature on November 15, 2046, but		
have an initial mandatory repurchase in February 2025.	75,000	75,000

2408-4588520

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

10. Bonds and Notes Payable (continued)

	 2024	2023
2024A Bond Series		
In January 2024, the Harris County Cultural Education		
Facilities Finance Corp. issued for the College \$100 million		
of tax-exempt fixed rate notes. The interest rate is 5.00%,		
payable semiannually. These bonds mature on May 15, 2029,		
but have an initial optional repurchase in February 2029.	\$ 100,000 \$	_
2024B Bond Series		
In February 2024, the Harris County Cultural Education		
Facilities Finance Corp. issued for the College \$75 million		
of tax-exempt floating rate notes. The proceeds from this		
issuance were used to advance refund the Bonds Series		
2019A. The interest rate resets weekly at a variable spread		
of over the Securities Industry and Financial Markets		
Association (SIFMA) rate. The interest rate at June 30, 2024		
was 4.38% and the spread 0.5%. These bonds mature on		
November 15, 2046 and can be repurchase at any time	 75,000	
Total outstanding	652,096	566,976
Less deferred issuance costs	(4,578)	(4,052)
Plus original issue premium – 2016 Bond Series	6,136	6,905
Plus original issue premium – 2024A Bond Series	8,592	
	\$ 662,246 \$	569,829

The aggregate annual scheduled maturities of long-term debt as of June 30, 2024, for the next five fiscal years and thereafter are as follows (in thousands):

2025	\$ 15,410
2026	15,980
2027	16,585
2028	17,235
2029	17,875
Thereafter	 569,011
	\$ 652,096

In addition, the College must purchase a portion of its debt within these fiscal years unless remarketed, as described above.

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

10. Bonds and Notes Payable (continued)

Advance refunding tax-exempt debt is subject to arbitrage rules under Code Section 103(c) and related regulations that, in general, prohibit the yield realized from the investment of the proceeds of the new debt from exceeding the yield on the debt itself. Compliance with those rules is necessary for the interest on the debt to be exempt from federal income tax, and the College believes that it is in compliance with those rules.

As of June 30, 2024, all bonds outstanding have been issued under terms of the Second Amended and Restated Master Trust Indenture, dated November 1, 2020, between the Master Trustee and the College. The Master Trustee has a secured interest in all gross receipts and substantially all College land, including all improvements, appurtenances, personal property, and proceeds now or hereafter placed, acquired, or arising from the land.

Bond Compliance

As of June 30, 2024, the College is in compliance with financial covenants per the Second Amended and Restated Master Trust Indenture, dated November 1, 2020.

Revolving Credit Line

The College maintains a \$150.0 million revolving line of credit that is scheduled to expire on June 29, 2025. The College had drawn \$75 million and \$107.5 million from this line of credit for working capital purposes as of June 30, 2024 and 2023, respectively. During fiscal year 2023, the College secured a supplemental line of credit of \$100.0 million that expires on June 30, 2026 that replaced a 364-day \$100.0 million line of credit that the College originally negotiated in April 2020 and that expired in October 2023. The College had drawn \$80 million and \$0 million from this line of credit for working capital purposes as of June 30, 2024 and 2023, respectively.

11. Derivative and Other Financial Instruments

The College has derivative financial instruments, as allowed by its Debt and Swap Policies' Guidelines, both of which specifically preclude their use for speculation. The College has three fixed payor swaps outstanding at June 30, 2024 and 2023. The College has not elected hedge treatment of these swap agreements; as such, the change in the fair value of interest rate swaps is recorded in nonoperating unrealized gain on interest rate swaps on the consolidated statements of activities and as an adjustment to reconcile operating activities on the consolidated statements of cash flows. These long-dated swaps have a predetermined annual notional amortization or accretion that occurs in November of each year.

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

11. Derivative and Other Financial Instruments (continued)

The following table summarizes the fair value from the College's perspective at June 30, and the income (loss) recorded related to the interest rate swap agreements as of and for the years ended June 30 (dollars in thousands):

В	arclays			Bank	of America/		
Ba	nk PLC	PN	NC Bank	Mer	rill Lynch		Total
							_
F:	ixed rate	F	ixed rate	F	ixed rate		
Feb:	ruary 2032	Feb	ruary 2020	Jan	uary 2012		
Nove	ember 2045	Feb	ruary 2032	Nove	ember 2047		
\$	_	\$	103,830	\$	39,970	\$	143,800
	4.274%		4.542%		4.554%		
\$	(9,966)	\$	(11,443)	\$	(7,460)	\$	(28,869)
	(13,180)		(14,458)		(9,534)		(37,172)
\$	_	\$	_	\$	_	\$	_
	_		_		_		_
\$	3,214	\$	3,015	\$	2,074	\$	8,303
	1,661		6,628		3,015		11,304
	Feb. Nove \$	\$ (9,966) (13,180) \$ - \$ 3,214	Bank PLC PM Fixed rate F February 2032 Feb November 2045 Feb \$ - 4.274% \$ \$ (9,966) \$ (13,180) \$ \$ - 5 \$ \$ 3,214 \$	Bank PLC PNC Bank Fixed rate Fixed rate February 2032 February 2020 November 2045 February 2032 \$ - \$ 103,830 4.274% 4.542% \$ (9,966) \$ (11,443) (13,180) (14,458) \$ \$ 3,214 \$ 3,015	Bank PLC PNC Bank Mer Fixed rate Fixed rate Fixed rate February 2032 February 2020 Jan November 2045 February 2032 Nove \$ - \$ 103,830 \$ 4.542% \$ (9,966) \$ (11,443) \$ (14,458) \$ - \$ - \$ - \$ - \$ - \$ - \$ - \$ \$ 3,214 \$ 3,015 \$	Bank PLC PNC Bank Merrill Lynch Fixed rate Fixed rate Fixed rate February 2032 February 2020 January 2012 November 2045 February 2032 November 2047 \$ - \$ 103,830 \$ 39,970 4.274% 4.542% 4.554% \$ (9,966) \$ (11,443) \$ (7,460) \$ (13,180) (14,458) (9,534) \$ - \$ - - \$ 3,214 \$ 3,015 \$ 2,074	Bank PLC PNC Bank Merrill Lynch Fixed rate Fixed rate Fixed rate February 2032 February 2020 January 2012 November 2045 February 2032 November 2047 \$ - \$ 103,830 \$ 39,970 \$ 4.274% \$ (9,966) \$ (11,443) \$ (7,460) \$ (13,180) \$ - \$ - \$ - \$ - \$ - - \$ - \$ - \$ - - - - \$ - - - - \$ - - - - \$ 3,214 \$ 3,015 \$ 2,074 \$

12. Fair Value of Assets and Liabilities

The estimated fair values of all significant financial instrument amounts have been determined by the College using available market information and appropriate valuation methodologies. The estimates are not necessarily indicative of the amounts the College could realize in a current market exchange.

The carrying amounts of cash and cash equivalents, accounts receivable, patient accounts receivable, accounts payable, and short-term line of credit approximate fair value because of their short maturity.

The College's bonds payable are reported at carrying value (par) net of unamortized premiums/discounts.

2408-4588520

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

12. Fair Value of Assets and Liabilities (continued)

The College records investments, investments loaned under its security lending agreements, the related payable under security lending agreements, and its bond interest rate swap instruments at fair value in accordance with ASC 820.

ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The statement establishes consistency and comparability by providing a fair value hierarchy that prioritizes the inputs to valuation techniques into three broad levels, which are described below.

Level 1 – Inputs are quoted market prices in active markets for identical assets or liabilities (these are observable market inputs) that the College has the ability to access at the reporting date.

Level 2 – Inputs are other than quoted prices included within Level 1 that are either directly or indirectly observable for the asset or liability, including quoted market prices for similar assets in active markets, quoted prices for identical or similar assets in markets in which there are few transactions, inputs other than quoted prices that are observable for the asset, and inputs that are derived from observable market data by correlation or other means.

Level 3 – Inputs are generally unobservable market inputs that typically reflect the entity's estimate of assumptions that market participants would use in pricing the asset or liability (used when little or no market data is available).

ASC 820 requires the use of observable market inputs (quoted market prices) when measuring fair value whenever possible and requires Level 1 quoted prices to be used to measure fair value whenever possible.

ASC 820 provides guidance for estimating the fair value of investments in certain entities that calculate net asset value per share (or its equivalent). As such, the College utilizes net asset value as a practical expedient of fair value and other available information to determine fair value for investments meeting the prescribed requirements.

Level 1 investments are able to be liquidated as of the reporting date at published market values. Level 2 and 3 investments may contain restrictions on the ability to liquidate assets at the reporting date. Investments that can be liquidated within 90 days of the reporting date at net asset value or

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

12. Fair Value of Assets and Liabilities (continued)

its equivalent are classified as Level 2 investments. Investments classified as Level 3 have significant liquidity restrictions that would prevent redemption within 90 days of the reporting date, if at all. Private equity investments are measured at fair value using net asset value as a practical expedient as of the measurement date.

Financial assets and liabilities included in the College's consolidated financial statements and measured at fair value on a recurring basis as of June 30 are classified based on the applicable valuation technique level in the following tables (in thousands). Private equity investments and other financial assets are not categorized in the fair value hierarchy but are presented for reconciliation purposes:

Assets: Cash and cash equivalents U.S. equities 389,787 311,780 78,007 - International equities 361,100 223,604 137,496 - Fixed income 52,091 Security lending collateral 88,257 - 88,257 - 1,025,252 669,401 355,851 - Investments measured at NAV Assets held in trust and other Real assets Direct equity investments Total assets 1,669			Total 2024		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant nobservable Inputs (Level 3)
U.S. equities 389,787 311,780 78,007 — International equities 361,100 223,604 137,496 — Fixed income 52,091 — 52,091 — Security lending collateral 88,257 — 88,257 — Investments measured at NAV Assets held in trust and other Real assets 2,656 — — — — Direct equity investments 1,669 — — — — Liabilities: Interest rate swap liability Payable under security lending agreements Assets held on behalf of others (state tobacco funds) 38,032 38,032 — — —		Φ	124 017	Φ	124.017	C		©	
International equities 361,100 223,604 137,496		Þ		Þ		Þ	78 007	Þ	_
Security lending collateral S2,091 - S2,091 - Security lending collateral S8,257 - S8,257 - Investments measured at NAV Assets held in trust and other Real assets 2,656 - - - Direct equity investments 1,669 - - - Total assets S1,583,055 S - S - Liabilities: Interest rate swap liability S28,869 S - S28,869 S - Payable under security lending agreements S8,257 - S8,257 - S8,257 - Assets held on behalf of others (state tobacco funds) 38,032 38,032 - -			,						_
1,025,252 669,401 355,851			,		_				_
Investments measured at NAV	Security lending collateral		88,257		_		88,257		
Assets held in trust and other Real assets Direct equity investments Total assets 1,669			1,025,252		669,401		355,851		_
Real assets 2,656 - - - Direct equity investments 1,669 - - - Total assets \$ 1,583,055 \$ - \$ - Liabilities: Interest rate swap liability \$ 28,869 \$ - \$ 28,869 \$ - Payable under security lending agreements 88,257 - 88,257 - Assets held on behalf of others (state tobacco funds) 38,032 38,032 - -					_		_		_
Direct equity investments Total assets 1,669					_		_		_
Liabilities: Interest rate swap liability \$ 28,869 \$ - \$ 28,869 \$ - Payable under security lending agreements 88,257 - 88,257 - Assets held on behalf of others (state tobacco funds) 38,032 38,032	Direct equity investments		,		_		_		_
Interest rate swap liability \$ 28,869 \$ - \$ 28,869 \$ - \$ Payable under security lending agreements 88,257 - 88,257 - Assets held on behalf of others (state tobacco funds) 38,032 38,032	Total assets	\$	1,583,055	\$	_	\$	_	\$	_
lending agreements 88,257 - 88,257 - Assets held on behalf of others (state tobacco funds) 38,032 38,032	Interest rate swap liability	\$	28,869	\$	_	\$	28,869	\$	-
others (state tobacco funds) 38,032	lending agreements		88,257		_		88,257		_
			38,032		38,032		_		_
1 otal habilities \$ 155,158 \$ 38,032 \$ 117,126 \$ -	Total liabilities	\$	155,158	\$	38,032	\$	117,126	\$	

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

12. Fair Value of Assets and Liabilities (continued)

		Total 2023		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant nobservable Inputs (Level 3)
Assets:		4 (0 =0 (4 - 2 - 2 - 2				
Cash and cash equivalents	\$	163,736	\$	163,736	\$	-	\$	_
U.S. equities		358,799		316,964		41,835		_
International equities		323,181		206,647		116,534		_
Fixed income		77,092		37,146		39,946		_
Security lending collateral		84,259		724 402		84,259		
		1,007,067		724,493		282,574		_
Investments measured at NAV		556,537		_		_		_
Assets held in trust and other		5,335						
Real assets		2,656		_		_		_
Direct equity investments	Φ	1,157	Ф		Φ.		Φ.	
Total assets	\$	1,572,752	\$		\$		\$	
Liabilities:								
Interest rate swap liability Payable under security	\$	37,172	\$	_	\$	37,172	\$	_
lending agreements Assets held on behalf of		84,259		_		84,259		_
others (state tobacco funds)		38,440		38,440		_		_
Total liabilities	\$	159,871	\$	38,440	\$	121,431	\$	

Cash and cash equivalents and U.S. and international equities included in Level 1 are measured using quoted market prices in active markets for the identical equities. U.S. and international equities and fixed-income investments, included in Level 2, are measured using quoted market prices for similar assets and use the net asset value per share.

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

12. Fair Value of Assets and Liabilities (continued)

Private equity investments consist of leveraged buy-outs, venture capital, distressed debt, and real assets and real estate investments. Capital is allocated to domestic and international markets in various investment vehicles, primarily limited partnerships, but also includes private real estate investment trusts. Most of the underlying assets in the private equity partnerships are not immediately liquid. All private equity investments are held as long-term investments. Leveraged buy-outs, venture capital, and distressed debt investments are structured as closed-end, commitment-based investment funds where the investor commits a specified amount of capital upon inception of the fund, which is then drawn down over a specified period of the fund's life. These funds generally cannot be withdrawn or redeemed prior to the specified termination date and will only receive distributions upon a disposition of the underlying assets in the portfolio. As a limited partner, the College will not generally have any influence over the amount or timing of capital contributions and distributions. As of June 30, 2024, the remaining specified term of the leveraged buy-outs, venture capital, and distressed debt partnerships ranged from 1 to 12 years. However, a partnership's life may be (and normally is) extended beyond the original specified term by approval of the limited partners. Some of the College's real estate investments are different from the other private equity partnerships, as they are structured as open-ended, commingled investment vehicles. The underlying investments consist of large, diversified portfolios of existing real properties, primarily income-producing assets, such as office buildings, apartments, retail, and industrial properties, located across the United States. Subject to certain restrictions, redemptions of all or part of the College's investments in private equity real estate may be requested each quarter, and such redemptions will be made at the net asset value for the fund. Private equity investment valuation is determined by the private equity general partner using proprietary information that is unobservable to a market participant.

Interest rate swap liability (see Note 11) valuation is determined using market valuation techniques, including discounted cash flow analysis on the expected cash flow of each agreement. This analysis reflects the contractual terms of the agreement, including the period to maturity, and uses observable market-based inputs, including forward interest rate curves. These observable (Level 2) inputs are available to a market participant.

The securities lending collateral (see Note 2) consists of U.S. and non-U.S. obligations, government agency obligations, corporate debt securities, equities from indexes as approved by the securities lending agent's risk committee, and exchange-traded funds. The collateral and associated liability, included in Level 2, are determined using a mark-to-market valuation that is performed each business day.

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

13. Functional Expenses

The College's expenses relate principally to providing education, research, and clinical services. The functional expenses for these services are recorded directly or are allocated. Operation and maintenance of plant expense, depreciation expense, and interest expense are allocated to the various functional areas of the College based on the square footage of space occupied by each program and supporting service.

For the years ended June 30, expenses related to providing these services are as follows (in thousands):

							2024					
				Program	Ac	tivities		Supporting	g Acı	tivities		
	In	struction	I	Research		Medical Services	Affiliated Hospital Programs	nagement l General	Fu	ndraising	To	otal Expenses
Direct Salaries, wages, and benefits Services, supplies, and others	\$	154,129 28,662	\$	472,105 231,611	\$	382,647 112,027	\$ 1,078,312 66,986	\$ 52,104 22,920	\$	6,681 4,557	\$	2,145,978 466,763
Allocated Operations and maintenance of plant Depreciation and interest		8,058 8,634		45,671 66,236		1,803 8,551	- 4,664	 _ _	-	- -		55,532 88,085
Allocated expenses by functional area	_\$_	199,483	\$	815,623	\$	505,028	\$ 1,149,962	\$ 75,024	\$	11,238	<u>\$</u>	2,756,358
							2023					
				Program	Ac	tivities		Supporting	g Acı	tivities		
	In	struction	I	Research		Medical Services	Affiliated Hospital Programs	nagement l General	Fu	ndraising	To	otal Expenses
Direct Salaries, wages, and benefits Services, supplies, and others	\$	148,878 19,747	\$	421,945 235,215	\$	355,706 134,702	\$ 965,848 48,838	\$ 59,986 28,149	\$	7,446 2,703	\$	1,959,809 469,354
Allocated Operations and maintenance of plant Depreciation and interest		7,473 7,512		44,554 63,459		1,645 12,168	_ 66	 - -	_	- -		53,672 83,205
Allocated expenses by functional area	\$	183,610	\$	765,173	\$	504,221	\$ 1,014,752	\$ 88,135	\$	10,149	\$	2,566,040

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

14. Employee Benefits

Retirement Plan

Substantially all faculty and staff participate in the College's defined contribution retirement plan (the Plan). The Plan is a core benefit, and contributions are made by the College based on a formula using the employee's base annual salary. The College's contributions to the Plan in the years ended June 30, 2024 and 2023 were \$97 million and \$94.9 million, respectively. The assets of the Plan are administered by third parties.

15. Leases

The components of lease cost for the fiscal years ended June 30 were as follows (in thousands):

	 2024		2023
Operating lease expense	\$ 16,693	\$	14,024
Other information:			
Cash paid for amounts included in the measurement of operating			
leases	\$ 14,375	\$	14,133
Right-of-use assets obtained in exchange for new operating			
lease liabilities	48,669		2,867
Weighted average remaining lease term – operating leases			
(in years)	7.98		2.59
Weighted discount rate – operating leases	4.12%	·)	2.32%

The annual payments based on maturities are reported under commitments and contingencies (see Note 16).

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

16. Commitments and Contingencies

Leases

Annual payments based on maturities of the College's leases as of June 30, 2024 are as follows (in thousands):

	Operat Lease	
2025	\$ 15	,504
2026	10	,488
2027	7	,859
2028	6	,829
2029	6	,187
Thereafter	32	,427
Total undiscounted lease payments	79	,294
Less present value adjustment	13	,122
Total discounted lease payments	\$ 66	,172

Private Investments

The College has committed to invest in certain private investments over a period of time. The remaining private investment commitment as of June 30, 2024 and 2023 is \$125.5 million and \$254.9 million, respectively. Based on historical patterns, the College expects those amounts will be called into the partnerships for investment over the next three to five years and will be funded by assets of the endowment.

Self-Insurance Program for Professional Liability

Medical malpractice and other actions alleging wrongful conduct and seeking punitive damages are sometimes filed against physicians and the College's affiliated institutions. Since 1977, the College has maintained a medical malpractice self-insurance program (the Program) that, until July 1, 2003, had been supplemented by reinsurance or excess insurance agreements with private insurance companies. Due to sharply increased costs, the College's favorable loss experience, and the positive effects of tort reform legislation, the College, effective July 1, 2003, elected not to

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

16. Commitments and Contingencies (continued)

purchase excess insurance coverage. To date, there has not been a settlement or jury verdict on a case that exceeded the self-insurance retention level that would have been required by the insurance market had the College decided to purchase coverage. The College continued to monitor the insurance market, and during fiscal year 2011, the College started purchasing reinsurance above a \$15.0 million self-insured retention. For the years ended June 30, 2024 and 2023, the College purchased \$50.0 million in reinsurance above the \$15.0 million per occurrence and \$35.0 million aggregate self-insurance retention.

The Program's dedicated account is funded on a quasi-occurrence basis, meaning it is designed to cover the health care provider for an incident that happened while he or she was a participant no matter when the claim or lawsuit was filed, but if the incident upon which the claim or lawsuit is based was not reported to the College's Risk Management office, the matter would be asserted against the coverage in the fiscal year in which reporting occurred. Settlements, judgments, and costs of defense are paid from a pool of a self-insured retention, depending on the year the claim occurred or was filed; several layers of excess coverage are available to respond to them. Funding for the Program has been actuarially determined to the level of \$35.0 million per occurrence and \$70.0 million aggregate for payment of medical malpractice losses and related expenses. For the period from July 1, 2003 through September 1, 2010, all risk of loss is borne by the College.

The College has been named as a defendant in various claims for damages resulting from alleged medical malpractice. The malpractice reserve, which includes reserves for incurred but not reported claims, is \$53.6 million and \$53.2 million as of June 30, 2024 and 2023, respectively.

This liability was determined on a discounted basis without consideration of any insurance recoveries. The discount rate used in calculating the actuarial present value at June 30, 2024 and 2023 was 4%.

Financial Responsibility Supplemental Schedule (continued) (In Thousands)

17. Transactions With Affiliates

Included among the College's Board of Trustees are members from the banking, insurance, and legal communities who provide assistance in the development of policies and programs for the College. Also, certain trustees, faculty, and staff of the College participate in the management of affiliated hospitals with which the College has contracts to provide services. During fiscal years 2024 and 2023, the College paid legal and other professional fees of approximately \$2.6 million and \$1.9 million, respectively, to law firms and other organizations with which several board members are affiliated. A portion of the College's pooled investments with a market value of \$86.9 million and \$71.6 million for fiscal years 2024 and 2023, respectively, was managed by an investment firm affiliated with a trustee. Also, the College has received, from time to time, significant contributions from various board members and corporations with which board members are affiliated. These transactions have been entered into in the normal course of business. The College also enters into transactions in the normal course of business with BSLMC and Baylor Genetics.

Reports and Schedules Required by the Uniform Guidance



Ernst & Young LLP 1401 McKinney Street Suite 2400 Houston, TX 77010 Tel: +1 713 750 1500 Fax: +1 713 750 1501 ev.com

Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*

Management and The Board of Trustees Baylor College of Medicine

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*), the consolidated financial statements of Baylor College of Medicine, which comprise the consolidated balance sheet as of June 30, 2024 and the related consolidated statements of activities and cash flows for the year then ended, and the related notes (collectively referred to as the "financial statements"), and have issued our report thereon dated November 25, 2024.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered Baylor College of Medicine's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of Baylor College of Medicine's internal control. Accordingly, we do not express an opinion on the effectiveness of Baylor College of Medicine's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements, on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.



Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies and therefore, material weaknesses or significant deficiencies may exist that were not identified. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. We identified a deficiency in internal control, described in the accompanying schedule of findings and questioned costs as item 2024-001 that we consider to be a significant deficiency.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether Baylor College of Medicine's financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Ernst & Young LLP

November 25, 2024



Ernst & Young LLP 1401 McKinney Street Suite 2400 Houston, TX 77010 Tel: +1 713 750 1500 Fax: +1 713 750 1501 ev com

Report of Independent Auditors on Compliance for Each Major Federal and State Program; Report on Internal Control Over Compliance Required by the Uniform Guidance and Texas Grant Management Standards

Management and The Board of Trustees Baylor College of Medicine

Report of Independent Auditors on Compliance for Each Major Federal and State Program

Opinion on Each Major Federal and State Program

We have audited the Baylor College of Medicine's (the College's) compliance with the types of compliance requirements identified as subject to audit in the U.S. Office of Management and Budget (OMB) *Compliance Supplement* that could have a direct and material effect on each of the College's major federal programs for the year ended June 30, 2024 and the types of compliance requirements identified as subject to audit in the Texas Grant Management Standards (TxGMS) that could have a direct and material effect on the College's major state programs for the year ended June 30, 2024. The College's major federal and state programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the College complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal and state programs for the year ended June 30, 2024.

Basis for Opinion on Each Major Federal and State Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and TxGMS for State Awards. Our responsibilities under those standards and the Uniform Guidance and TxGMS are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the College and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on compliance for each major federal and state program. Our audit does not provide a legal determination of the College's compliance with the compliance requirements referred to above.



Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules, and provisions of contracts or grant agreements applicable to the College's federal and state programs.

Auditor's Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the College's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, and TxGMS will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the College's compliance with the requirements of each major federal and state program as a whole.

In performing an audit in accordance with GAAS, Government Auditing Standards, the Uniform Guidance and TxGMS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the College's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the College's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance and TxGMS, but not for the purpose of expressing an opinion on the effectiveness of the College's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.



Other Matters

The results of our auditing procedures disclosed instances of noncompliance, which are required to be reported in accordance with the Uniform Guidance and TxGMS and which are described in the accompanying schedule of findings and questioned costs and summarized below. Our opinion on each major federal and state program is not modified with respect to these matters.

Finding No.	Assistance Listing No.	Program Name	Compliance Requirement
2024-002	93.855	Research and Development Cluster	I. Procurement
2024-004	21.027 N/A (State Program)	Coronavirus State and Local Fiscal Recovery Funds/ Texas Child Mental Health Care Consortium	L. Reporting
2024-005	84.268	Student Financial Assistance Cluster	C. Cash Management

Government Auditing Standards requires the auditor to perform limited procedures on the College's response to the noncompliance findings identified in our audit described in the accompanying schedule of findings and questioned costs. The College's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

The College is responsible for preparing a corrective action plan to address each audit finding included in our auditor's report. The College's corrective action plan was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on it.

We performed audit procedures with respect to the Student Financial Assistance Cluster major federal program related to compliance requirements in Special Tests and Provisions N11 Gramm-Leach Bliley Act – Student Information Security as outlined in the OMB Compliance Supplement for the year ended June 30, 2024. We determined whether the College has designated a "Qualified Individual," as described in the OMB Compliance Supplement, to be responsible for implementing and monitoring the information security program in accordance with 16 CFR 314.4(a). We determined whether the College has a written information security program and that the written information security program documents the seven minimum elements required by 16 CFR 314.4(a)-(g). Our audit procedures did not evaluate whether the designated Qualified Individual is competent to oversee the implementation and monitoring of the information security program nor whether the Qualified Individual possessed the adequate authority to carry out those duties. Our audit procedures also did not determine whether



the written information security program sufficiently and completely addressed the seven minimum elements required by 16 CFR 314.4(a)-(g). Our opinion on the Student Financial Assistance Cluster major federal program is not modified with respect to this matter.

Report on Internal Control Over Compliance

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance, and therefore, material weaknesses or significant deficiencies may exist that were not identified. However, as discussed below, we did identify certain deficiencies in internal control over compliance that we consider to be material weaknesses.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct noncompliance with a type of compliance requirement of a federal and state program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal and state program will not be prevented, or detected and corrected on a timely basis. We consider the deficiencies in internal control over compliance described in the accompanying schedule of findings and questioned costs and summarized below to be material weaknesses.

Finding No.	Assistance Listing No.	Program Name	Compliance Requirement
2024-003	Various/21.027	Research and Development Cluster/COVID-19 Coronavirus State and Local Fiscal Recovery Funds	A. Activities Allowed or Unallowed; B. Allowable Costs/Cost Principles
2024-004	21.027 N/A (State Program)	Coronavirus State and Local Fiscal Recovery Funds/ Texas Child Mental Health Care Consortium	L. Reporting



A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal and state program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance. We consider these deficiencies in internal control over compliance described in the accompanying schedule of findings and questioned costs and summarized below to be significant deficiencies.

Finding No.	Assistance Listing No.	Program Name	Compliance Requirement
2024-002	93.855	Research and Development Cluster	L. Procurement
2024-005	84.268	Student Financial Assistance Cluster	C. Cash Management

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

Government Auditing Standards requires the auditor to perform limited procedures on the College's response to the internal control over compliance findings identified in our audit described in the accompanying schedule of findings and questioned costs. The College's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

The College is responsible for preparing a corrective action plan to address each audit finding included in our auditor's report. The College's corrective action plan was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on it.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance and TxGMS. Accordingly, this report is not suitable for any other purpose.

Ernst + Young LLP

March 31, 2025

Schedule of Expenditures of Federal Awards

Year Ended June 30, 2024

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF AGRICULTURE							
AGRICULTURAL RESEARCH-BASIC AND APPLIED RESEARCH	10.001		\$ 14,160,217 \$	_	\$ -	\$ 14,160,217	\$ 114,882
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310		361,802	-	=	361,802	108,872
PASS-THROUGH AWARD FROM:							
TEXAS A&M UNIVERSITY							
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI) THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	10.310	2022-67015-36335	55,301	_	_	55,301	=
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310	2023-68015-40967	62.810	_	_	62,810	_
Total ALN 10.31			479,913	-	-	479,913	108,872
PASS-THROUGH AWARD FROM: PRAIRIE VIEW A&M STATE ADMINISTRATIVE MATCHING GRANTS FOR THE SUPPLEMENTAL NUTRITIONAL ASSISTANCE PROGRAM TOTAL DEPARTMENT OF AGRICULTURE	10.561	HHS001018600002	14,640,130	<u>-</u>	96,852 96,852	96,852 14,736,982	
DEPARTMENT OF COMMERCE							
MEASUREMENT AND ENGINEERING RESEARCH AND STANDARDS	11.609	70NANB21H101	35,283	_	_	35,283	
TOTAL DEPARTMENT OF COMMERCE			35,283	-	-	35,283	=
DEPARTMENT OF DEFENSE PASS-THROUGH AWARD FROM: NATIONAL MARROW DONOR PROGRAM BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	1702	1,529	-	-	1,529	-
MILITARY MEDICAL RESEARCH AND DEVELOPMENT PASS-THROUGH AWARD FROM:	12.420		14,461,317			14,461,317	1,147,918
BOSTON CHILDRENS HOSPITAL MILITARY MEDICAL RESEARCH AND DEVELOPMENT BOSTON UNIVERSITY	12.420	W81XWH-22-1-0301	13,390	-	-	13,390	_
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0488	9,972	-	_	9,972	=

56 2503-1117-CS

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF DEFENSE (continued)							_
PASS-THROUGH AWARD FROM (continued):							
CEDARS-SINAI MEDICAL CENTER							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0222	\$ 66,690 \$	_	\$ -	\$ 66,690	\$ -
CHILDRENS HOSPITAL MEDICAL CENTER, CINCINNATI							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0689	(2,247)	_	_	(2,247)	_
GEORGE WASHINGTON UNIVERSITY							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0672	23,031	_	_	23,031	_
THE METHODIST HOSPITAL RESEARCH INSTITUTE							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0285	375	_	_	375	_
JOHNS HOPKINS UNIVERSITY							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	DARPA 175076	2,108	_	_	2,108	_
HENRY JACKSON FOUNDATION							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0375	89,905	_	_	89,905	_
JOHNS HOPKINS UNIVERSITY							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W911QY-20-9-12	(224)	-	-	(224)	_
STANFORD UNIVERSITY							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-1031	12,999	-	_	12,999	=
MOFFITT CANCER CENTER							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0921	9,715	-	_	9,715	=
NOVA SOUTHEASTERN UNIVERSITY							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-2-0062	38,198	-	_	38,198	=
RESEARCH TRIANGLE INSTITUTE							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-2-0077	33,399	-	_	33,399	_
RESEARCH TRIANGLE INSTITUTE							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-2-0044	687,644	-	_	687,644	_
RICE UNIVERSITY							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-9-0016	973	_	_	973	_
RICE UNIVERSITY							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	DARPA N6001-19-C-4020	300,097	-	-	300,097	=
RICE UNIVERSITY							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W911NF-23-0017	82,273	_	_	82,273	_
SEATTLE CHILDREN'S RESEARCH							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0992	44,651	-	_	44,651	_
STATE UNIVERSITY OF NEW YORK							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-1089	152,617	_	_	152,617	=
TULANE UNIVERSITY		*************	co. a				
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0026	62,307	_	_	62,307	_
UNIVERSITY OF ALABAMA AT BIRMINGHAM	10.422	***************	170.011			150.011	
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0135	172,211	_	_	172,211	_

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF DEFENSE (continued)							
PASS-THROUGH AWARD FROM (continued):							
UNIVERSITY OF CHICAGO							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-C-0058	\$ 30,495 \$	- \$	-	\$ 30,495	\$ -
UNIVERSITY OF MICHIGAN							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0829	39	-	_	39	_
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-2-0042	11,606	-	_	11,606	_
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-9-0001	85,939	_	_	85,939	_
UNIVERSITY OF PENNSYLVANIA							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0861	7,665	-	_	7,665	_
UNIVERSITY OF PITTSBURGH							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-D-0024	25,012	-		25,012	_
UNIVERSITY OF PITTSBURGH							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-9-0014	1,993	_	_	1,993	-
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0243	62,962	-	-	62,962	_
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0963	22,802	-	-	22,802	_
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0187	52,962	-	-	52,962	_
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-2-0008	6,946	-	-	6,946	_
WASHINGTON UNIVERSITY							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-9-0021	24,664	-	-	24,664	_
WILLIAM BEAUMONT HOSPITAL RESEARCH INSTITUTE							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0288	(12,503)	_		(12,503)	<u> </u>
	Total ALN 12.420		16,581,983	_	_	16,581,983	1,147,918
DAGG THROUGH AWARD FROM							
PASS-THROUGH AWARD FROM: HENRY JACKSON FOUNDATION							
UNIFORMED SERVICES UNIVERSITY MEDICAL RESEARCH PROJECTS	12.750	HU001-17-2-0023	471 427			471,437	
UNIFORMED SERVICES UNIVERSITY MEDICAL RESEARCH PROJECTS	12.750	HU001-17-2-0023	471,437	_	_	4/1,43/	-
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800		150.394			150,394	152,242
TOTAL DEPARTMENT OF DEFENSE	12.800		17,205,343			17,205,343	1,300,160
TOTAL DELANTMENT OF DEFENSE			17,400,543	_	_	17,205,345	1,300,100

Federal Grantor/Pass-Through Grantor/Program Title		Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF JUSTICE PASS-THROUGH AWARD FROM: UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER – NORTH TEXAS NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION AND DEVELOPMENT PROJECT GRANTS		16.560	2022 - GG-04414-MUMU	\$ 42,629 \$	-	\$ -	\$ 42,629	s –
PASS-THROUGH AWARD FROM: SANTA MARIA HOSTEL NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION AND DEVELOPMENT PROJECT GRANTS TOTAL DEPARTMENT OF JUSTICE		16.812	15PBJA-22-GG-01768-SCAX	42,629		29,209 29,209	29,209 71,838	
DEPARTMENT OF THE TREASURY PASS-THROUGH AWARD FROM: SANTA MARIA HOSTEL COVID-19 CORONAVIRUS STATE AND LOCAL FISCAL RECOVERY		21.027	ARPA-LFRF	_	_	377,182	377,182	_
THE UNIVERSITY OF TEXAS AT AUSTIN COVID-19 CORONAVIRUS STATE AND LOCAL FISCAL RECOVERY THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON		21.027	2021-CS-21027	-	-	3,846,786	3,846,786	-
COVID-19 CORONAVIRUS STATE AND LOCAL FISCAL RECOVERY DEPARTMENT OF THE TREASURY		21.027	OOG 4546301			686,188 4,910,156	686,188 4,910,156	<u></u>
NATIONAL AERONAUTICS AND SPACE ADMINISTRATION PASS-THROUGH AWARD FROM: TEXAS TECH UNIVERSITY SCIENCE		43.001	80NSSC22K0250	222,459	_	_	222,459	_
EXPLORATION		43.003		14,243,785	-	_	14,243,785	7,959,102
PASS-THROUGH AWARD FROM: UNIVERSITY OF WASHINGTON EXPLORATION		43.003	NNX16AE78G	9,853	_	_	9,853	_
TOTAL NATIONAL AERONAUTICS AND SPACE ADMINISTRATION	Total ALN 43.003			14,253,638 14,476,097	_	_ _	14,253,638 14,476,097	7,959,102 7,959,102
TOTAL PATIONAL AERONAUTICS AND STACE ADMINISTRATION				17,70,097	_	_	17,7/0,09/	1,737,104

Federal Grantor/Pass-Through Grantor/Program Title		Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
NATIONAL SCIENCE FOUNDATION ENGINEERING GRANTS		47.041		\$ 139,396 \$	§ –	\$ –	\$ 139,396	s –
PASS-THROUGH AWARD FROM: NORTHWESTERN UNIVERSITY		77.071		Ψ 157,570	,	y .	133,330	Ψ
ENGINEERING GRANTS TEXAS A&M UNIVERSITY		47.041	NSF-1830961	(5,277)	=	=	(5,277)	=
ENGINEERING GRANTS THE UNIVERSITY OF TEXAS AT AUSTIN		47.041	NSF-2037383	15,212	-	=	15,212	=
ENGINEERING GRANTS	Total ALN 47.041	47.041	NSF-0000183	131,220 280,551			131,220 280,551	
MATHEMATICAL AND PHYSICAL SCIENCES		47.049		2,796,250	-	-	2,796,250	1,514,923
PASS-THROUGH AWARD FROM: RICE UNIVERSITY								
MATHEMATICAL AND PHYSICAL SCIENCES UNIVERSITY OF HOUSTON		47.049	PHY-2019745	480,615	-	-	480,615	-
MATHEMATICAL AND PHYSICAL SCIENCES	Total ALN 47.049	47.049	DBI-1707400	194,692 3,471,557	<u> </u>		194,692 3,471,557	1,514,923
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING		47.070		261,212	_	_	261,212	=
PASS-THROUGH AWARD FROM:								
RICE UNIVERSITY MATHEMATICAL AND PHYSICAL SCIENCES	Total ALN 47.070	47.070	CNS-1801865	104,885 366,097		<u>–</u>	104,885 366,097	
BIOLOGICAL SCIENCES	Total ALN 47.070	47.074		923,648	_	_	923,648	47,910
PASS-THROUGH AWARD FROM:		17.071		723,010			723,010	47,510
CARNEGIE INSTITUTE OF WASHINGTON BIOLOGICAL SCIENCES		47.074	DBI-2213983	(7)	_	_	(7)	_
UNIVERSITY OF NORTH TEXAS BIOLOGICAL SCIENCES		47.074	NSF-2241573	26,019	_	_	26,019	=
UNIVERSITY OF ILLINOIS AT CHICAGO BIOLOGICAL SCIENCES		47.074	NSF- 2107527	67,135	_	_	67,135	
UNIVERSITY OF MICHIGAN BIOLOGICAL SCIENCES		47.074	NSF- 1935265	161,352	_	_	161,352	
	Total ALN 47.074			1,178,147	_	_	1,178,147	47,910

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
NATIONAL SCIENCE FOUNDATION (continued)							
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075		\$ 114,163 \$	-	\$ -	\$ 114,163	\$ 17,339
EDUCATION AND HUMAN RESOURCES	47.076		507,752	-	-	507,752	=
NSF TECHNOLOGY, INNOVATION, AND PARTNERSHIPS	47.084		12,046	_	_	12,046	<u> </u>
TOTAL NATIONAL SCIENCE FOUNDATION			5,930,313	-	-	5,930,313	1,580,172
U.S. ENVIRONMENTAL PROTECTION AGENCY							
PASS-THROUGH AWARD FROM: LELAND STANFORD JUNIOR UNIVERSITY							
SCIENCE TO ACHIEVE RESULTS PROGRAM	66.509	84047801	180,304	=	=	180,304	<u> </u>
TOTAL U.S. ENVIRONMENTAL PROTECTION AGENCY			180,304	-	-	180,304	-
DEPARTMENT OF EDUCATION							
FEDERAL WORK-STUDY PROGRAM	84.033		_	26,046	-	26,046	_
FEDERAL PERKINS LOANS	84.038		-	630,976	-	630,976	-
FEDERAL DIRECT STUDENT LOANS	84.268		-	24,021,602	-	24,021,602	-
EDUCATION STABILIZATION FUND							
GOVERNOR'S EMERGENCY EDUCATION RELIEF (GEER II) FUND TOTAL DEPARTMENT OF EDUCATION	84.425C			24,678,624	115,369 115,369	115,369 24,793,993	<u> </u>
TOTAL DEPARTMENT OF EDUCATION			-	24,078,024	115,309	24,/93,993	-
DEPARTMENT OF HEALTH AND HUMAN SERVICES PASS-THROUGH AWARD FROM:							
ARKANSAS CHILDREN'S HOSPITAL							
BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES – PREVENTION AND SURVEILLANCE THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	93.073	DD001285	14,663	=	=	14,663	-
BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES – PREVENTION AND SURVEILLANCE	93.073	DD001309	78,661	_	_	78,661	_
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	02.072	11110000062600001	15.977			15.076	
BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES – PREVENTION AND SURVEILLANCE Total ALN 93.07.	93.073	HHS000962600001	15,876 109,200			15,876 109,200	
EAMILY SMOUTING DREVENTION AND TODAGGO CONTROL ACT DECLIFATORY DESCRAPOR	02.077		104.802			104 802	
FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	93.077		104,802	_	_	104,802	_

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued) PASS-THROUGH AWARD FROM:							
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080	DD000020	\$ 21,369 \$	- !	-	\$ 21,369	\$ -
PASS-THROUGH AWARD FROM: UNIVERSITY OF MARYLAND							
PREVENTION OF DISEASE, DISABILITY AND DEATH BY INFECTIOUS DISEASES	93.084	CK000615	63,306	-	_	63,306	_
FOOD AND DRUG ADMINISTRATION-RESEARCH	93.103		1,433,102	-	-	1,433,102	738,324
PASS-THROUGH AWARD FROM: UNIVERSITY OF FLORIDA							
FOOD AND DRUG ADMINISTRATION-RESEARCH Total ALN 93	93.103 i.103	FD005407	89,204 1,522,306			89,204 1,522,306	738,324
PASS-THROUGH AWARD FROM:							
CITY OF HOUSTON							
COMPREHENSIVE COMMUNITY MENTAL HEALTH SERVICES FOR CHILDREN WITH SED	93.104	SM082256	484,140			484,140	54,000
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS PASS-THROUGH AWARD FROM:	93.110		_	-	950,682	950,682	59,967
ASSOCIATION OF UNIVERSITY CENTERS ON DISABILITIES MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS UNIVERSITY OF CALIFORNIA - SAN FRANCISCO	93.110	#01-8800-23	-	-	2,925	2,925	-
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER	93.110	MC31881	_	_	238	238	_
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	93.110	MC43532	-	_	277,127	277,127	=
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110 93.110	MC24051-PROGRAM INCOME MC24051	_	_	1,338,891 12,160	1,338,891 12,160	_
Total ALN 93		WC24031		_	2,582,023	2,582,023	59,967
					7 7-	, , , ,	,
ENVIRONMENTAL HEALTH	93.113		3,796,911	=	_	3,796,911	846,733
PASS-THROUGH AWARD FROM: BOSTON CHILDREN'S HOSPITAL							
ENVIRONMENTAL HEALTH	93.113	ES034713	203,315	_	-	203,315	=
THE METHODIST HOSPITAL RESEARCH INSTITUTE ENVIRONMENTAL HEALTH	93.113	ES031511	132,294	-	-	132,294	-

Federal Grantor/Pass-Through Grantor/Program Title		Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)								
PASS-THROUGH AWARD FROM (continued):								
MAINE HEALTH		02 112	E5020101	¢ (90 ¢		e.	\$ 680	e
ENVIRONMENTAL HEALTH TEXAS A&M UNIVERSITY		93.113	ES030101	\$ 680 \$	=	\$ -	\$ 680	2 –
ENVIRONMENTAL HEALTH		93.113	ES033601	325,094	_	_	325,094	_
UNIVERSITY OF MASSACHUSETTS		75.115	125025001	323,074	_	_	323,074	
ENVIRONMENTAL HEALTH		93.113	ES032552	(960)	_	_	(960)	_
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON				()			()	
ENVIRONMENTAL HEALTH		93.113	ES031063	55,355	_	_	55,355	_
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO								
ENVIRONMENTAL HEALTH		93.113	ES031063	42,806	=	=	42,806	
	Total ALN 93.113			4,555,495	-	-	4,555,495	846,733
ORAL DISEASES AND DISORDERS RESEARCH		93.121		2,354,544	_	_	2,354,544	42,271
PASS-THROUGH AWARD FROM:								
THE METHODIST HOSPITAL RESEARCH INSTITUTE ORAL DISEASES AND DISORDERS RESEARCH		93.121	DE021863	11,916			11,916	
UNIVERSITY OF NORTH CAROLINA		93.121	DE021863	11,916	_	_	11,916	_
ORAL DISEASES AND DISORDERS RESEARCH		93.121	DE029754	53,270	_		53,270	_
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER		93.121	DE027754	33,270			33,270	
ORAL DISEASES AND DISORDERS RESEARCH		93.121	DE025248	(3,038)	_	_	(3,038)	_
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER				(-,)			(-,/	
ORAL DISEASES AND DISORDERS RESEARCH		93.121	DE030104	94,114	_	_	94,114	_
ORAL DISEASES AND DISORDERS RESEARCH		93.121	DE032168	51,406	_	-	51,406	_
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON								
ORAL DISEASES AND DISORDERS RESEARCH		93.121	DE033147	26,376	-	-	26,376	-
UNIVERSITY OF UTAH								
ORAL DISEASES AND DISORDERS RESEARCH		93.121	DE027493	672	_	_	672	_
UNIVERSITY OF PITTSBURGH		02.121	DE020227	161 471			171 471	
ORAL DISEASES AND DISORDERS RESEARCH FRED HUTCHINSON CANCER RESEARCH CENTER		93.121	DE032337	161,471	_	_	161,471	_
ORAL DISEASES AND DISORDERS RESEARCH		93.121	DE027850	10,996	_	=	10,996	
OKAL DISEASES AND DISORDERS RESEARCH	Total ALN 93.121	93.121	DE027830	2,761,727			2,761,727	42,271
	100017121			2,701,727			2,701,727	72,2/1
EMERGENCY MEDICAL SERVICES FOR CHILDREN		93.127		_	_	215,361	215,361	_
PASS-THROUGH AWARD FROM:								
COLUMBIA UNIVERSITY								
EMERGENCY MEDICAL SERVICES FOR CHILDREN		93.127	MC00007	_	_	229,660	229,660	_

Federal Grantor/Pass-Through Grantor/Program Title		Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued) PASS-THROUGH AWARD FROM (continued): RESEARCH FOUNDATION FOR STATE OF NEW YORK								
EMERGENCY MEDICAL SERVICES FOR CHILDREN UNIVERSITY OF TEXAS DELL MEDICAL SCHOOL		93.127	MC33154	\$ - \$	-	\$ 95,525	\$ 95,525	\$ -
EMERGENCY MEDICAL SERVICES FOR CHILDREN	Total ALN 93.127	93.127	MC37471			6,923 547,469	6,923 547,469	
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS		93.136		294,765	-	-	294,765	71,914
PASS-THROUGH AWARD FROM: MICHIGAN PUBLIC HEALTH INSTITUTE INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	Total ALN 93.136	93.136	NCFRP/CDC	32,588 327,353			32,588 327,353	
NIEHS SUPERFUND HAZARDOUS SUBSTANCES – BASIC RESEARCH AND EDUCATION		93.143		1,634,668	_	_	1,634,668	673,497
HIV-RELATED TRAINING AND TECHNICAL ASSISTANCE PASS-THROUGH AWARD FROM:								
UNIVERSITY OF NEW MEXICO		93.145	HA33225	506,111	-	-	506,111	_
UNIVERSITY OF ILLINOIS – CHICAGO	Total ALN 93.145	93.145	HA32109	5,735 511,846			5,735 511,846	
CENTERS OF EXCELLENCE		93.157		5,211	-	_	5,211	_
HUMAN GENOME RESEARCH PASS-THROUGH AWARD FROM:		93.172		14,663,746	-	-	14,663,746	3,589,005
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH HUMAN GENOME RESEARCH RICE UNIVERSITY		93.172	HG011711	180,806			180,806	-
RICE UNIVERSITI HUMAN GENOME RESEARCH UNIVERSITY OF COLORADO BOULDER		93.172	HG012206	138,642	-	-	138,642	_
HUMAN GENOME RESEARCH UNIVERSITY OF FLORIDA		93.172	HG011774	56,064	-	-	56,064	-
HUMAN GENOME RESEARCH UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL		93.172	HG010925	36,805	-	-	36,805	=
HUMAN GENOME RESEARCH		93.172	HG009650	72,497	-	-	72,497	-

Federal Grantor/Pass-Through Grantor/Program Title		Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)								
PASS-THROUGH AWARD FROM (continued):								
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON								
HUMAN GENOME RESEARCH		93.172	HG011803	\$ 10,104 \$	=	\$	\$ 10,104	\$ -
HARVARD MEDICAL SCHOOL								
HUMAN GENOME RESEARCH		93.172	HG011016	567,050	_	_	567,050	=
YALE UNIVERSITY HUMAN GENOME RESEARCH		02 172	110012100	20.702			20.702	
HUMAN GENOME RESEARCH	Total ALN 93,172	93.172	HG012108	28,792 15,754,506			28,792 15,754,506	3,589,005
	10tai ALN 95.172			13,734,300	_	_	13,734,306	3,389,003
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS		93.173		3,242,272	-	=	3,242,272	476,755
PASS-THROUGH AWARD FROM:								
UNIVERSITY OF SOUTHERN CALIFORNIA								
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS		93.173	DC014450	18,447	_	_	18,447	-
HARVARD MEDICAL SCHOOL		02 172	DC021.602	10.207			10.207	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS UNIVERSITY OF COLORADO DENVER		93.173	DC021692	19,387	_	_	19,387	_
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS		93.173	DC019642	44,072	_		44,072	_
THE UNIVERSITY OF TEXAS AT AUSTIN		75.175	Bed17012	11,072			11,072	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS		93.173	DC018579	181,613	_	_	181,613	_
	Total ALN 93.173			3,505,791	-	_	3,505,791	476,755
COVID-19 IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION								
TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS		93.185		663,307	_	_	663,307	_
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION TRAINING		02.105		014.554			014.556	
AND CLINICAL SKILLS IMPROVEMENT PROJECTS	Total ALN 93.185	93.185		914,776 1,578,083			914,776	
	10tai ALN 93.185			1,3 /8,083	_	_	1,5/8,083	-
NATIONAL RESEARCH SERVICE AWARD IN PRIMARY CARE MEDICINE		93.186		400,172	-	_	400,172	_
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH		93.213		24,879	-	_	24,879	_
PASS-THROUGH AWARD FROM:								
TEXAS A&M HEALTH SCIENCE CENTER								
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH		93.213	AT011587	85,345		_	85,345	<u> </u>
	Total ALN 93.213			110,224		_	110,224	
NATIONAL RESEARCH SERVICE AWARDS HEALTH SERVICES RESEARCH TRAINING		93.225		(1,577)	_	_	(1,577)	_

	Assistance Listing Number	Pass-Through Entity/Oth	*	Student Financial Assistance	Other Federal	Total Federal	Amounts Provided to
Federal Grantor/Pass-Through Grantor/Program Title	(ALN)	Identifying Number	Cluster	Cluster	Expenditures	Expenditures	Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		\$ 3,502,340	\$ -	\$ -	\$ 3,502,340	\$ 478,487
PASS-THROUGH AWARD FROM:							
MEDSTAR RESEARCH INSTITUTE							
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS029356	280,281	-	-	280,281	-
STANFORD UNIVERSITY							
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS027990	15,185	_	-	15,185	-
UNIVERSITY OF MICHIGAN							
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS026622	8,508			8,508	
	Total ALN 93.226		3,806,314	_	_	3,806,314	478,487
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233		1,724,409			1 724 400	
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233		1,/24,409	_	_	1,724,409	_
MENTAL HEALTH RESEARCH GRANTS	93,242		12,523,928	_	_	12,523,928	2,085,194
PASS-THROUGH AWARD FROM:	33.212		12,020,920			12,020,020	2,003,17
BOSTON CHILDREN'S HOSPITAL							
MENTAL HEALTH RESEARCH GRANTS	93.242	MH130356	477,561	_	_	477,561	_
ALLEN BRAIN INSTITUTE							
MENTAL HEALTH RESEARCH GRANTS	93.242	MH130981	361,882	_	_	361,882	_
PENDLETON BRADLEY HOSPITAL							
MENTAL HEALTH RESEARCH GRANTS	93.242	MH128595	172,638	-	_	172,638	-
CHILDREN'S HOSPITAL OF PHILADELPHIA							
MENTAL HEALTH RESEARCH GRANTS	93.242	MH125958	520,005	-	_	520,005	_
UNIVERSITY OF COLORADO DENVER							
MENTAL HEALTH RESEARCH GRANTS	93.242	MH121362	58,815	-	=	58,815	=
LOUISIANA STATE UNIVERSITY							
MENTAL HEALTH RESEARCH GRANTS	93,242	MH128557	85,564	_	_	85,564	_
RHODE ISLAND HOSPITAL	02.242	N#1106125	5.240			5.240	
MENTAL HEALTH RESEARCH GRANTS UNIVERSITY OF MINNESOTA	93.242	MH106435	5,249	_	_	5,249	_
MENTAL HEALTH RESEARCH GRANTS	93.242	MH126923	85,763		_	85,763	
UNIVERSITY OF MINNESOTA	93.242	MH120923	83,763	_	_	65,765	_
MENTAL HEALTH RESEARCH GRANTS	93.242	MH124687	261,396	_	_	261,396	_
UNIVERSITY OF ILLINOIS	73.272	141112-4007	201,370			201,370	
MENTAL HEALTH RESEARCH GRANTS	93.242	MH131248	32,366	_	_	32,366	_
UNIVERSITY OF PENNSYLVANIA			,			,	
MENTAL HEALTH RESEARCH GRANTS	93.242	MH129439	324,900	-	_	324,900	=
THE UNIVERSITY OF TEXAS AT AUSTIN			*			,	
MENTAL HEALTH RESEARCH GRANTS	93.242	MH127842	78,745	_	_	78,745	_

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON							
MENTAL HEALTH RESEARCH GRANTS	93.242	MH100930	\$ 29,302 \$	- \$	_	\$ 29,302	\$ -
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI							
MENTAL HEALTH RESEARCH GRANTS	93,242	MH111932	15,669	_	_	15,669	=
UNIVERSITY OF PITTSBURGH							
MENTAL HEALTH RESEARCH GRANTS	93.242	MH124983	10,740	_	_	10,740	_
UNIVERSITY OF NORTH CAROLINA							
MENTAL HEALTH RESEARCH GRANTS	93.242	MH128439	56,127	_	_	56,127	_
MENTAL HEALTH RESEARCH GRANTS	93.242	MH118249	17,306	-	-	17,306	=
MENTAL HEALTH RESEARCH GRANTS	93.242	MH124526	42,770	=	_	42,770	=
UNIVERSITY OF WISCONSIN							
MENTAL HEALTH RESEARCH GRANTS	93.242	MH123422	273,561	_	_	273,561	
	Total ALN 93.242		15,434,287	-	-	15,434,287	2,085,194
CURCHANCE ADUCE C MENTAL HEALTH CERVICES DROJECTS OF RECIONAL C							
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES – PROJECTS OF REGIONAL & NATIONAL SIGNIFICANCE	93.243				767,084	767,084	231,317
NATIONAL SIGNIFICANCE	93.243		=	=	707,004	767,084	231,317
PASS-THROUGH AWARD FROM:							
AMERICAN ACADEMY OF ADDICTION PSYCHIATRY							
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL &							
NATIONAL SIGNIFICANCE	93.243	T1081358	_	_	67,911	67,911	_
BEHAVIORAL HEALTH SOLUTIONS	,				V.,	0,1,222	
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL &							
NATIONAL SIGNIFICANCE	93.243	SP082149	_	_	30,214	30,214	_
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL &							
NATIONAL SIGNIFICANCE	93,243	TI086081	_	_	21,938	21,938	=
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL &							
NATIONAL SIGNIFICANCE	93.243	TI086247	_	_	22,261	22,261	_
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL &							
NATIONAL SIGNIFICANCE	93.243	TI085219	_	-	131,068	131,068	=
SANTA MARIA HOSTEL							
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL &							
NATIONAL SIGNIFICANCE	93.243	TI086411	_	_	19,705	19,705	_
HOUSTON RECOVERY CENTER							
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL &	02.5.13	T1003000			20.410	22 ***	
NATIONAL SIGNIFICANCE	93.243	TI083986	=	=	32,418	32,418	=

Federal Grantor/Pass-Through Grantor/Program Title		Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued) PASS-THROUGH AWARD FROM (continued): CITY OF HOUSTON								
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL &		02.242	GB000200	d d		e 12.42	m 12.642	e.
NATIONAL SIGNIFICANCE	Total ALN 93.243	93.243	SP080300	<u>\$</u> - \$	_	\$ 13,643 1,106,242	\$ 13,643 1,106,242	231,317
OCCUPATIONAL SAFETY AND HEALTH PROGRAM		93.262		215,179	-	-	215,179	249,074
PASS-THROUGH AWARD FROM: NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES		93.262	ОН012201	(218)	_	-	(218)	_
UNIVERSITY OF PITTSBURGH								
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	Total ALN 93.262	93.262	ОН009077	98,900 313,861			98,900 313,861	249,074
	Total ALIV 93.202			313,601	_	_	313,601	247,074
ALCOHOL RESEARCH PROGRAMS		93.273		697,963	=	=	697,963	281,713
PASS-THROUGH AWARD FROM:								
VANDERBILT UNIVERSITY				40.044				
ALCOHOL RESEARCH PROGRAMS SCRIPPS RESEARCH INSTITUTE		93.273	AA029542	19,344	_	_	19,344	_
ALCOHOL RESEARCH PROGRAMS		93.273	AA021667	47,286	_	_	47,286	_
	Total ALN 93.273			764,593	-	-	764,593	281,713
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS		93.279		1,479,386			1,479,386	208,733
PASS-THROUGH AWARD FROM:								
MASSACHUSETTS GENERAL HOSPITAL								
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS		93.279	DA047933	122,993	_	_	122,993	_
UNIVERSITY OF ALABAMA AT BIRMINGHAM DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS		93.279	DA056673	(1,243)	_	_	(1,243)	_
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON								
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS		93.279	DA053241	343,084	-	-	343,084	_
UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS		93.279	DA040621	48,688	_	_	48,688	_
	Total ALN 93.279			1,992,908	_	_	1,992,908	208,733

Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster			Total Federal Expenditures	Amounts Provided to Subrecipients
93.286		\$ 1,315,446 \$	- \$	- 5	1,315,446	\$ 372,074
93.286	EB028520	(6,697)	=	_	(6,697)	=
93.286	EB028156	17,885	-	_	17,885	_
93.286	EB030772	6,228	-	-	6,228	=
93.286	EB034652	131,741	_	-	131,741	_
93.286	EB029064	8,902	-	_	8,902	-
93.286	EB032169	69,473	-	-	69,473	_
93.286	E026453	(180)			(180)	
93.307		2,723,803	-	-	2,723,803	510,198
93.307	MD014127	16,860	_	_	16,860	_
93.307	MD007597	30 302	_	-		_
93.307	MD018933	52,076	_	_	52,076	_
	Listing Number (ALN) 93.286 93.286 93.286 93.286 93.286 93.286 93.286 93.286 93.307 93.307 93.307	Listing Number (ALN) Pass-Through Entity/Other Identifying Number 93.286 EB028520 93.286 EB028156 93.286 EB030772 93.286 EB030772 93.286 EB034652 93.286 EB029064 93.286 EB032169 93.286 E026453 93.307 MD014127 93.307 MD007597 93.307 MD007605	Listing Number (ALN) Pass-Through Entity/Other Identifying Number Research and Development Cluster 93.286 \$ 1,315,446 \$ 93.286 EB028520 (6,697) 93.286 EB028156 17,885 93.286 EB030772 6,228 93.286 EB034652 131,741 93.286 EB029064 8,902 93.286 EB032169 69,473 93.286 E026453 (180) 93.307 MD014127 16,860 93.307 MD007597 32 93.307 MD007605 39,392	Listing Number Pass-Through Entity/Other Identifying Number Research and Development Cluster Financial Assistance Cluster Ex 93.286 \$ 1,315,446 \$ - \$ \$ 93.286 EB028520 (6,697) - \$ 93.286 EB028156 17,885 - \$ 93.286 EB030772 6,228 - \$ 93.286 EB034652 131,741 - \$ 93.286 EB029064 8,902 - \$ 93.286 EB032169 69,473 - \$ 93.286 EB032169 69,473 - \$ 93.307 MD014127 16,860 - \$ 93.307 MD014127 16,860 - \$ 93.307 MD007597 32 - \$ 93.307 MD007605 39,392 - \$	Listing Number (ALN) Pass-Through Entity/Other Identifying Number Research and Development Cluster Assistance Cluster Pederal Expenditures 93.286 \$ 1,315,446 \$ \$ \$ 93.286 \$ 28028520 \$	Number Pass-Through Entity/Other (ALN) Pass-Through Entity/Other (ALN) Research and Development Cluster Cluster Expenditures Expenditures

Federal Grantor/Pass-Through Grantor/Program Title		Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)								
PASS-THROUGH AWARD FROM (continued):								
UNIVERSITY OF HOUSTON								
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH		93.307	MD15946	\$ 83,440 \$	-	\$ -	83,440	\$ -
THE UNIVERSITY OF TEXAS AT AUSTIN MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH		93.307	MD37471	81,827			81,827	
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH		93.307	MD009675	32.847	_	_	32,847	_
	Total ALN 93.307	75.507	MD007075	3,030,277	_		3,030,277	510,198
				, ,			, ,	,
COVID-19 TRANS-NIH RESEARCH SUPPORT		93.310		4,306	_	_	4,306	=
TRANS-NIH RESEARCH SUPPORT		93.310		12,690,740	_	_	12,690,740	1,764,146
DAGG TUDOUGU AWADD FROM								
PASS-THROUGH AWARD FROM: BETH ISRAEL DEACONESS MEDICAL CENTER								
TRANS-NIH RESEARCH SUPPORT		93.310	TR002881	2,774	_	_	2,774	=
HARVARD MEDICAL SCHOOL		23.310	11002001	2,77.			2,77.	
TRANS-NIH RESEARCH SUPPORT		93.310	HG007530	103,386	_	_	103,386	_
MASSACHUSETTS GENERAL HOSPITAL								
TRANS-NIH RESEARCH SUPPORT		93.310	OD023253	23,908	-	_	23,908	-
MEDICAL COLLEGE OF WISCONSIN								
TRANS-NIH RESEARCH SUPPORT		93.310	HG010423	90	_	_	90	_
RTI INTERNATIONAL TRANS-NIH RESEARCH SUPPORT		93.310	OD034190	35,545			35,545	
UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAGNE		93.310	00034190	33,343	_	_	33,343	_
TRANS-NIH RESEARCH SUPPORT		93.310	OD023272	6,630	_	_	6,630	_
UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER				,			,	
TRANS-NIH RESEARCH SUPPORT		93.310	OD032581	421,432	_	_	421,432	
	Total ALN 93.310			13,288,811	_	_	13,288,811	1,764,146
RARE DISORDERS: RESEARCH, SURVEILLANCE, HEALTH PROMOTION, AND EDUCATION		93.315		49,599			49,599	
RARE DISORDERS. RESEARCH, SURVEILLANCE, HEALTH PROMOTION, AND EDUCATION		93.313		49,399	_	_	49,399	=
PASS-THROUGH AWARD FROM:								
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON								
EPIDEMIOLOGY AND LABORATORY CAPACITY FOR INFECTIOUS DISEASE		93.323	HHS001089700001		_	1,041,309	1,041,309	<u> </u>
	Total ALN 93.323			_	-	1,041,309	1,041,309	_
COVID-19 STRENGTHENING PUBLIC HEALTH THROUGH SURVEILLANCE, EPIDEMIOLOGIC RESEARCH. DISEASE DETECTION		93.326		101.530			101,530	
RESEARCH, DISEASE DETECTION STRENGTHENING PUBLIC HEALTH THROUGH SURVEILLANCE, EPIDEMIOLOGIC RESEARCH	ı	93.320		101,530	_	_	101,530	_
DISEASE DETECTION	^,	93.326		627,164	_	_	627,164	_
	Total ALN 93.326			728,694	=	_	728,694	=
70				•			•	2503-1117-CS
· -								2505 1117 00

Federal Grantor/Pass-Through Grantor/Program Title		Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)								
HEALTH PROFESSIONS STUDENT LOANS, INCLUDING PRIMARY CARE LOANS/								
LOANS FOR DISADVANTAGED STUDENTS		93.342		\$ - \$	183,497	\$ -	\$ 183,497	\$ -
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES		93.350		583,091	_	_	583,091	80,047
PASS-THROUGH AWARD FROM:								
THE BRIGHAM & WOMEN'S HOSPITAL								
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES DYSTONIA MEDICAL RESEARCH FOUNDATION		93.350	TR003201	86,323	-	-	86,323	-
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES		93.350	TR001456	24,117	_	_	24,117	=
WASHINGTON UNIVERSITY		33.550	11001150	21,117			2 1,111	
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES		93.350	TR002764	37,652	_	_	37,652	_
	Total ALN 93.350			731,183	-	-	731,183	80,047
RESEARCH INFRASTRUCTURE PROGRAMS		93.351		6,431,922	-	-	6,431,922	341,615
PASS-THROUGH AWARD FROM:								
UNIVERSITY OF WISCONSIN								
RESEARCH INFRASTRUCTURE PROGRAMS		93.351	OD011106	71,619	_	_	71,619	<u> </u>
	Total ALN 93.351			6,503,541	_	_	6,503,541	341,615
21ST CENTURY CURES ACT – BEAU BIDEN CANCER MOONSHOT		93.353		767,028	_	_	767,028	2,499
PASS-THROUGH AWARD FROM:								
CHILDREN'S HOSPITAL OF PHILADELPHIA								
21ST CENTURY CURES ACT – BEAU BIDEN CANCER MOONSHOT		93.353	CA023568	70,828	_	_	70,828	=
FRED HUTCHINSON CANCER RESEARCH CENTER		02.252	0.154067	(150)			(150)	
21ST CENTURY CURES ACT – BEAU BIDEN CANCER MOONSHOT THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER		93.353	CA154967	(150)	_	_	(150)	_
21ST CENTURY CURES ACT – BEAU BIDEN CANCER MOONSHOT		93.353	DE028233	101,052			101,052	
21ST CENTURY CURES ACT – BEAU BIDEN CANCER MOONSHOT		93.353	CA224081	6,227			6,227	_
21ST CENTURY CURES ACT – BEAU BIDEN CANCER MOONSHOT		93.353	CA224081 CA274321	505,215	_	_	505,215	_
UNIVERSITY OF ALABAMA AT BIRMINGHAM		75.555	0.12.113.21	303,213			303,213	
21ST CENTURY CURES ACT – BEAU BIDEN CANCER MOONSHOT		93.353	CA246567	51,944	_	_	51,944	=
UNIVERSITY OF UTAH				,			**	
21ST CENTURY CURES ACT – BEAU BIDEN CANCER MOONSHOT		93.353	CA224076	313,470	-	-	313,470	<u> </u>
	Total ALN 93.353			1,815,614		=	1,815,614	2,499

Federal Grantor/Pass-Through Grantor/Program Title		Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued) NURSING RESEARCH		93,361		\$ 1,654,899	s _	\$ -	\$ 1,654,899	\$ 335,784
		75.501		ф 1,03 4 ,0 <i>7</i>)	ф	Ψ	ψ 1,05 1 ,077	\$ 333,764
PASS-THROUGH AWARD FROM: <i>UNIVERSITY OF MICHIGAN</i>								
NURSING RESEARCH		93.361	NR013658	126,863	_	_	126,863	94,335
AKRON CHILDREN'S HOSPITAL		00.054	NAME OF THE PARTY					
NURSING RESEARCH UNIVERSITY OF IOWA		93.361	NR020608	54,615	=	_	54,615	_
NURSING RESEARCH		93.361	NR017610	119,285	-	_	119,285	_
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON NURSING RESEARCH		93.361	NR017837	(390)	=	_	(390)	
NORSING RESEARCH	Total ALN 93.361	93.301	141017657	1,955,272			1,955,272	430,119
21ST CENTURY CURES ACT – PRECISION MEDICINE INITIATIVE		93.368		40,699,024	-	_	40,699,024	3,636,113
PASS-THROUGH AWARD FROM:								
UNIVERSITY OF UTAH								
21ST CENTURY CURES-ACT – PRECISION MEDICINE INITIATIVE	Total ALN 93.368	93.368	OD028414	31,545 40,730,569	_	_	31,545 40,730,569	3,636,113
	10tal ALIN 93.308			40,730,309	_	_	40,730,309	3,030,113
ACTIVITIES TO SUPPORT STATE, TRIBAL, LOCAL AND TERRITORIAL (STLT) HEALTH								
DEPARTMENT RESPONSE TO PUBLIC HEALTH OR HEALTHCARE CRISES		93.391		153,325	-	_	153,325	_
CANCER CAUSE AND PREVENTION RESEARCH		93.393		11,074,845	-	-	11,074,845	2,313,347
PASS-THROUGH AWARD FROM:								
CITY OF HOPE RESEARCH INSTITUTE CANCER CAUSE AND PREVENTION RESEARCH		93,393	CA242218	87,793		_	87,793	
DARTMOUTH COLLEGE		93.393	CA242216	87,793			81,193	
CANCER CAUSE AND PREVENTION RESEARCH		93.393	CA243449	41,958	=	-	41,958	-
GEORGE WASHINGTON UNIVERSITY CANCER CAUSE AND PREVENTION RESEARCH		93.393	CA181255	321,161	_	_	321,161	_
BRIGHAM AND WOMEN'S HOSPITAL								
CANCER CAUSE AND PREVENTION RESEARCH MAYO CLINIC		93.393	CA124633	6,966	_	_	6,966	_
CANCER CAUSE AND PREVENTION RESEARCH		93.393	CA275065	55,312	-	-	55,312	_
MEDICAL UNIVERSITY OF SOUTH CAROLINA CANCER CAUSE AND PREVENTION RESEARCH		93,393	CA282165	31,604		_	31,604	
CANCER CAUSE AND PREVENTION RESEARCH		35.575	CA262103	31,004	_	_	31,004	_

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEBARTMENT OF HEALTH AND HUMAN CERVICES / d. D.							
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued) PASS-THROUGH AWARD FROM (continued):							
VNIVERSITY OF NORTH CAROLINA – CHAPEL HILL							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA276663	\$ 21,361 \$	_	\$ -	\$ 21,361	e
NORTHWESTERN UNIVERSITY	93.393	CA2/0003	\$ 21,301 \$	_	.	\$ 21,301	5 –
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA225002	65,831		_	65,831	
CANCER CAUSE AND PREVENTION RESEARCH UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	93.393	CA225002	05,831	_	_	05,831	_
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA225478	3,133		_	3,133	
TEXAS A&M HEALTH SCIENCE CENTER	93.393	CA223478	3,133	_	_	3,133	_
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA262623	(794)			(794)	
UNIVERSITY OF ALABAMA AT BIRMINGHAM	93.393	CA202023	(794)	_	-	(794)	_
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA213140	23,920		_	23,920	
CANCER CAUSE AND PREVENTION RESEARCH		CA213140 CA220502		_			_
	93.393	CA220502	29,557	_	-	29,557	_
UNIVERSITY OF SOUTHERN CALIFORNIA	93.393	CA250000	25 744			25.744	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA258808	35,744	_	_	35,744	_
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA214253 CA257328	28,309 12	_	_	28,309	_
CANCER CAUSE AND PREVENTION RESEARCH				_	-	12	_
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA262263	54,684	_	-	54,684	_
RUTGERS UNIVERSITY	02.202	CA277012	22.241			22.241	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA277812	22,341	_	_	22,341	_
ST JUDE CHILDREN'S RESEARCH HOSPITAL	02.202	G1250056	10.045			10.047	
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA258856	18,047	=	_	18,047	=
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA284455	257,177	_	_	257,177	=
VANDERBILT UNIVERSITY		G					
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA275082	247,197	_	_	247,197	=
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA269589	18,118	-	-	18,118	=
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA225005	8,186	_	_	8,186	=
STANFORD UNIVERSITY							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA217105	299,569	-	_	299,569	-
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA232754	258,834	_	_	258,834	_
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA239342	72,022	_	_	72,022	_
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA231141	4,750	_	-	4,750	_
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA260761	30,940	_	_	30,940	_
UNIVERSITY OF MINNESOTA							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA239701	45,295	-	-	45,295	=
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA212008	26,825	_	_	26,825	_

Federal Grantor/Pass-Through Grantor/Program Title		Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)								
PASS-THROUGH AWARD FROM (continued):								
UNIVERSITY OF WISCONSIN								
CANCER CAUSE AND PREVENTION RESEARCH		93.393	CA253911	\$ 61,965 \$	- \$	- 5	61,965	\$ -
ARIZONA STATE UNIVERSITY								
CANCER CAUSE AND PREVENTION RESEARCH		93.393	CA237118	277,078	_	_	277,078	
	Total ALN 93.393			13,529,740	_	_	13,529,740	2,313,347
CANCER DETECTION AND DIAGNOSIS RESEARCH		93.394		3,995,944	_	_	3,995,944	840,031
PASS-THROUGH AWARD FROM:								
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER								
CANCER DETECTION AND DIAGNOSIS RESEARCH		93.394	CA214263	64,790	-	_	64,790	-
CANCER DETECTION AND DIAGNOSIS RESEARCH		93.394	CA271888	45,522	_	_	45,522	=
CANCER DETECTION AND DIAGNOSIS RESEARCH		93.394	CA280980	95,970	_	_	95,970	=
CANCER DETECTION AND DIAGNOSIS RESEARCH		93.394	CA195524	56,967	_	_	56,967	=
CHILDREN'S HOSPITAL OF PHILADELPHIA								
CANCER DETECTION AND DIAGNOSIS RESEARCH		93.394	CA193776	72,372	_	_	72,372	=
DANA-FARBER CANCER INSTITUTE								
CANCER DETECTION AND DIAGNOSIS RESEARCH		93.394	CA230503	5,741	_	_	5,741	_
UNIVERSITY OF NORTH CAROLINA								
CANCER DETECTION AND DIAGNOSIS RESEARCH		93.394	CA259926	8,365	-	_	8,365	_
FRED HUTCHINSON CANCER RESEARCH CENTER								
CANCER DETECTION AND DIAGNOSIS RESEARCH		93.394	CA271873	16,281	-	_	16,281	-
CANCER DETECTION AND DIAGNOSIS RESEARCH		93.394	CA230144	2,357	-	_	2,357	-
ARIZONA STATE UNIVERSITY								
CANCER DETECTION AND DIAGNOSIS RESEARCH		93.394	CA281660	53,306	-	_	53,306	=
NORTHWESTERN UNIVERSITY								
CANCER DETECTION AND DIAGNOSIS RESEARCH		93.394	CA200064	15,732	=	=	15,732	=
RICE UNIVERSITY								
CANCER DETECTION AND DIAGNOSIS RESEARCH		93.394	CA252245	317,870	-	_	317,870	_
CANCER DETECTION AND DIAGNOSIS RESEARCH		93.394	CA255894	70,144	_	_	70,144	_
UNIVERSITY OF MARYLAND								
CANCER DETECTION AND DIAGNOSIS RESEARCH		93.394	CA255753	6,775	_	_	6,775	-
OREGON HEALTH SCIENCE UNIVERSITY								
CANCER DETECTION AND DIAGNOSIS RESEARCH		93.394	CA281902	200,923	_	_	200,923	_
UNIVERSITY OF PITTSBURGH								
CANCER DETECTION AND DIAGNOSIS RESEARCH		93.394	CA139408	1,512	_	-	1,512	-
WASHINGTON UNIVERSITY		02.204	N. COORDO	100.000			100 000	
CANCER DETECTION AND DIAGNOSIS RESEARCH		93.394	MC027865	182,988	_	_	182,988	=
CANCER DETECTION AND DIAGNOSIS RESEARCH		93.394	CA273194	54,283	_	_	54,283	_
74								2503-1117-CS

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Li Nu	sistance .isting umber ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)								
PASS-THROUGH AWARD FROM (continued):								
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER								
CANCER DETECTION AND DIAGNOSIS RESEARCH		3.394	CA086368	\$ 173,675 \$	-	\$ -		\$ -
CANCER DETECTION AND DIAGNOSIS RESEARCH	93	3.394	CA271887	187,165	_	_	187,165	=
NSABP								
CANCER DETECTION AND DIAGNOSIS RESEARCH		3.394	CA196067	220,668	_		220,668	
	Total ALN 93.394			5,849,350	_	_	5,849,350	840,031
CANCER TREATMENT RESEARCH	93	3.395		10,715,823	-	-	10,715,823	1,575,298
PASS-THROUGH AWARD FROM:								
CHILDREN'S HOSPITAL OF LOS ANGELES								
CANCER TREATMENT RESEARCH	93	3.395	CA252236	1,393	_	_	1,393	_
EMORY UNIVERSITY								
CANCER TREATMENT RESEARCH	93	3.395	CA277686	35,624	_	_	35,624	_
CEDARS-SINAI MEDICAL CENTER								
CANCER TREATMENT RESEARCH	93	3.395	CA266694	32,932	-	-	32,932	=
DANA FARBER CANCER INSTITUTE								
CANCER TREATMENT RESEARCH	93	3.395	CA222486	5,823	-	_	5,823	_
RICE UNIVERSITY								
CANCER TREATMENT RESEARCH	93	3.395	CA277838	236,962	-	_	236,962	_
TEXAS A&M HEALTH SCIENCE CENTER								
CANCER TREATMENT RESEARCH	93	3.395	CA277257	50,821	_	_	50,821	=
UNIVERSITY OF CHICAGO	0.3	2 205	CA260420	17.001			17 001	
CANCER TREATMENT RESEARCH UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER - HOUSTON	93	3.395	CA269429	17,881	_	_	17,881	_
CANCER TREATMENT RESEARCH	O.S.	3.395	CA276513	7,907		_	7,907	
WRIGHT STATE UNIVERSITY	9-	3.373	CA270313	1,901	_	_	7,907	_
CANCER TREATMENT RESEARCH	93	3.395	CA280075	11,388	_	_	11,388	_
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	,	0.000	5.20076	77,000			11,000	
CANCER TREATMENT RESEARCH	93	3.395	CA039542	262,207	_	_	262,207	_
JACKSON LABORATORY				,			,	
CANCER TREATMENT RESEARCH	93	3.395	CA237307	9,726	_	_	9,726	_
KAISER PERMANENTE								
CANCER TREATMENT RESEARCH	93	3.395	CA260689	305,570	_	_	305,570	=
MASSACHUSETTS GENERAL HOSPITAL								
CANCER TREATMENT RESEARCH	93	3.395	CA261669	55,580	-	=	55,580	-

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
NORTHWESTERN UNIVERSITY							
CANCER TREATMENT RESEARCH	93.395	CA120813	\$ 105,684	s –	s –	\$ 105,684	s –
CANCER TREATMENT RESEARCH	93.395	CA228272	298,081	_	_	298,081	_
ST JUDE CHILDREN'S RESEARCH HOSPITAL	75.575	0.1220272	250,001			270,001	
CANCER TREATMENT RESEARCH	93.395	CA181457	70,156	_	_	70,156	_
UNIVERSITY OF MINNESOTA	,5.5,5	0.1101.157	, 0,150			70,150	
CANCER TREATMENT RESEARCH	93.395	CA239701	30,924	_	_	30,924	_
TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	0.20,101	00,52			20,,2	
CANCER TREATMENT RESEARCH	93.395	CA263988	134,913	_	_	134,913	_
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	75.075	0.1205700	10 1,5 10			12 1,5 12	
CANCER TREATMENT RESEARCH	93,395	CA254988	14,821	_	_	14,821	_
CANCER TREATMENT RESEARCH	93.395	CA275138	26,765	_	_	26,765	_
CANCER TREATMENT RESEARCH	93.395	CA275762	45,494	_	_	45,494	_
CANCER TREATMENT RESEARCH	93,395	CA255596	54,556	_	_	54,556	_
CANCER TREATMENT RESEARCH	93.395	CA235620	87,019	_	_	87,019	_
NRG ONCOLOGY FOUNDATION, INC			,			<i>'</i>	
CANCER TREATMENT RESEARCH	93.395	CA180868	4,414	_	_	4,414	_
OREGON HEALTH & SCIENCE UNIVERSITY			,			ŕ	
CANCER TREATMENT RESEARCH	93.395	CA180888	56,042	_	_	56,042	_
PUBLIC HEALTH INSTITUTE			,			<i>'</i>	
CANCER TREATMENT RESEARCH	93.395	CA180886	479,593	_	_	479,593	_
CANCER TREATMENT RESEARCH	93.395	CA189955	8,350	_	_	8,350	_
CANCER TREATMENT RESEARCH	93.395	CA228823	346,906	_	_	346,906	_
CANCER TREATMENT RESEARCH	93.395	CA233249	37,655	_	_	37,655	_
SEATTLE CHILDREN'S RESEARCH INSTITUTE							
CANCER TREATMENT RESEARCH	93.395	CA222486	23,578	_	_	23,578	_
UNIVERSITY OF NORTH CAROLINA							
CANCER TREATMENT RESEARCH	93.395	CA148761	249,657	-	_	249,657	_
CANCER TREATMENT RESEARCH	93.395	CA259926	7,426	_	_	7,426	_
CHILDREN'S HOSPITAL OF PHILADELPHIA							
CANCER TREATMENT RESEARCH	93.395	CA180886	153,654	_	_	153,654	_
CANCER TREATMENT RESEARCH	93.395	CA228823	37,127	_	_	37,127	_
CANCER TREATMENT RESEARCH	93.395	CA233249	627			627	
	Total ALN 93.395		14,023,079	-	-	14,023,079	1,575,298

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued) CANCER BIOLOGY RESEARCH	93.396		\$ 16,791,328 \$	- \$	=	\$ 16,791,328	\$ 2,258,618
CANCER BIOLOGT RESEARCH	93.390		\$ 10,791,326 \$	_ ı	_	5 10,791,328	\$ 2,236,016
PASS-THROUGH AWARD FROM:							
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER							
CANCER BIOLOGY RESEARCH	93.396	CA255080	6,759	_	_	6,759	_
CANCER BIOLOGY RESEARCH	93.396	CA240526	6,817	_	_	6,817	_
CANCER BIOLOGY RESEARCH	93.396	CA248731	52,158	_	_	52,158	_
CANCER BIOLOGY RESEARCH	93.396	CA262437	2,331	_	_	2,331	_
CANCER BIOLOGY RESEARCH	93.396	CA236781	9,912	_	_	9,912	_
CANCER BIOLOGY RESEARCH	93.396	CA266187	6,432	_	_	6,432	_
BRIGHAM AND WOMEN'S HOSPITAL							
CANCER BIOLOGY RESEARCH	93.396	CA285308	5,760	_	_	5,760	_
OHIO STATE UNIVERSITY							
CANCER BIOLOGY RESEARCH	93.396	CA264525	289,019	_	_	289,019	_
UNIVERSITY OF CALIFORNIA - SAN FRANCISCO							
CANCER BIOLOGY RESEARCH	93.396	CA255369	14,419	-	_	14,419	_
WASHINGTON UNIVERSITY							
CANCER BIOLOGY RESEARCH	93.396	CA275304	7,977	_	_	7,977	_
HEALTH RESEARCH, INC.							
CANCER BIOLOGY RESEARCH	93.396	CA251545	189,457	_	_	189,457	_
LURIE CHILDREN'S HOSPITAL OF CHICAGO							
CANCER BIOLOGY RESEARCH	93.396	CA217613	23,776	_	_	23,776	_
THE METHODIST HOSPITAL RESEARCH INSTITUTE							
CANCER BIOLOGY RESEARCH	93.396	CA253553	312,685	_	_	312,685	_
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI							
CANCER BIOLOGY RESEARCH	93.396	CA154947	370,764	_	_	370,764	_
RICE UNIVERSITY							
CANCER BIOLOGY RESEARCH	93.396	CA258512	352	-	_	352	_
UNIVERSITY OF CALIFORNIA, BERKELEY							
CANCER BIOLOGY RESEARCH	93.396	CA260205	209,465	_	_	209,465	=
UNIVERSITY OF CALIFORNIA, IRVINE							
CANCER BIOLOGY RESEARCH	93.396	CA228140	46,018	=	_	46,018	=
UNIVERSITY OF COLORADO DENVER							
CANCER BIOLOGY RESEARCH	93.396	CA224867	133,291	_	_	133,291	=
UNIVERSITY OF FLORIDA							
CANCER BIOLOGY RESEARCH	93.396	CA263574	199,929	-	_	199,929	=
UNIVERSITY OF HOUSTON							
CANCER BIOLOGY RESEARCH	93.396	CA256543	41,904	-	_	41,904	_

Federal Grantor/Pass-Through Grantor/Program Title		Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued) PASS-THROUGH AWARD FROM (continued):								
UNIVERSITY OF NEW MEXICO								
CANCER BIOLOGY RESEARCH		93.396	CA206980	\$ 485 \$	_	\$ -	\$ 485	\$
	Total ALN 93.396			18,721,038	-	-	18,721,038	2,258,618
COVID-19 CANCER CENTERS SUPPORT GRANTS		93.397		(35,826)	_	_	(35,826)	=
CANCER CENTERS SUPPORT GRANTS		93.397		9,443,323	=	-	9,443,323	711,040
PASS-THROUGH AWARD FROM:								
UNIVERSITY OF UTAH								
CANCER CENTERS SUPPORT GRANTS THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER		93.397	CA224076	204,296	-	=	204,296	=
CANCER CENTERS SUPPORT GRANTS		93.397	CA127001	243,038	_	_	243,038	-
SOUTHWEST ONCOLOGY GROUP		03.207	G1100000	122.000			122 000	
CANCER CENTERS SUPPORT GRANTS UNIVERSITY OF ALABAMA AT BIRMINGHAM		93.397	CA180888	123,908	_	_	123,908	_
CANCER CENTERS SUPPORT GRANTS		93.397	CA107399	11,171	_	_	11,171	<u> </u>
	Total ALN 93.397			9,989,910	-	-	9,989,910	711,040
CANCER RESEARCH MANPOWER		93.398		1,953,150	-	-	1,953,150	=
CANCER CONTROL		93.399		1,708,473			1,708,473	646,006
PASS-THROUGH AWARD FROM:								
CHILDREN'S HOSPITAL OF PHILADELPHIA			~					
CANCER CONTROL NRG ONCOLOGY FOUNDATION, INC		93.399	CA189955	16,158	_	_	16,158	_
CANCER CONTROL		93.399	CA189867	208,181	-	_	208,181	_
<i>NSABP</i> CANCER CONTROL		93.399	FB-13	(0.040)			(0.040)	
PUBLIC HEALTH INSTITUTE		93.399	FB-13	(9,949)	-	_	(9,949)	=
CANCER CONTROL		93.399	CA189955	102,427	_		102,427	
	Total ALN 93.399			2,025,290	-	_	2,025,290	646,006
PASS-THROUGH AWARD FROM:								
AMERICAN PUBLIC HEALTH ASSOCIATION								
STRENGTHENING PUBLIC HEALTH SYSTEMS AND SERVICES THROUGH NATIONAL PARTNERSHIPS TO IMPROVE AND PROTECT THE NATION'S HEALTH		93.421	CDC OT000294	(381)	-	_	(381)	_

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM:							
TIRR MEMORIAL HERMANN							
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING & REHABILITATION RESEARCH	93.433	90DPCP0010	\$ 30,212 \$	-	s –	\$ 30,212	\$
UNIVERSITY OF HOUSTON	93.433	90DFCF0010	\$ 50,212 4	-	, –	5 30,212	.
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING &							
REHABILITATION RESEARCH	93.433	90IFST006	29,966	_	_	29,966	
Total ALN 93.433			60,178	-	-	60,178	_
CONGRESSIONAL DIRECTIVES	93.493		328,490	-	-	328,490	13,277
GLOBAL TUBERCULOSIS: DEVELOPING, EVALUATING, IMPLEMENTING EVIDENCE-BASED AND INNOVATIVE APPROACHES TO FIND. CURE. AND PREVENT TUBERCULOSIS GLOBALLY	93,494				1,323,728	1,323,728	819.080
AND INNOVATIVE APPROACHES TO FIND, CORE, AND PREVENT TOBERCOLOSIS GLOBALLY	93.494		_	_	1,323,726	1,323,726	819,080
PASS-THROUGH AWARD FROM:							
TEXAS DEPARTMENT OF FAMILY AND PROTECTIVE SERVICES							
TEMPORARY ASSISTANCE FOR NEEDY FAMILIES	93.558	HHS000791900013	=	-	913,683	913,683	=
PASS-THROUGH AWARD FROM:							
TEXAS DEPARTMENT OF FAMILY AND PROTECTIVE SERVICES							
COMMUNITY-BASED CHILD ABUSE PREVENTION GRANTS	93.590	HHS000855300003	_	-	1,826,790	1,826,790	336,065
TEXAS COUNCIL FOR DEVELOPMENTAL DISABILITIES							
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	23511	_	_	198,258	198,258	_
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	22411	_	_	40,547	40,547	_
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	22412	_	_	(968)	(968)	_
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS Total ALN 93.630	93.630	23102			140,851 378,688	140,851 378,688	
Total AEN 95.050	'		_	_	370,000	370,000	_
PASS-THROUGH AWARD FROM:							
HARRIS HEALTH SYSTEM							
MATERNAL OPIOID MISUSE MODEL	93.687	CMS331766	_	-	81,346	81,346	=
MENTAL AND BEHAVIORAL HEALTH EDUCATION AND TRAINING GRANTS	93.732		198,532	-	_	198,532	_

Federal Grantor/Pass-Through Grantor/Program Title (ALN) Identifying Number Cluster Expenditures Expenditures	
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued) CARDIOVASCULAR DISEASES RESEARCH 93.837 \$ 14,732,747 \$ - \$ - \$ 14,732,747 \$	1,356,211
CAMDIOVASCULAR DISEASES RESEARCH 9 14,732,747 4 4 4 14,732,747 4	1,330,211
PASS-THROUGH AWARD FROM:	
THE BRIGHAM & WOMEN'S HOSPITAL, INC	
CARDIOVASCULAR DISEASES RESEARCH 93.837 HL135008 31,191 – – 31,191	_
CARDIOVASCULAR DISEASES RESEARCH 93.837 HL148218 (19,721) – – (19,721)	_
CARDIOVASCULAR DISEASES RESEARCH 93.837 HL150342 5,769 – – 5,769	_
CARDIOVASCULAR DISEASES RESEARCH 93.837 HL150311 3,315 3,315	_
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	
CARDIOVASCULAR DISEASES RESEARCH 93.837 HL152108 17,430 – – 17,430	_
CARDIOVASCULAR DISEASES RESEARCH 93.837 HL163549 23,639 – – 23,639	_
CARDIOVASCULAR DISEASES RESEARCH 93.837 HL156059 155,573 – – 155,573	_
EAST CAROLINA UNIVERSITY	
CARDIOVASCULAR DISEASES RESEARCH 93.837 HL142544 26,379 – – 26,379	_
JOHNS HOPKINS UNIVERSITY	
CARDIOVASCULAR DISEASES RESEARCH 93.837 HL096812 240,923 – – 240,923	_
CARDIOVASCULAR DISEASES RESEARCH 93.837 HL146907 167,116 – – 167,116	_
MASSACHUSETTS GENERAL HOSPITAL	
CARDIOVASCULAR DISEASES RESEARCH 93.837 HL123336 217 217	_
PENNSYLVANIA STATE UNIVERSITY	
CARDIOVASCULAR DISEASES RESEARCH 93.837 HL137763 3,600 – – 3,600	_
UNIVERSITY OF HOUSTON	
CARDIOVASCULAR DISEASES RESEARCH 93.837 HL146745 107,257 - - - 107,257	_
CARDIOVASCULAR DISEASES RESEARCH 93.837 HL126145 22,917 - - - 22,917	_
NEW YORK UNIVERSITY	
CARDIOVASCULAR DISEASES RESEARCH 93.837 HL096812 14,469 - - - 14,469	_
BOSTON CHILDREN'S HOSPITAL	
CARDIOVASCULAR DISEASES RESEARCH 93.837 HL164373 39,538 - - - 39,538	_
UNIVERSITY OF LOUISVILLE	
CARDIOVASCULAR DISEASES RESEARCH 93.837 HL168688 5,604 - - - 5,604	_
UNIVERSITY OF MICHIGAN	
CARDIOVASCULAR DISEASES RESEARCH 93.837 HL135691 1,452 - - - 1,452	_
UNIVERSITY OF PITTSBURGH	
CARDIOVASCULAR DISEASES RESEARCH 93.837 HL152740 15,479 - - - 15,479	-
UNIVERSITY OF TEXAS SOUTHWEST	
CARDIOVASCULAR DISEASES RESEARCH 93.837 HL148218 60,023 - - - 60,023	_
UNIVERSITY OF KENTUCKY	
CARDIOVASCULAR DISEASES RESEARCH 93.837 HL166280 144,292 – 144,292	=

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
EMORY UNIVERSITY							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL157323	\$ 35,609 \$	_	\$ -	\$ 35,609	\$ -
STANFORD UNIVERSITY							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL159176	263,007	_	_	263,007	_
UNIVERSITY OF ALABAMA AT BIRMINGHAM							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL120338	31,506	_	_	31,506	_
UNIVERSITY OF MINNESOTA							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL059367	97,596	_	_	97,596	_
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL155509	42,025	_	_	42,025	=
UNIVERSITY OF NORTH CAROLINA							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL152034	37,981	_	_	37,981	=
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	02.025	VV 150040	15014			15014	
CARDIOVASCULAR DISEASES RESEARCH UNIVERSITY OF WISCONSIN	93.837	HL159960	15,814	_	_	15,814	_
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL149404	42,071			42,071	
RICE UNIVERSITY	93.837	IIL149404	42,071	_	_	42,071	_
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL140305	7,350		_	7,350	
WASHINGTON UNIVERSITY	93.837	HL140303	7,330	_	_	7,550	_
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL105400	9,453		_	9,453	
YALE UNIVERSITY	75.657	1112103400	7,433			7,455	
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL141852	7,121	_	_	7,121	_
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL163984	55,125	_	_	55,125	_
	I ALN 93.837		16,443,867	_	_	16,443,867	1,356,211
			,,			,,	-,,
LUNG DISEASES RESEARCH	93.838		1,681,680	-	-	1,681,680	30,150
PASS-THROUGH AWARD FROM:							
THE BRIGHAM & WOMEN'S HOSPITAL, INC							
LUNG DISEASES RESEARCH	93.838	HL130974	366,659	-	-	366,659	=
CHILDRENS HOSPITAL MEDICAL CENTER, CINCINNATI							
LUNG DISEASES RESEARCH	93.838	HL157392	42,334	=	=	42,334	=
CHILDREN'S HOSPITAL OF PHILADELPHIA							
LUNG DISEASES RESEARCH	93.838	HL148054	(2)	_	_	(2)	_
JOHNS HOPKINS UNIVERSITY							
LUNG DISEASES RESEARCH	93.838	HL151458	6,927	-	-	6,927	_
RUTGERS UNIVERSITY	92.926	III 161047	00.052			00.052	
LUNG DISEASES RESEARCH	93.838	HL161847	99,052	_	_	99,052	_

Federal Grantor/Pass-Through Grantor/Program Title		Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
rederal Grantof/rass-1 mough Grantof/rrogram Title		(ALN)	ruentifying Number	Cluster	Cluster	Expenditures	Expenditures	Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)								
PASS-THROUGH AWARD FROM (continued):								
UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER								
COVID-19 LUNG DISEASES RESEARCH		93.838	6922-03-COVID-S012	\$ 158,866 \$	=	\$ -	\$ 158,866	\$ -
UNIVERSITY OF ALABAMA AT BIRMINGHAM								
LUNG DISEASES RESEARCH		93.838	HL133232	9,287	-	_	9,287	_
LUNG DISEASES RESEARCH		93.838	HL155806	20,147	_	_	20,147	_
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON								
LUNG DISEASES RESEARCH		93.838	HL157100	14,506	_	_	14,506	_
THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON								
LUNG DISEASES RESEARCH		93.838	HL145477	562,302	-	_	562,302	_
WAYNE STATE UNIVERSITY								
LUNG DISEASES RESEARCH		93.838	HL148247	24,719	_	_	24,719	_
YALE UNIVERSITY								
LUNG DISEASES RESEARCH		93.838	HL141852	8,902	_		8,902	
	Total ALN 93.838			2,995,379	_	_	2,995,379	30,150
BLOOD DISEASES AND RESOURCES RESEARCH		93.839		5,479,223	-	=	5,479,223	658,148
PASS-THROUGH AWARD FROM:								
AUGUSTA UNIVERSITY								
BLOOD DISEASES AND RESOURCES RESEARCH		93.839	HL106365	3,317	-	_	3,317	_
BLOOD DISEASES AND RESOURCES RESEARCH		93.839	HL106635	5,170		_	5,170	_
CHILDRENS HOSPITAL MEDICAL CENTER, CINCINNATI								
BLOOD DISEASES AND RESOURCES RESEARCH		93.839	HL133883	10,969	_	_	10,969	_
CLEVELAND CLINIC FOUNDATION								
BLOOD DISEASES AND RESOURCES RESEARCH		93.839	HL140097	(9,340)	_	_	(9,340)	_
EMORY UNIVERSITY								
BLOOD DISEASES AND RESOURCES RESEARCH		93.839	HL148560	71,839	-	_	71,839	_
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER								
BLOOD DISEASES AND RESOURCES RESEARCH		93.839	HL124112	44,485	_	_	44,485	_
BLOOD WORKS NORTHWEST								
BLOOD DISEASES AND RESOURCES RESEARCH		93.839	HL152200	40,298	-	_	40,298	_
MEDICAL COLLEGE OF WISCONSIN								
BLOOD DISEASES AND RESOURCES RESEARCH		93.839	HL157560	458	_	_	458	_
RUTGERS UNIVERSITY								
BLOOD DISEASES AND RESOURCES RESEARCH		93.839	HL133817	369	_	_	369	_
UNIVERSITY OF HOUSTON								
BLOOD DISEASES AND RESOURCES RESEARCH		93.839	HL151858	151,155			151,155	
	Total ALN 93.839			5,797,943	-	_	5,797,943	658,148

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM: NEW YORK UNIVERSITY							
TRANSLATION AND IMPLEMENTATION SCIENCE	93.840	HL169364	\$ 17,803 \$	_	s –	\$ 17,803	s –
THE HOLITICAL THE BEIND ATTENDED TO BE SEED	75.010	TIDIO530 I	Ψ 17,000 Ψ		•	17,000	•
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846		9,355,826	_	_	9,355,826	2,411,945
PASS-THROUGH AWARD FROM:							
LURIE CHILDREN'S HOSPITAL OF CHICAGO							
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR079113	1,243	_	_	1,243	_
UNIVERSITY OF MASSACHUSETTS CHAN MEDICAL SCHOOL ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR076411	6,894			6,894	
TUFTS UNIVERSITY	93.040	AR0/0411	0,094	_	_	0,094	_
BLOOD DISEASES AND RESOURCES RESEARCH	93.846	AR076411	(1,532)	_	_	(1,532)	_
UNIVERSITY OF ROCHESTER			(-,)			(-,)	
BLOOD DISEASES AND RESOURCES RESEARCH	93.846	AR080627	30,983	_	_	30,983	_
UNIVERSITY OF MICHIGAN							
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR078073	47,616	-	=	47,616	=
UNIVERSITY OF MINNESOTA	02.046	A P.O.42.422	110 200			110 200	
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH Total ALN 93	93.846	AR042423	119,390 9,560,420			9,560,420	2,411,945
Total ALIV 5.	3.040		9,300,420	_	_	9,500,420	2,411,943
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		30,582,849	=	=	30,582,849	5,572,199
PASS-THROUGH AWARD FROM:							
UNIVERSITY OF IOWA							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK108334	98,492	=	=	98,492	=
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	22.045	DV-194049	660.040			660.240	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	DK126042 DK122708	669,249 3,246	_	_	669,249 3,246	_
CHILDREN'S HOSPITAL OF CHICAGO	93.847	DK122/08	3,240	_	_	3,240	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118612	53,527	_	_	53,527	_
CHILDREN'S HOSPITAL COLORADO	351017		05,011			00,02	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK062453	(75)	_	_	(75)	-
CASE WESTERN RESERVE UNIVERSITY							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK130931	144,003	_	_	144,003	=
COLUMBIA UNIVERSITY							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK104309	21,577	_	_	21,577	_
DUKE UNIVERSITY DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121710	10,967		_	10,967	
UNIVERSITY OF UTAH	73.077	DK121/10	10,507	_	_	10,907	_
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK114456	43,411	_	_	43,411	_
			,				

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK119200	\$ 12,670 \$	- :	\$	\$ 12,670	\$ -
UNIVERSITY OF COLORADO							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126710	3,691	_	_	3,691	_
UNIVERSITY OF COLORADO DENVER							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117001	(2,561)	-	_	(2,561)	_
UNIVERSITY OF MICHIGAN							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK081943	7,837	_	_	7,837	=
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK083912	2,537	_	_	2,537	_
JOHNS HOPKINS UNIVERSITY							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126825	98,282	_	_	98,282	_
GEORGE WASHINGTON UNIVERSITY							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK098246	1,566	_	_	1,566	=
LURIE CHILDREN'S HOSPITAL OF CHICAGO	02.847	DK 127005	16.547			16.547	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	DK127995	16,547 3,223	_	=	16,547	_
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH NEW YORK UNIVERSITY	93.847	DK072493	3,223	_	=	3,223	_
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK130517	234,497			234,497	
OREGON HEALTH & SCIENCE UNIVERSITY	93.847	DK130317	234,497	_	_	234,497	_
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK123115	61,639			61,639	
SAINT LOUIS UNIVERSITY	93.047	DK123113	01,039			01,039	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK061718	173,073	_	_	173,073	_
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134531	121,526	_	_	121,526	_
UNIVERSITY OF TEXAS MEDICAL BRANCH - GALVESTON	351617	51215 1551	121,020			121,020	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129474	22,769	_	_	22,769	_
TEMPLE UNIVERSITY			,			,	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK132642	253,282	_	_	253,282	_
SEATTLE CHILDREN'S RESEARCH INSTITUTE							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121224	92,838	_	_	92,838	_
UNIVERSITY OF CALIFORNIA, LOS ANGELES							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122013	8,982	_	_	8,982	=
UNIVERSITY OF CALIFORNIA, SAN DIEGO							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK097771	82,634	-	_	82,634	_
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120886	(677)	=	=	(677)	=
UNIVERSITY OF SOUTHERN CALIFORNIA							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124789	61,668	_	_	61,668	_

84 2503-1117-CS

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK115761	\$ - \$	- \$	_	\$ -	\$ -
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK108328	(148)	-	-	(148)	=
VANDERBILT UNIVERSITY		777424045	#0.00 <i>c</i>			#0.00 6	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124845	70,996	_	_	70,996	=
CHILDREN'S HOSPITAL OF PHILADELPHIA	93.847	DV0//174	1 207			1 207	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH CHILDRENS HOSPITAL MEDICAL CENTER. CINCINNATI	93.847	DK066174	1,207	_	_	1,207	_
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK107436	17,214		_	17,214	
UNIVERSITY OF HOUSTON	93.047	DK107430	17,217	_	_	17,214	_
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117476	686	_	_	686	_
UNIVERSITY OF KENTUCKY	75.017	DICTI TO	000			000	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK095662	20,250	_	_	20,250	_
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL						,	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124614	17,827	_	_	17,827	_
RESEARCH INSTITUTE AT NATIONWIDE							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK100866	2,208	_	_	2,208	=
AMERICAN PSYCHOLOGICAL ASSOCIATON							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118763	23,446	-	_	23,446	_
UNIVERSITY OF SOUTH FLORIDA							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128847	174,602	_		174,602	<u> </u>
Total ALN 9	3.847		33,211,557	-	_	33,211,557	5,572,199
EVED AND DATA DESCRIPCIO DE OCRAMO IN THE NEUDOSCIENCES & NEUDOLOGICAL DISORDERS	02.952		22.082.660			22.092.660	5.052.120
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS PASS-THROUGH AWARD FROM:	93.853		32,082,669	_	_	32,082,669	5,952,139
CHILDREN'S RESEARCH INSTITUTE							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS118008	934	_	_	934	_
THE BRIGHAM & WOMEN'S HOSPITAL, INC							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS113890	268,754	_	_	268,754	-
CHILDREN'S HOSPITAL OF PHILADELPHIA							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS115052	22,459	-	-	22,459	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS130216	7,560	-	_	7,560	_

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS113329	\$ 592	\$ -	\$ -	\$ 592	\$ -
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS113893	(2,226)	_	_	(2,226)	_
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS121040	30,068	_	_	30,068	_
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL	02.052	2/01/22/55	255 505			255.505	
DISORDERS	93.853	NS133657	255,785	_	_	255,785	_
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NG110806	07.262			07.262	
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL	93.833	NS110806	97,363	_	_	97,363	_
DISORDERS	93.853	NS115886	281			281	
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL	93.033	NS113660	201	_	_	201	_
DISORDERS	93.853	NS128921	14,192	_	_	14,192	_
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL	73.033	115120921	14,172			14,172	
DISORDERS	93.853	NS125487	(30,863)	_	_	(30,863)	_
COLUMBIA UNIVERSITY	75.055	110120107	(50,005)			(30,003)	
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS078059	24,722	_	_	24,722	_
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL			,			,	
DISORDERS	93.853	NS110826	198,920	_	_	198,920	_
HARVARD MEDICAL SCHOOL			· · · · · · · · · · · · · · · · · · ·			,	
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS118402	339,085	_	_	339,085	_
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS132415	913,424	_	_	913,424	_
FEINSTEIN INSTITUTE OF MEDICAL RESEARCH							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS113893	20,881	_	_	20,881	_
KENNEDY KRIEGER INSTITUTE							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS098482	139,400	_	_	139,400	_
NORTHWESTERN UNIVERSITY							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL	02.052	NG100074	24.552			24.552	
DISORDERS	93.853	NS108874	24,553	_	_	24,553	_
TEXAS A&M UNIVERSITY							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS106907					
	93.833	N2100A01	_	_	_	_	_
86							2503-1117-CS

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
UNIVERSITY OF MICHIGAN							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL				_			_
DISORDERS	93.853	NS099046	\$ 119,678 \$	- \$	_	\$ 119,678	\$ -
DUKE UNIVERSITY							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS112917	375,173			375,173	
MAYO CLINIC	93.833	NS112917	3/3,1/3	_	_	3/3,1/3	_
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS115198	24,511			24,511	
HOUSTON METHODIST RESEARCH INSTITUTE	93.833	N3113176	24,311			24,511	
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS126115	80,147	_	_	80,147	_
RICE UNIVERSITY	73.003	115120115	00,117			00,117	
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS126063	105,716	_	_	105,716	_
RUSH UNIVERSITY MEDICAL CENTER			,			,	
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS125294	8,924	_	_	8,924	=
THE ROCKEFELLER UNIVERSITY							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS126057	128,579	_	_	128,579	_
STANFORD UNIVERSITY							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS114042	43,755	_	-	43,755	_
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS112280	901	_	_	901	=
UNIVERSITY OF ALABAMA AT BIRMINGHAM							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS124141	206,462	_	_	206,462	=
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL	00.040	277420500	46440			46440	
DISORDERS	93.853	NS128600	16,413	_	_	16,413	=
UNIVERSITY OF PITTSBURGH							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL	93.853	NIC101557	11 025			11 025	
DISORDERS UNIVERSITY OF COLORADO DENVER	93.833	NS121557	11,835	_	_	11,835	_
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL							
DISORDERS	93.853	NS114312	23,292	_	_	23,292	_
DISTABLAS	73.033	110111312	23,292	_		23,292	_

Federal Grantor/Pass-Through Grantor/Program Title		Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)								
PASS-THROUGH AWARD FROM (continued):								
UNIVERSITY OF HOUSTON								
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL		00.050	270104650			•		
DISORDERS		93.853	NS124650	\$ 5,089 \$	_	\$ -	\$ 5,089	\$ -
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL		93.853	NC117044	6 207			6 207	
DISORDERS UNIVERSITY OF MINNESOTA		93.833	NS117944	6,397	_	_	6,397	_
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL								
DISORDERS		93.853	NS132207	28,112	_	_	28,112	_
ST. JUDE RESEARCH HOSPITAL		75.055	110132207	20,112			20,112	
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL								
DISORDERS		93.853	CA280978	114,222	_	_	114,222	_
UNIVERSITY OF PENNSYLVANIA								
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL								
DISORDERS		93.853	NS113339	21,178	_	_	21,178	_
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL								
DISORDERS		93.853	NS114140	17,167	_	-	17,167	=
UNIVERSITY OF ROCHESTER								
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL		02.052	NG110246	24.250			24.250	
DISORDERS		93.853	NS118246	34,250	_	_	34,250	_
UNIVERSITY OF UTAH EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL								
DISORDERS		93,853	NS107486	20,605	_	_	20,605	_
UNIVERSITY OF WISCONSIN		93.633	11310/480	20,003			20,003	
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL								
DISORDERS		93.853	NS115102	101,399	_	_	101,399	_
WILLIAM BEAUMONT HOSPITAL RESEARCH INSTITUTE				,			,	
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL								
DISORDERS		93.853	NS110838	16,344		=	16,344	
	Total ALN 93.853			35,918,702	-	_	35,918,702	5,952,139
COVID-19 ALLERGY AND INFECTIOUS DISEASES RESEARCH		93.855		1,643,056	_	_	1,643,056	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH		93.855		23,704,262	_	_	23,704,262	2,868,566
PASS-THROUGH AWARD FROM: BENAROYA RESEARCH INSTITUTE								
ALLERGY AND INFECTIOUS DISEASES RESEARCH		93,855	AI109565	3,358			3,358	
BOSTON CHILDREN'S HOSPITAL		13.633	A1107505	3,330	_	_	3,336	_
ALLERGY AND INFECTIOUS DISEASES RESEARCH		93,855	AI125051	(7)	_	_	(7)	_
			****	(1)			(/)	

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
Tederal Grancol Pass Through Grancol Program Tele	(FEET)	rumber	Cluster	Cluster	Lapenditures	Expenditures	Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
BOSTON CHILDREN'S HOSPITAL (continued)							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI173142	\$ 142,356 \$	- 5	\$	\$ 142,356	\$
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI126614	127,965	_	_	127,965	=
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI154470	48,594	_	_	48,594	=
THE BRIGHAM & WOMEN'S HOSPITAL, INC							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI165967	6,926	_	-	6,926	_
CHILDREN'S HOSPITAL OF PENNSYLVANIA							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI171055	12,499	_	_	12,499	_
EAST CAROLINA UNIVERSITY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI146930	104,397	_	_	104,397	_
GEORGE WASHINGTON UNIVERSITY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI117970	(1,584)	_	_	(1,584)	_
WASHINGTON UNIVERSITY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI141716	132,033	_	_	132,033	_
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI159677	117,046	_	_	117,046	_
UNIVERSITY OF UTAH							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI125301	24,982	_	_	24,982	_
EMORY UNIVERSITY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI148684	80,332	_	_	80,332	_
THE METHODIST HOSPITAL RESEARCH INSTITUTE						ŕ	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI176558	89,039	_	_	89,039	_
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI152999	869,544	_	_	869,544	=
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI165372	5,188	_	_	5,188	_
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI167659	7,684	_	_	7,684	=
OHIO STATE UNIVERSITY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI156732	32,653	_	_	32,653	_
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI055449	30,584	_	_	30,584	_
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI152999	598	_	_	598	=
COLUMBIA UNIVERSITY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI067773	96,251	_	_	96,251	_
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI120989	14,910	_	_	14,910	_
GEORGIA STATE UNIVERSITY			,			,	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI170014	417,061	_	_	417,061	_
UNIVERSITY OF ARKANSAS						, , , , ,	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI156101	24,335	_	_	24,335	_
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI170892	125,501	_	_	125,501	_
		*****	.==,= 0.1			,,,,,,,	

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
UNIVERSITY OF CALIFORNIA, LOS ANGELES							
COVID-19 ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI159946	\$ 60,806 \$	_	\$ -	\$ 60,806	\$ -
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI068636	13,718	-	_	13,718	_
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI066967	66,014	_	_	66,014	_
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI169239	692	-	-	692	_
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI082973	452	-	_	452	_
UNIVERSITY OF FLORIDA							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI042288	14,639	-	_	14,639	=
LIBERTY UNIVERSITY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI164100	2,591	_	_	2,591	_
UNIVERSITY OF SOUTH CAROLINA							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI165560	264,086	_	_	264,086	_
UNIVERSITY OF PITTSBURGH							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI032539	94,967	_	-	94,967	_
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI174526	82,740	_	-	82,740	_
TEXAS A&M HEALTH SCIENCE CENTER							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI144459	9,514	_	_	9,514	_
TEXAS TECH UNIVERSITY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI135197	63,652	_	-	63,652	_
UNIVERSITY OF CALGARY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI165327	89,573	-	-	89,573	=
UNIVERSITY OF HOUSTON							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI133697	(370)	_	_	(370)	=
UNIVERSITY OF KENTUCKY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI169231	87,002	_	_	87,002	_
UNIVERSITY OF MINNESOTA							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI171954	1,132,423	_	_	1,132,423	_
MASSACHUSETTS GENERAL HOSPITAL							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI153558	26,454	_	_	26,454	_
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI175965	119,450	_	_	119,450	_
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI134940	(8,016)	_	_	(8,016)	_
JOHNS HOPKINS UNIVERSITY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI068632	18,694	_	_	18,694	_
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI130836	939,302	_	_	939,302	_
WASHINGTON UNIVERSITY - ST. LOUIS	02.055	11152260	#0.0:=			-0.0:-	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI173360	59,013	=	=	59,013	=

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
PENNSYLVANIA STATE UNIVERSITY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI176505	\$ 223,175 \$	_	\$ -	\$ 223,175	\$ -
UNIVERSITY OF OKLAHOMA							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI170605	8,405	_	_	8,405	-
UNIVERSITY OF WISCONSIN-MADISON							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI154597	134,324	_	_	134,324	_
CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI117804	49,945	_	_	49,945	=
NEW YORK STATE HEALTH							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI144891	10,221	-	_	10,221	=
RICE UNIVERSITY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI167037	65,926	-	_	65,926	_
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI171477	106,967	_	_	106,967	_
TULANE UNIVERSITY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI062907	81,467	_	_	81,467	_
VANDERBILT UNIVERSITY							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI167799	3,658	_		3,658	
	Total ALN 93.855		31,681,047	_	_	31,681,047	2,868,566
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		15,785,362	_	_	15,785,362	187,329
PASS-THROUGH AWARD FROM:							
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM072804	22,415	_	_	22,415	_
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM139801	37,590	_	_	37,590	_
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM125640	9,226	_	_	9,226	_
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM130838	8,462	_	_	8,462	_
PACIFIC NORTHWEST RESEARCH INSTITUTE							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM132589	16,296	_	_	16,296	=
TEXAS A&M UNIVERSITY							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM132436	69,501	-	_	69,501	_
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM145416	641,965	_	_	641,965	-
COLUMBIA UNIVERSITY							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	AI150470	118,158	_	_	118,158	_
UNIVERSITY OF ILLINOIS							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM136384	29,193	_	-	29,193	
	Total ALN 93.859		16,738,168	_	_	16,738,168	187,329

91 2503-1117-CS

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		\$ 24,779,469	s –	s –	\$ 24,779,469	\$ 2,925,861
PASS-THROUGH AWARD FROM:			,,,,,,,,			, , , , , ,	, , , , , , , ,
BOSTON UNIVERSITY							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD101421	43,717	_	_	43,717	=
CHILDREN'S HOSPITAL OF PHILADELPHIA							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD101528	118,149	_	_	118,149	=
CHILDREN'S NATIONAL MEDICAL CENTER			,			ŕ	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD099131	6,313	_	_	6,313	_
CHILDREN'S RESEARCH INSTITUTE							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD061221	179,946	_	_	179,946	_
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD094213	11,859	_	_	11,859	_
COLUMBIA UNIVERSITY			,			<u> </u>	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD055651	231,905	_	_	231,905	_
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD107451	84,374	_	_	84,374	_
CORNELL UNIVERSITY			- ,			. , , .	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD109392	17,004	_	_	17,004	_
INDIANA UNIVERSITY	301000	120,00,2	17,001			11,001	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD107120	253,866	_	_	253,866	_
THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD095976	10,134	_	_	10,134	_
THE NEMOURS FOUNDATION	351005	113032370	10,12			10,151	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD100985	110,296	_	_	110,296	_
HARVARD MEDICAL SCHOOL	30.000		,			,	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD103133	564,394	_	_	564,394	_
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD101351	28,708	_	_	28,708	_
GEORGE WASHINGTON UNIVERSITY	73.000	115101331	20,700			20,700	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD036801	10,298	_	_	10,298	_
WEILL MEDICAL COLLEGE	75.005	115030001	10,290			10,270	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD111089	161,707	_	_	161,707	_
TEMPLE UNIVERSITY	75.000	115111005	101,707			101,707	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD109362	35,259	_	_	35,259	_
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	33.005	115103502	20,207			20,207	
COVID-19 CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD105618	28,000	_	_	28,000	_
JOHNS HOPKINS UNIVERSITY	73.000	115100010	20,000			20,000	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD103811	3,904	_	_	3,904	_
UNIVERSITY OF COLORADO DENVER	75.005	115103011	3,701			3,201	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD098415	11,411	_	=	11,411	=
UNIVERSITY OF HOUSTON	75.005	110070410	11,711			11,711	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93,865	HD095520	1,156	_	_	1,156	=
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD086765	157,834	_	_	157,834	_
92	75.005	1115000705	157,054			157,654	
94							2503-1117-CS

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
UNIVERSITY OF MISSOURI	22.065	HD100100	d 00.410 d			A 00.410	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH UNIVERSITY OF UT4H	93.865	HD108198	\$ 89,418 \$	- 5	-	\$ 89,418	5 –
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD105462	11,201		_	11,201	
UNIVERSITY OF WISCONSIN	93.803	HD103402	11,201	_	_	11,201	_
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	75N93021C00006	75,269		_	75,269	
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	95.805	751493021200000	13,209			73,209	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD093660	(522)	_	_	(522)	_
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD105173	18,655	_	_	18,655	_
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD108201	10,813	_	_	10,813	_
NEW YORK UNIVERSITY							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD100929	8,727	_	_	8,727	_
	Total ALN 93.865		27,063,264	-	_	27,063,264	2,925,861
COVID-19 AGING RESEARCH	93.866		342	_	_	342	=
AGING RESEARCH	93.866		19,594,868	-	_	19,594,868	1,184,599
PASS-THROUGH AWARD FROM:							
BAYLOR SCOTT AND WHITE RESEARCH INSTITUTE							
AGING RESEARCH	93.866	AG061973	174,200	_	_	174,200	=
BOSTON UNIVERSITY	02.066	4.00.50.500	255.245			255.265	
AGING RESEARCH	93.866	AG058589	277,365	_	_	277,365	=
DUKE UNIVERSITY AGING RESEARCH	93,866	A C070140	2.776			2.776	
AGING RESEARCH EMORY UNIVERSITY	93.800	AG070149	2,776	_	_	2,776	_
AGING RESEARCH	93.866	AG061357	37.643		_	37,643	
AGING RESEARCH	93.866	AG065187	125,768	_	_	125,768	_
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	75.000	AG005187	123,700			123,700	
AGING RESEARCH	93.866	AG078755	182,119	_	_	182,119	_
NEW YORK UNIVERSITY	351666	113010700	102,117			102,117	
AGING RESEARCH	93.866	AG069822	12,374	_	_	12,374	=
OREGON HEALTH & SCIENCE			,			ŕ	
AGING RESEARCH	93.866	AG079356	6,071	_	_	6,071	_
PENNINGTON BIOMEDICAL RESEARCH CENTER							
AGING RESEARCH	93.866	AG073204	10,396	_	_	10,396	_
OHIO STATE UNIVERSITY							
AGING RESEARCH	93.866	AG058822	6,601	_	_	6,601	-

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
RICE UNIVERSITY							
AGING RESEARCH	93.866	AG061597	\$ 6,143 \$	- 5	-	\$ 6,143	s _
AGING RESEARCH	93.866	AG075946	12.974	_ `	_	12,974	_
AGING RESEARCH	93.866	AG062690	15,106	_	_	15,106	_
AGING RESEARCH	93.866	AG074229	89,998	_	_	89,998	_
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE	75.000	1100/122)	07,770			0,,,,0	
AGING RESEARCH	93.866	AG071464	54,767	_	_	54,767	_
WAKE FOREST UNIVERSITY HEALTH SCIENCES	75.000	1100/1404	54,707			54,707	
AGING RESEARCH	93,866	AG062689	790,475	_	_	790,475	_
AGING RESEARCH	93.866	AG058969	37,241	_	_	37,241	_
AGING RESEARCH	93.866	AG063744	10,670	_	_	10,670	_
AGING RESEARCH	93.866	AG064440	100,565		_	100,565	_
UNIVERSITY OF ARIZONA	75.000	110004440	100,303			100,505	
AGING RESEARCH	93.866	AG065169	261,515	_	_	261,515	_
UNIVERSITY OF CALIFORNIA, LOS ANGELES	33.000	110003109	201,515			201,515	
AGING RESEARCH	93.866	AG036695	427	_	_	427	_
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	75.000	110030073	427			72/	
AGING RESEARCH	93.866	AG064025	12,049	_	_	12,049	_
UNIVERSITY OF HOUSTON	33.000	11004025	12,049			12,049	
AGING RESEARCH	93.866	AG065170	8,471	_	_	8,471	_
UNIVERSITY OF FLORIDA	75.000	710003170	0,471			0,471	
AGING RESEARCH	93.866	AG083902	21,815	_	_	21,815	_
UNIVERSITY OF SOUTHERN CALIFORNIA	33.000	110003702	21,013			21,015	
AGING RESEARCH	93.866	AG010483	80,150	_	_	80,150	_
AGING RESEARCH	93.866	AG024904	68,429	_	_	68,429	_
AGING RESEARCH	93.866	AG053798	580	_	_	580	_
AGING RESEARCH	93.866	AG063689	127,925	_	_	127,925	_
AGING RESEARCH	93.866	AG054029	334,966	_	_	334,966	_
AGING RESEARCH	93.866	AG061848	94,802	_	_	94,802	_
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	75.000	110001040	74,002			74,002	
AGING RESEARCH	93.866	AG069466	37,772	_	_	37,772	_
AGING RESEARCH	93.866	AG078523	13,797	_	_	13,797	_
AGING RESEARCH	93.866	AG082132	36,506	_	_	36,506	_
AGING RESEARCH	93.866	AG083962	24,781	_	_	24,781	_
AGING RESEARCH	93.866	AG084130	5,426	_	_	5,426	_
AGING RESEARCH	93.866	AG074226	211,719	_	_	211,719	=
AGING RESEARCH	93.866	AG076144	2,850	_	_	2,850	=
AGING RESEARCH	93.866	AG057587	223,289	_	_	223,289	_
. Total and the state of the st	75.000	11003/30/	223,207			223,267	

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued): UNIVERSITY OF WISCONSIN							
AGING RESEARCH	93.866	AG068515	\$ 27,732 \$	_	\$ -	\$ 27,732	•
WASHINGTON UNIVERSITY	23.000	A000313	\$ 27,732 \$		Ψ —	\$ 21,132	<u> </u>
AGING RESEARCH	93.866	AG070436	61,926	_	_	61,926	_
Total ALN 93.866			23,205,389	-	-	23,205,389	1,184,599
VISION RESEARCH	93.867		13,927,686		_	13,927,686	1,194,965
PASS-THROUGH AWARD FROM:	93.807		13,927,000	_	_	13,927,080	1,194,903
JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC							
VISION RESEARCH	93.867	EY011751	29,104	_	_	29,104	_
VISION RESEARCH	93.867	EY014231	92,699	_	_	92,699	_
VISION RESEARCH	93.867	EY030030	9,828	_	_	9,828	_
RICE UNIVERSITY							
VISION RESEARCH	93.867	EY032596	83,114	_	_	83,114	_
JOHNS HOPKINS UNIVERSITY							
VISION RESEARCH	93.867	EY033103	19,058	-	=	19,058	=
NEW YORK UNIVERSITY		TV-100-00-00	(0.000)			(2.22)	
COVID-19 VISION RESEARCH	93.867	EY026869	(2,230)	_	_	(2,230)	_
UNIVERSITY OF HOUSTON VISION RESEARCH	93.867	EY034671	3,407		_	3,407	
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO	93.807	E10346/1	3,407	_	_	3,407	_
VISION RESEARCH	93.867	EY032898	24,455	_	_	24,455	_
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	75.007	E1032030	21,133			21,133	
VISION RESEARCH	93.867	EY032768	31,759	_	_	31,759	_
Total ALN 93.867			14,218,880	-	_	14,218,880	1,194,965
PASS-THROUGH AWARD FROM:							
RICE UNIVERSITY							
MEDICAL LIBRARY ASSISTANCE	93.879	LM007093	(3,203)	_	_	(3,203)	_
UNIVERSITY OF CENTRAL OKLAHOMA							
MEDICAL LIBRARY ASSISTANCE	93.879	LM013938	82,702		=	82,702	
Total ALN 93.879			79,499	-	_	79,499	_
PRIMARY CARE TRAINING AND ENHANCEMENT	93.884		98,339	_	_	98,339	_
NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	93.889		_	_	2,055,150	2,055,150	840,908

PASS-TRECOUGH AWARD FROM	Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
### RECULUP_INC HEAD_PASS—THROUGH AWARD FROME TAXS DEPIRTMENT OF STATE HEALITH DEPARTMENT BASED **PASS—THROUGH AWARD FROME THEVEREPTOR ACTIVITIES, HEALITH DEPARTMENT BASED **PASS—THROUGH AWARD FROME **FORGULA STATE LEARITHES, HEALITH DEPARTMENT BASED **PASS—THROUGH AWARD FROME **FORGULA STATE LEARITHES, HEALITH DEPARTMENT BASED **PASS—THROUGH AWARD FROME **FORGULA STATE LEARITHES, HEALITH DEPARTMENT BASED **PASS—THROUGH AWARD FROME **FORGULA STATE LEARITHES, HEALITH DEPARTMENT BASED **PASS—THROUGH AWARD BROME **FORGULA STATE LEARITHES, HEALITH DEPARTMENT BASED **PASS—THROUGH AWARD BROME **BURDENIOL SERIES ARE TRUBLES OF ALIDS AND HIV INFECTION IN SELECTED **POPULATION GROUPS **POPULATI	· · · · · · · · · · · · · · · · · · ·							
PASS-TIROUGH AW AND FROM: TAXA SEPARMENT OF SLATE HALITHISERVICES HAVE PREVENTION ACTIVITIES, HEALTH DEPARTMENT BASED PASS-TIROUGH AW AND FROM: FLORIDA STATE LIMITHISERVICES HAVE PREVENTION ACTIVITIES, HEALTH DEPARTMENT BASED PASS-TIROUGH AW AND FROM: FLORIDA STATE LIMITHISERVICES HAVE PROBLEM STATE HALITH SERVICES HAVE PROBLEM STATE LIMITHISERVICES HAVE PROBLEM STATE LIMITHISER PROBLEM STATE HALITH SERVICES HAVE PROBLEM STATE LIMITHISER PR								
PASS-THROUGH AWARD FROM: TEXAS DEPARTMENT OF STATE HEALTH SERVICES HIV PREVENTION ACTIVITIES LIEACHT DEPARTMENT BASED 93.940 BISGOGT7800010 - 138,003 138,003 - 188,005 138,005 138,005 - 188,005 138,005 138,005 138,005 138,005 138,005 138,005 1							_	
### PREVISION ACTIVITIES BEALTH DEPARTMENT BASED 93.940 18.000077800100	HEALTHY START INITIATIVE	93.926	H49MC12793	\$ - \$	=	\$ -	\$ -	\$ -
HIV PREVENTION ACTIVITIES_HEALTH DEPARTMENT BASED	PASS-THROUGH AWARD FROM:							
PASS-THROUGH AWARD FROM: FLORIDA STATE LOWIZERSHTY HIV DEMONSTRATION, RISEARCH, PUBLIC AND PROFESSIONAL EDUCATION PROJECTS 93.941 PS005246 7,067 - 0 7,067 - 7,067 - 7 PASS-THROUGH AWARD FROM: CUNIPERSITY OF ILLINOIS EPIDEMOLOGIC RESEARCH STUDIES OF AIDS AND HIV INFECTION IN SELECTED POPULATION GROUPS 93.943 PS005246 5,775 - 0 5,775 - 0 COOPERATIVE AGREEMENTS TO SUPPORT STATE-BASED SAFE MOTHERHOOD AND INFERNAT HEALTH PASS-THROUGH AWARD FROM: SANTA MARIA HOSTIEL BLOCK GRANTS FOR PREVENTION AND TREATMENT OF SUBSTANCE ABUSE 93.959 B08T1083545 - 0 95.486 95.486 - 0 PHILE JUNIFICATION FOR PREVENTION AND TREATMENT OF SUBSTANCE ABUSE 93.959 HINSO104250003 - 0 95.601 576.017 576.017 - 0 PPHF GERIATRIC EDUCATION CENTERS 93.969 TW012940 50.01 13.401 - 1 113.401 - 1 INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 TW01294 16.911 - 0 16.911 - 0 INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 TW012974 26.540 - 1 26.540 - 2 26.540 - 0 INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 TW012974 26.540 - 0 26.540 - 2 26.540 - 0 26.	TEXAS DEPARTMENT OF STATE HEALTH SERVICES							
### DRIND ASSTATE UNIVERSITY HIV DEMONSTRATION, RESEARCH, PUBLIC AND PROFESSIONAL EDUCATION PROJECTS 93.941 PS005246 7,067 - 7,067 - 7,067 - 7 PASS-TIRROUGH AWARD FROM: UNIVERSITY OF ILLINOIS EPIDEMIOLOGIC RESEARCH STUDIES OF AIDS AND HIV INFECTION IN SELECTED POPULATION GROUPS 93.943 PS005246 5,775 - 0 5,775 - COOPERATIVE AGREEMENTS TO SUPPORT STATE-BASED SAFE MOTHERHOOD AND INFANT HEALTH 93.946 93.946 34.911 - 0 34.911 - PASS-TIRROUGH AWARD FROM: SMATL MARKA HOSTEL BLOCK GRANTS FOR PREVENTION AND TREATMENT OF SUBSTANCE ABUSE 93.959 B0ST083545 - 0 95,486 95.486 - ### THE UNIVERSITY OF TEXAS AT LUSTIN BLOCK GRANTS FOR PREVENTION AND TREATMENT OF SUBSTANCE ABUSE 70 14.04 93.959 HINSIO(194230003 - 0 480.531 40.531 - ### PASS-TIRROUGH AWARD FROM: TOTAL AND ASSESSED SAFE MOTHER OF SUBSTANCE ABUSE 93.969 HINSIO(194230003 - 0 576,017 576,017 576,017 - ### PASS-TIRROUGH AWARD FROM: SEXUALLY TRANSMITTED DISEASES (STD) PREVENTION AND CONTROL GRANTS 93.969 TWO 113.401 - 0 1 113.401 - **INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 TWO 11898 16.911 - 0 529,715 99.375 1 113.401 - 0 1 16.911 - ### PASS-TIRROUGH AWARD FROM: MINTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 TWO 11898 16.911 - 0 1 16.911 - ### UNIVERSITY OF MARYLAND UNIVERSITY OF MARYLAND NITERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 TWO 11898 16.911 - 0 2 236.340 - ### PASS-TIRROUGH AWARD FROM: ### PASS-TIRROUGH AWARD FROM: ### PASS-TIR	HIV PREVENTION ACTIVITIES_HEALTH DEPARTMENT BASED	93.940	HS000077800010	-	-	138,063	138,063	_
PASS-THROUGH AWARD FROM: UNIVERSITY OF ILLINOYS PROVIDED NOT STATE-BASED SAFE MOTHER HOOD AND INFASTITY OF ILLINOYS PROVIDED NOT STATE-BASED SAFE MOTHER HOOD AND INFASTITY OF ILLINOYS PROVIDED NOT STATE-BASED SAFE MOTHER HOOD AND INFASTITY OF ILLINOYS PROVIDED NOT STATE-BASED SAFE MOTHER HOOD AND INFASTITY OF ILLINOYS PROVIDED NOT STATE-BASED SAFE MOTHER HOOD AND INFAST HEALTH PROVIDED NOT STATE-BASED SAFE MOTHER HOOD AND INFAST HEALTH PROVIDED NOT STATE-BASED SAFE MOTHER HOOD AND INFAST HEALTH PROVIDED NOT STATE-BASED SAFE MOTHER HOOD AND INFAST HEALTH PROVIDED NOT STATE-BASED SAFE MOTHER HOOD AND INFAST HEALTH PROVIDED NOT STATE-BASED SAFE MOTHER HOOD AND INFAST HEALTH PROVIDED NOT STATE-BASED SAFE MOTHER HOOD AND INFAST HEALTH PROVIDED NOT STATE-BASED SAFE MOTHER HOOD AND INFAST HEALTH PROVIDED NOT STATE-BASED SAFE MOTHER HOOD AND INFAST HEALTH PROVIDED NOT STATE-BASED SAFE MOTHER HOOD AND INFAST HEALTH PROVIDED NOT STATE HOOD AND INFAST HEALTH PROVIDED NOT STATE HOOD AND INFAST HEALTH PROVIDED NOT STATE HOOD AND INFAST HOO	PASS-THROUGH AWARD FROM:							
PASS-THROUGH AWARD FROM: UNIVERSITY OF ILLINOIS EPIDEMIOLOGIC RESEARCH STUDIES OF AIDS AND HIV INFECTION IN SELECTED POPULATION GROUPS 93,943 PS005246 5,775 - 5,775 - 5,775 COOPERATIVE AGREEMENTS TO SUPPORT STATE-BASED SAFE MOTHERHOOD AND INFANT HEALTH PASS-THROUGH AWARD FROM: SANTA MARIA HOSTEL BLOCK GRANTS FOR PREVENTION AND TREATMENT OF SUBSTANCE ABUSE BLOCK GRANTS FOR PREVENTION AND TREATMENT OF SUBSTANCE ABUSE TOTAL ALN 93,959 PAGE OF A SO,5017 POPHIF GERIATRIC EDUCATION CENTERS SEXUALLY TRANSMITTED DISEASES (STD) PREVENTION AND CONTROL GRANTS NITERNATIONAL RESEARCH AND RESEARCH TRAINING MAKEAGER UNIVERSITY INTERNATIONAL RESEARCH AND RESEARCH TRAINING MAKEAGER UNIVERSITY INTERNATIONAL RESEARCH AND RESEARCH TRAINING MAKEAGER UNIVERSITY INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93,989 TWO 1898 TWO 1898 TWO 1898 TWO 1898 TWO 1898 TWO 1898 TWO 1897 TWO 1896 TWO 1897 TO 1897 TWO 1897	FLORIDA STATE UNIVERSITY							
UNIVERSITY OF ILLINOIS PIDEMIOLOGIC RESEARCH STUDIES OF AIDS AND HIV INFECTION IN SELECTED POPULATION GROUPS 93,943 PS005246 5,775 5,775	HIV DEMONSTRATION, RESEARCH, PUBLIC AND PROFESSIONAL EDUCATION PROJECTS	93.941	PS005246	7,067	-	_	7,067	_
POPULATION GROUPS 93.943 PS005246 5.775 - 0 5.775 - 0 5.775 - 0 - 0 5.775 - 0 - 0 5.775 - 0 -	PASS-THROUGH AWARD FROM:							
POPULATION GROUPS 93.943 PS005246 5.775 5.775	UNIVERSITY OF ILLINOIS							
COOPERATIVE AGREEMENTS TO SUPPORT STATE-BASED SAFE MOTHERHOOD AND INFANT HEALTH 93,946 34,911 - 34,911	EPIDEMIOLOGIC RESEARCH STUDIES OF AIDS AND HIV INFECTION IN SELECTED							
NFANT HEALTH 93.946 34.911 - - 34.911 - -	POPULATION GROUPS	93.943	PS005246	5,775	-	-	5,775	-
NFANT HEALTH 93.946 34.911 - - 34.911 - -	COOPERATIVE AGREEMENTS TO SUPPORT STATE-RASED SAFE MOTHERHOOD AND							
SANTA MARIA HOSTEL BLOCK GRANTS FOR PREVENTION AND TREATMENT OF SUBSTANCE ABUSE 93.959 B08T1083545 - - 95.486 95.486 - 1		93.946		34,911	-	_	34,911	=
BLOCK GRANTS FOR PREVENTION AND TREATMENT OF SUBSTANCE ABUSE 93,959 B08T1083545 - 95,486 95,486 -	PASS-THROUGH AWARD FROM:							
### UNIVERSITY OF TEXAS AT AUSTIN BLOCK GRANTS FOR PREVENTION AND TREATMENT OF SUBSTANCE ABUSE 10	SANTA MARIA HOSTEL							
BLOCK GRANTS FOR PREVENTION AND TREATMENT OF SUBSTANCE ABUSE 93.959 HHS00104230003	BLOCK GRANTS FOR PREVENTION AND TREATMENT OF SUBSTANCE ABUSE	93.959	B08TI083545	_	_	95,486	95,486	=
Total ALN 93.959 TW011898 16,911 - 576,017 576,017 -								
PPHF GERIATRIC EDUCATION CENTERS 93.969 777,374 - - 777,374 252,366 SEXUALLY TRANSMITTED DISEASES (STD) PREVENTION AND CONTROL GRANTS 93.977 113,401 - - 113,401 - - 113,401 - - 113,401 - - 529,715 - - 529,715 99,375 PASS-THROUGH AWARD FROM: MAKERER UNIVERSITY INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 TW011898 16,911 - - - 16,911 - UNIVERSITY OF MARYLAND 1NTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 TW012274 236,340 - - 236,340 - - 236,340 - - 236,340 - - 236,340 - - 236,340 - - 236,340 - - 236,340 - - 236,340 - - 236,340 - - 236,340 - - - 236,340 - - - - 236,340 - - - - - -			HHS00104230003					
SEXUALLY TRANSMITTED DISEASES (STD) PREVENTION AND CONTROL GRANTS 93.977 INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 529,715 529,715 99,375 PASS-THROUGH AWARD FROM: MAKERER UNIVERSITY INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 TW011898 16,911 16,911 - UNIVERSITY OF MARYLAND INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 TW01274 236,340 - 236,340 - 236,340 - 236,340 - 236,340 - 36,940 - 36,	I Otal As	LIN 93.939		_	_	370,017	370,017	_
INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 529,715 - - 529,715 99,375	PPHF GERIATRIC EDUCATION CENTERS	93.969		777,374	-	-	777,374	252,366
PASS-THROUGH AWARD FROM: **MAKERER UNIVERSITY** INTERNATIONAL RESEARCH AND RESEARCH TRAINING** **INTERNATIONAL RESEARCH AND RESEARCH TRAINING** INTERNATIONAL RESEARCH AND RESEARCH TRAINING** **93.989** **TW01274** **236,340** - 236,340** - 236,340** - 236,340** - 236,340** - 326	SEXUALLY TRANSMITTED DISEASES (STD) PREVENTION AND CONTROL GRANTS	93.977		113,401	_	_	113,401	_
PASS-THROUGH AWARD FROM: **MAKERER UNIVERSITY** INTERNATIONAL RESEARCH AND RESEARCH TRAINING** **INTERNATIONAL RESEARCH AND RESEARCH TRAINING** INTERNATIONAL RESEARCH AND RESEARCH TRAINING** **93.989** **TW01274** **236,340** - 236,340** - 236,340** - 236,340** - 236,340** - 36,340	DITERMATIONAL DEGEARCH AND DEGEARCH TRADING	02.000		520 715			520 715	00.275
INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 TW011898 16,911 - - 16,911 - - 16,911 - - 16,911 - - 16,911 - - 236,340 - - 236,340 - - 236,340 - - 236,340 - - 236,340 - - 236,340 - - 236,340 - - 236,340 - - 236,340 - - 236,340 - - 236,340 - - 236,340 - - 236,340 - - 236,340 - - - 236,340 - - - 236,340 - <td>PASS-THROUGH AWARD FROM:</td> <td>93.989</td> <td></td> <td>529,/15</td> <td>_</td> <td>_</td> <td>529,/15</td> <td>99,3/3</td>	PASS-THROUGH AWARD FROM:	93.989		529,/15	_	_	529,/15	99,3/3
INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 TW012274 <u>236,340 236,340 -</u>	INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	TW011898	16,911		-	16,911	-
		93.989	TW012274	236.340	_	_	236,340	=
					_	_		99,375

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
		¥ 8				•	•
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued) PASS-THROUGH AWARD FROM:							
PASS-THROUGH AWARD FROM: THE UNIVERSITY OF TEXAS AT AUSTIN (TEXAS DEPARTMENT OF STATE HEALTH SERVICES)							
THE CHANGE OF TEXAS IT ACCIDE TEXAS DEL MATRIENT OF STATE HEIERIT SERVICES						_	
	93RD	COVID-19 CDC #75D30122C14673	390,198	_	-	390,198	=
	93RD	HHSN268201600033I	4,637,172	_	_	4,637,172	4,626,122
	93RD	NIH 75N91023P00542	114,292	_	_	114,292	_
	93RD	NIH 75N93023P00568	235,974	-	-	235,974	_
	93RD	NIH 75N92023D00012	481,770	_	_	481,770	_
	93RD	NIH 75N93022P00766	9,852	_	_	9,852	_
	93RD	NIH 75N93022P00891	1,184,879	_	_	1,184,879	=
	93RD	NIH 75N95023P00006	154,558	-	-	154,558	_
	93RD	NIH 75N93023P01316	9,383	_	_	9,383	=
	93RD	75N93019F00132	6,232	-	-	6,232	-
PASS-THROUGH AWARD FROM:							
PASS-THROUGH AWARD FROM: ATLANTA RESEARCH AND EDUCATION FOUNDATION	93RD	CDC 75D30119C04211	623,155			623,155	
COVID-19 BOSTON CHILDREN'S HOSPITAL	93RD 93RD	CDC 75D30119C04211	9,508	_	_	9,508	_
COVID-19 BOSTON CHILDREN'S HOSPITAL COVID-19 BOSTON CHILDREN'S HOSPITAL	93RD 93RD	CDC 75D30120C07723	31,686	_	_	31,686	_
COVID-19 BOSTON CHILDREN'S HOSPITAL	93RD	CDC 75D30121C10297	7,698	_	_	7,698	_
BOSTON CHILDREN'S HOSPITAL	93RD 93RD	CDC 75D30122C1333	26,388	_	_	26,388	_
COLUMBIA UNIVERSITY	93RD 93RD	80ARC023CA004	37,235		_	37,235	_
DUKE UNIVERSITY	93RD	HHSN-275201800003I	113,903		_	113,903	_
HENNEPIN RESEARCH INSTITUTE	93RD	75N-94019C00006	29,972		_	29,972	_
MEDSTAR RESEARCH INSTITUTE	93RD	HHSP233201500022I	207,698	_	_	207,698	_
NATIONAL MARROW DONOR PROGRAM	93RD	NUMBER 1703	23,068	_	_	23,068	_
NATIONAL MARROW DONOR PROGRAM	93RD	NUMBER 1704	3,922	_	_	3,922	_
NATIONAL MARROW DONOR PROGRAM	93RD	NUMBER 1705	27,729	_	_	27,729	_
NATIONAL MARROW DONOR PROGRAM	93RD	NUMBER 1903	11,562	_	_	11,562	_
NRG ONCOLOGY FOUNDATION, INC	93RD	NCORP	57,900	_	_	57,900	_
UNIVERSITY OF ALABAMA AT BIRMINGHAM	93RD	HHSN272201600018C	71,094	_	_	71,094	_
UNIVERSITY OF CHICAGO	93RD	75Q80120D00018	103,194	_	_	103,194	_
UNIVERSITY OF MICHIGAN	93RD	HHSN268201800002I	118,897	_	_	118,897	_
UNIVERSITY OF NORTH CAROLINA	93RD	75N92022F0001	455,493	_	_	455,493	_
UNIVERSITY OF SOUTH FLORIDA	93RD	NIDDK-TRIALNET	297	_	_	297	=
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES			422,629,513	183,497	12,570,508	435,383,518	56,897,440

97 2503-1117-CS

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HOMELAND SECURITY							
PASS-THROUGH AWARD FROM:							
HARRIS COUNTY							
COVID-19 DISASTER GRANTS Ý PUBLIC ASSISTANCE (PRESIDENTIALLY DECLARED							
DISASTERS)	97.036	SMARTPOD	\$ -	\$ -	- \$ 4,563	\$ 4,563	\$ -
DISASTER GRANTS – PUBLIC ASSISTANCE (PRESIDENTIALLY DECLARED DISASTERS)	97.036	SMARTPOD			- 35,488	35,488	<u> </u>
Total ALN 97.0	36			-	- 40,051	40,051	<u> </u>
TOTAL DEPARTMENT OF HOMELAND SECURITY			-	-	- 40,051	40,051	_
TOTAL EXPENDITURES OF FEDERAL AWARDS			\$ 475,139,612	\$ 24,862,12	1 \$ 17,762,145	\$ 517,763,878	\$ 67,960,628

98 2503-1117-CS

Schedule of Expenditures of State Awards

Year Ended June 30, 2024

State of Texas: Direct & Pass-through CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS PRESCRICT AWARD: PRESCRICT AWARD:	Program Description	Pass-Through Entity/Other Identifying Number	Total Expenditures	Amounts Provided to Subrecipients
DIRECT AWARD:	State of Texas: Direct & Pass_through			
RP230285 \$ 234,514 \$ — PP170094 (518) — PP190051 24,620 19,487 PP20068 524,282 70,000 PP210007 144,417 142,672 PP210031 32,456 — PP210044 547,495 — PP220017 336,115 — PP220024 164,689 67,200 PP220038 16,202 — PP240021 54,290 — RP120685 (18) — RP150169 (1,338) — RP180196 2,393 — RP180381 61,227 24,175 RP180672 418,946 — RP180875 472,226 — RP190876 2,393 — RP190902 24,623 — RP1901900 372,844 — RP1901907 30,487 21,930 RP190152 (2,071) — RP190621 724,809 15,991	CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS			
PP170094 (518) — PP190061 24,620 19,487 PP200068 524,282 70,000 PP210007 144,417 142,672 PP210031 32,456 — PP210044 547,495 — PP220017 336,115 — PP220018 16,602 — PP220038 16,202 — PP240021 54,290 — RP120685 (18) — RP170169 (1,338) — RP1801966 2,393 — RP180672 418,946 — RP180674 160,769 — RP180675 472,226 — RP190012 24,623 — RP19002 24,623 — RP190132 96,732 — RP190150 372,844 — RP190279 30,487 21,930 RP19052 (2,071) — RP19062 224,809 157,971 <td>DIRECT AWARD.</td> <td>PD220285</td> <td>\$ 224.514</td> <td>¢</td>	DIRECT AWARD.	PD220285	\$ 224.514	¢
PP190051				–
PP200068 524,282 70,000 PP210071 144,417 142,672 PP210013 32,456 — PP210044 547,495 — PP220017 336,115 — PP220024 164,689 67,200 PP220038 16,202 — PP220021 54,290 — PP220028 (18) — RP120685 (18) — RP120685 (18) — RP190169 (1,338) — RP180168 2,393 — RP180169 (1,338) — RP180672 418,946 — RP180674 106,769 — RP180785 472,226 — RP190132 96,732 — RP190160 372,844 — RP190279 30,487 21,930 RP190522 (2,071) — RP190621 724,809 157,971 RP190621 657,741 — </td <td></td> <td></td> <td></td> <td>10 487</td>				10 487
PP210007 144,417 142,672 PP210031 32,456 — PP210044 547,495 — PP220017 336,115 — PP220028 164,689 67,200 PP240021 54,290 — RP120685 (18) — RP170169 (1,338) — RP180196 2,393 — RP180197 418,946 — RP180672 418,946 — RP180674 106,769 — RP180675 472,226 — RP180676 106,769 — RP180677 72,200 — RP180678 472,226 — RP190012 96,732 — RP190150 372,844 — RP190160 372,844 — RP190522 (2,071) — RP19062 724,809 157,971 RP19061 657,741 —				
PP210031 32,456 - PP210044 547,495 - PP220017 336,115 - PP220024 164,689 67,200 PP220038 16,002 - PP240021 54,290 - RP120685 (18) - RP170169 (1,338) - RP180196 2,393 - RP180381 61,227 24,175 RP180672 418,946 - RP180785 472,226 - RP180785 472,226 - RP190152 96,732 - RP190152 96,732 - RP190279 30,487 21,930 RP190522 (2,071) - RP190602 724,809 157,971 RP190641 657,741 -			· · · · · · · · · · · · · · · · · · ·	· ·
PP210044 547,495 - PP220017 336,115 - PP220024 164,689 67,200 PP220038 16,202 - PP240021 54,290 - RP120685 (18) - RP170169 (1,338) - RP180196 (2,393) - RP180196 2,393 - RP180672 418,946 - RP180672 418,946 - RP180785 472,226 - RP190002 24,623 - RP190132 96,732 - RP190160 372,844 - RP190179 30,487 21,930 RP190522 (2,071) - RP190602 724,809 157,971 RP190641 657,741 -				142,072
PP220017 336,115 — PP220024 164,689 67,200 PP220038 16,202 — PP240021 54,290 — RP120685 (18) — RP170169 (1,338) — RP180196 2,393 — RP180381 61,227 24,175 RP180672 418,946 — RP180674 106,769 — RP180785 472,226 — RP19002 24,623 — RP190132 96,732 — RP190152 372,844 — RP190279 30,487 21,930 RP190522 (2,071) — RP19062 724,809 157,971 RP19061 657,741 —				_
PP220024 164,689 67,200 PP220038 16,202 — PP240021 54,290 — RP120685 (18) — RP170169 (1,338) — RP180196 2,393 — RP180381 61,227 24,175 RP180672 418,946 — RP180785 472,226 — RP180786 472,226 — RP190132 96,732 — RP190132 96,732 — RP190160 372,844 — RP190279 30,487 21,930 RP190522 (2,071) — RP190602 724,809 157,971 RP190641 657,41 —				=
PP220038 16,202 - PP240021 54,290 - RP120685 (18) - RP170169 (1,338) - RP180196 2,393 - RP180381 61,227 24,175 RP180672 418,946 - RP180674 106,769 - RP180785 472,226 - RP19079002 24,623 - RP190132 96,732 - RP190160 372,844 - RP190279 30,487 21,930 RP190522 (2,071) - RP190602 724,809 157,971 RP190641 657,741 -				67 200
PP240021 54,290 - RP120685 (18) - RP170169 (1,338) - RP180196 2,393 - RP180381 61,227 24,175 RP180672 418,946 - RP180674 106,769 - RP180785 472,226 - RP190002 24,623 - RP190132 96,732 - RP190160 372,844 - RP190279 30,487 21,930 RP190522 (2,071) - RP19062 724,809 157,971 RP190641 657,741 -				07,200
RP120685 (18) - RP170169 (1,338) - RP180196 2,393 - RP180381 61,227 24,175 RP180672 418,946 - RP180674 106,769 - RP180785 472,226 - RP19002 24,623 - RP190132 96,732 - RP190160 372,844 - RP190279 30,487 21,930 RP190522 (2,071) - RP190602 724,809 157,971 RP190641 657,741 -				_
RP170169 (1,338) - RP180196 2,393 - RP180381 61,227 24,175 RP180672 418,946 - RP180674 106,769 - RP180785 472,226 - RP190002 24,623 - RP190132 96,732 - RP190160 372,844 - RP190279 30,487 21,930 RP190522 (2,071) - RP19062 724,809 157,971 RP190641 657,741 -				_
RP180196 2,393 - RP180381 61,227 24,175 RP180672 418,946 - RP180674 106,769 - RP180785 472,226 - RP190002 24,623 - RP190132 96,732 - RP190160 372,844 - RP190279 30,487 21,930 RP190522 (2,071) - RP190602 724,809 157,971 RP190641 657,741 -			* *	_
RP180381 61,227 24,175 RP180672 418,946 — RP180674 106,769 — RP180785 472,226 — RP190002 24,623 — RP190132 96,732 — RP190160 372,844 — RP190279 30,487 21,930 RP190522 (2,071) — RP190602 724,809 157,971 RP190641 657,741 —				_
$\begin{array}{cccccccccccccccccccccccccccccccccccc$				24 175
RP180674 106,769 - RP180785 472,226 - RP190002 24,623 - RP190132 96,732 - RP190160 372,844 - RP190279 30,487 21,930 RP190522 (2,071) - RP190602 724,809 157,971 RP190641 657,741 -				24,175
RP180785 472,226 - RP190002 24,623 - RP190132 96,732 - RP190160 372,844 - RP190279 30,487 21,930 RP190522 (2,071) - RP190602 724,809 157,971 RP190641 657,741 -				_
RP190002 24,623 - RP190132 96,732 - RP190160 372,844 - RP190279 30,487 21,930 RP190522 (2,071) - RP190602 724,809 157,971 RP190641 657,741 -			*	_
RP190132 96,732 - RP190160 372,844 - RP190279 30,487 21,930 RP190522 (2,071) - RP190602 724,809 157,971 RP190641 657,741 -				_
RP190160 372,844 - RP190279 30,487 21,930 RP190522 (2,071) - RP190602 724,809 157,971 RP190641 657,741 -				_
RP190279 RP190522 RP190602 RP190641 30,487 (2,071) - RP190602 724,809 157,971 RP190641				_
RP190522 (2,071) – RP190602 724,809 157,971 RP190641 657,741 –				21 030
RP190602 724,809 157,971 RP190641 657,741 —				21,550
RP190641 657,741 –				157 071
				157,971
		RP200025	598,592	276,151

Schedule of Expenditures of State Awards (continued)

	250 0	_
	250 ft	
State of Texas: Direct & Pass-through (continued)	250 0	
CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS (continued)		
	,358 \$	_
RP200402	,895	_
	,241	_
	,778	_
	,651	_
	,475	47,912
	,541	_
RP200620	,367	_
	,597	_
RP210027 7	,449	_
RP210037 4	,503	_
RP210064 5	,345	166,770
RP210075	,302	_
RP210143	,756	85,331
RP210158	,602	12,616
RP210227 7	,915	_
RP220050 3	,858	_
RP220119 1	,942	40,977
RP220127 4	,503	_
RP220218 3	,397	96,792
RP220232 3	,225	_
RP220332 3	,223	_
	,655	_
	,763	_
	,113	_
	,007	161,152
	,913	14,215

Schedule of Expenditures of State Awards (continued)

		Total	Amounts Provided to
Program Description	Pass-Through Entity/Other Identifying Number	Expenditures	Subrecipients
State of Texas: Direct & Pass-through (continued) CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS (continued)			
CANCER TREVENTION & RESEARCH INSTITUTE OF TEXAS (concinued)	RP220666	\$ 122,990	\$ -
	RP230026	268,016	_
	RP230120	241,905	_
	RP230391	404,525	_
	RP240131	55,590	_
	RP240137	32,815	_
	RP240143	19,545	_
	RP240263	27,111	_
	RP240291	51,062	_
	RP240380	_	_
	RR160009	117,333	_
	RR160027	7,023	_
	RR170024	452,863	_
	RR170036	1,114	_
	RR170048	239,937	_
	RR180061	483,131	44,449
	RR180072	137,805	_
	RR190043	774,376	_
	RR190054	420,330	_
	RR190104	331,745	_
	RR200009	504,993	_
	RR200040	519,865	_
	RR200063	251,981	99,571
	RR200065	131,762	_
	RR200076	241,775	_
	RR200079	235,790	_
	RR200080	496,531	_
	RR210012	432,304	=

Schedule of Expenditures of State Awards (continued)

Program Description	Pass-Through Entity/Other Identifying Number	Total Expenditures	Amounts Provided to Subrecipients
1 rogi ani Description	1 ass-1 in ough Energy/Other ruentrying rumber	Expenditures	Subrecipients
State of Texas: Direct & Pass-through (continued)			
CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS (continued)			
	RR210013	\$ 320,697	\$ -
	RR210029	391,170	=
	RR210031	785,491	=
	RR210037	150,050	_
	RR210040	160,811	_
	RR210056	285,018	_
	RR210066	253,186	_
	RR210082	346,164	_
	RR220012	350,815	_
	RR220033	794,444	_
	RR220035	331,365	_
	RR220039	361,564	_
	RR220051	2,495,815	_
	RR220069	397,370	_
	RR220094	547,345	_
	RR230040	127,292	_
	RR230042	242,451	_
		30,301,163	1,549,371
PASS THROUGH AWARD FROM:			
PERIMETER MEDICAL IMAGING	DP190087	157	_
		157	_
RICE UNIVERSITY	RP210205	1,649	_
		1,649	_

Schedule of Expenditures of State Awards (continued)

Program Description	Pass-Through Entity/Other Identifying Number	Total Expenditures	Amounts Provided to Subrecipients
State of Texas: Direct & Pass-through (continued)			
CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS (continued) PASS THROUGH AWARD FROM (continued):			
TEXAS A&M UNIVERSITY HEALTH SCIENCE CENTER			
	RP170719	\$ 335,113	\$ -
	RP180131	_	_
	RR200043	239,129	_
	RP210043	123,022	_
		697,264	_
TEXAS TECH UNIVERSITY			
	RP230420	4,341	
		4,341	_
THE LUMBERSHOW OF THE VICENCE AND ENGANG ANGER OF VICEN			
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	DD100102		
	RP190192	2.014	_
	RP200383	3,814	_
	RP220208	65,508	_
	RP220021	31,066	_
	RP180712	8,265 108,653	
		108,633	_
THE METHODIST HOSPITAL RESEARCH INSTITUTE			
THE METHODIST HOST HAL RESEARCH INSTITUTE	RP210144	26,115	
	RP210144	(6,600)	_
	M 210177	19,515	
		17,515	_

Schedule of Expenditures of State Awards (continued)

Program Description	Pass-Through Entity/Other Identifying Number	Total Expenditures	Amounts Provided to Subrecipients
State of Texas: Direct & Pass-through (continued) CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS (continued) PASS THROUGH AWARD FROM (continued): THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON			
THE UNIVERSITI OF TEXAS MEDICAL BRANCH AT GALVESTON	RP1900019/0014308A PP200017 RR210018	\$ 27 (8) 24,052 24,071	\$ - - - -
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	PP180089 RP210111	32,743 5,079 37,823	- - -
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	RP230330 RP200554	60,590 53,367 113,957	
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO	RP220137	15,529 15,529	<u>-</u> _
TOTAL CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS		31,324,121	1,549,371
TEXAS COUNCIL ON ALZHEIMER'S DISEASE AND RELATED DISORDERS	TX COUNCIL ALZHEIMER/DISORDERS	38,969	
TOTAL TEXAS COUNCIL ON ALZHEIMER'S DISEASE AND RELATED DISORDERS	1 A COUNCIL ALZHEIMER/DISORDERS	38,969	

Program Description	Pass-Through Entity/Other Identifying Number	Total Expenditures	Amounts Provided to Subrecipients
TOBACCO SETTLEMENT FUNDS			
	BCM TOBACCO ENDOWMENT	\$ 1,081,345	\$
	STATE MANAGED TOBACCO FUNDS	1,798,324	
TOTAL TOBACCO SETTLEMENT FUNDS		2,879,669	_
JOINT ADMISSIONS MEDICAL PROGRAM (JAMP) COUNCIL			
` ,	MEDICAL SCHOOL PROGRAM	39,857	_
	SPECIAL PROJECTS FOR PROGRAM INITIATIVES	19,698	_
	SUMMER PROGRAM	93,428	_
TOTAL JOINT ADMISSIONS MEDICAL PROGRAM COUNCIL		152,983	_
TEXAS HIGHER EDUCATION COORDINATING BOARD			
FAMILY PRACTICE RESIDENCY PROGRAM	THE CB AGREEMENT NUMBER 28454	18,513	_
FAMILY PRACTICE RESIDENCY PROGRAM	THE CB AGREEMENT NUMBER 00111	161,551	_
		180,064	_
GRADUATE MEDICAL EDUCATION – RESIDENT SUPPORT			
GRADUATE MEDICAL EDUCATION – RESIDENT SUPPORT	THE CB # 25463	(253)	_
GRADUATE MEDICAL EDUCATION – RESIDENT SUPPORT	THE CB # 25309		=
GRADUATE MEDICAL EDUCATION – RESIDENT SUPPORT	THE CB #23	4,682,860	_
GRADUATE MEDICAL EDUCATION – RESIDENT SUPPORT	THE CB # 27872	1,327,237	_
GME EXPANSION GRANT	TX HIGHER EDUC COORD BOARD 26195	280,645	_
GME EXPANSION GRANT	TX HIGHER EDUC COORD BOARD 26196	918,409	_
GME EXPANSION GRANT	TX IHGHER EDUC COORD BOARD 22798	860	_
GME EXPANSION GRANT	TX HIGHER EDUC COORD BOARD 26197	504,441	_
GME EXPANSION GRANT	TX HIGHER EDUC COORD BOARD 26326	450,073	_
GME EXPANSION GRANT	TX HIGHER EDUC COORD BOARD 26436	1,037,599	_
GME EXPANSION GRANT	TX HIGHER EDUC COORD BOARD 26437	565,797	_
		9,767,668	_

Schedule of Expenditures of State Awards (continued)

Program Description	Pass-Through Entity/Other Identifying Number	Total Expenditures	Amounts Provided to Subrecipients
TEXAS HIGHER EDUCATION COORDINATING BOARD (continued)			
UNDERGRADUATE MEDICAL EDUCATION PROGRAM			
UNDERGRADUATE MEDICAL EDUCATION PROGRAM	THE CB # 27	\$ 24,270,606	\$ _
UNDERGRADUATE MEDICAL EDUCATION PROGRAM	HOLD HARMLESS	1,753,079	<u> </u>
UNDERGRADUATE MEDICAL EDUCATION PROGRAM	MISSION SUPPORT - ADMISSIONS	(338)	_
UNDERGRADUATE MEDICAL EDUCATION PROGRAM	MISSION SUPPORT	(281)	_
		26,023,066	_
EMERGENCY AND TRAUMA CARE EDUCATION	THE CB AGREEMENT NUMBER 27763 / 28902	151,560	_
		151,560	_
AUTISM GRANT PROGRAM - INNOVATIVE TREATMENT MODELS	THE CB AGREEMENT NUMBER 22971 / 23459	(195)	_
AUTISM GRANT PROGRAM - PARENT DIRECTED TREATMENT	THE CB AGREEMENT NUMBER 27507 / 29598	282,969	_
		282,774	_
PASS THROUGH AWARD FROM:			
THE UNIVERSITY OF TEXAS SYSTEM - TEXAS CHILD MENTAL HEALTH CARE CONSORTIUM			
		5,316,811	148,875
		5,316,811	148,875
TOTAL TEXAS HIGHER EDUCATION COORDINATING BOARD		41,721,942	148,875
TEXAL DEPARTMENT OF FAMILY & PROTECTIVE SERVICES			
PASS-THROUGH FROM DEPARTMENT OF FAMILY & PROTECTIVE SERVICES			
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT TYLER			
SAFE BABIES PROJECT	HHS000820100001	172,476	_
RESEARCH AND EVALUATION SERVICES	HHS000705200001	77,213	
TOTAL TEXAS DEPARTMENT OF FAMILY & PROTECTIVE SERVICES		249,689	_

106 2503-1117-CS

Schedule of Expenditures of State Awards (continued)

Program Description	Pass-Through Entity/Other Identifying Number	Total Expenditures	Amounts Provided to Subrecipients
TEXAS DEPARTMENT OF STATE HEALTH SERVICES			
DEPARTMENT OF HEALTH AND HUMAN SERVICES	537-18-0098-00001	\$ 3,482	\$ -
	HHS001277800001	35,944	
		39,426	_
PASS-THROUGH FROM TEXAS DEPARTMENT OF STATE HEALTH SERVICES HARRIS HEALTH			
HIV/STD Program	HIV PERI-NATAL TRANSMISSION PREVENTION FY24	122,861	_
•		122,861	_
THE UNIVERSITY OF TEXAS AT AUSTIN			
LONE STAR STROKE CLINICAL TRIAL NETWORK	LONE STAR STROKE CLINICAL TRIAL NETWORK	219,292	_
DSHS GENETIC SEMINARS	HHS001011000001	133,760	_
LONE STAR STROKE CLINICAL TRIAL NETWORK	COVID PILOT	14,619	_
LONE STAR STROKE CLINICAL TRIAL NETWORK	LONE STAR VAST	22,474	_
LONE STAR STROKE CLINICAL TRIAL NETWORK	LONE STAR STROKE CLINICAL TRIAL NETWORK	2,706	_
LONE STAR STROKE CLINICAL TRIAL NETWORK	LONE START STROKE FYWE	15,255	
		408,106	_
UT HEALTH SCIENCE CENTER AT HOUSTON			
ZIKA VIRUS	HHS000427700001	146,036	_
SAFE BABIES PROJECT	HHS001398400001	156,233	_
		302,269	_
UT HEALTH SCIENCE CENTER AT TYLER			
TEXAS COLLABORATIVE FOR HEALTHY MOTHERS AND BABIES	HHS001396000001	111,948	_
	HHS001001300001	129,346	_
		241,294	_
TOTAL TEXAS DEPARTMENT OF STATE HEALTH SERVICES		1,113,956	_

Schedule of Expenditures of State Awards (continued)

Program Description	Pass-Through Entity/Other Identifying Number	Total Expenditures	Amounts Provided to Subrecipients
TEXAS HEALTH AND HUMAN SERVICES COMMISSION			
HEALTHY TEXAS WOMEN'S GRANT PROGRAM	529-16-0132-00020	\$ -	\$
FAMILY PLANNING GRANT PROGRAM	HHS000073460036	3,332,705	=
FAMILY PLANNING GRANT PROGRAM	529-16-0102-00011	1,655	-
HOUSE BILL 1802 GRANT PROGRAM	HHS001195400001	410,654	=
TOTAL TEXAS HEALTH AND HUMAN SERVICES COMMISSION		3,745,014	_
TOTAL EXPENDITURES OF STATE AWARDS		\$ 81,226,344	\$ 1,698,246

Notes to Schedule of Expenditures of Federal and State Awards

Year Ended June 30, 2024

1. Basis of Presentation

The accompanying schedule of expenditures of federal awards and the schedule of expenditures of state awards (the Schedules) present a summary of the financial activities of Baylor College of Medicine (the College) for the year ended June 30, 2024, which have been funded by the federal and state governments. The information in the Schedules is presented in accordance with the requirements of the Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance) and the State of Texas Single Audit Circular. Because the Schedules present only federal and state expenditure activities of the College, they are not intended to and do not present the financial position, changes in net assets, or cash flows of the College as a whole.

2. Summary of Significant Accounting Policies

The Schedules have been prepared on a modified accrual basis of accounting and include all expenditures of federal and state awards, direct and pass-through, received by the College from federal and state grantor agencies. Direct costs are charged to sponsored agreements on a cash basis except for salaries and fringe benefits that are charged on an accrual basis. Indirect costs are expensed against sponsored agreements at the close of the month in which the direct costs are charged and, therefore, are a combination of modified accrual and cash basis accounting. Federal and state awards are deemed to be expended when the College incurs the expenses. Such expenditures are recognized following the cost principles contained in Uniform Guidance or the *Texas Grant Management Standards* (TxGMS), as applicable, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Federal and state direct programs and pass-through programs are presented by federal or state department and, where applicable, the funding agency within the department and the pass-through entity.

The College did not elect to use 10% de minimis indirect costs rate as allowed under the Uniform Guidance.

Notes to Schedule of Expenditures of Federal and State Awards (continued)

3. Administered Federal Loan Programs

Outstanding loans under administered federal loan programs as of June 30, 2024, were as follows:

	Assistance Listing Number]	itstanding Balance ne 30, 2024
Federal Perkins Loan Program Health Professions Student Loans, Including Primary	84.038	\$	343,952
Care Loans, Loans for Disadvantaged Students (Health Professions Student Loans)	93.342	\$	146,083

4. Federal Direct Student Loans Program

The College participated in the Federal Direct Student Loans Program (ALN 84.268), including Unsubsidized Stafford Loans and PLUS Loans. The College was not the recipient of the funds. The programs are considered as a component of the student financial assistance cluster. Loan disbursements under the programs for the year ended June 30, 2024, totaled \$24,021,602.

Schedule of Findings and Questioned Costs

For the Year Ended June 30, 2024

Section I – Summary of Auditor's Results

Financial Statements

Type of report the auditor issued on whether the financial statements audited were prepared in accordance with GAAP:	Unmodified
Internal control over financial reporting: Material weakness identified? Significant deficiency identified? Noncompliance material to financial statements noted? Federal Awards	Yes X No None reported Yes X No
Internal control over major federal programs: Material weaknesses identified? Significant deficiency identified? Type of auditor's report issued on compliance for major federal programs:	X Yes No X Yes None reported Unmodified
Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?	
State Awards	
Internal control over major federal programs: Material weaknesses identified? Significant deficiency identified?	X Yes No YesX None reported
Type of auditor's report issued on compliance for major state programs:	Unmodified
Any audit findings disclosed that are required to be reported in accordance with State of Texas Single Audit Circular?	X Yes No

Schedule of Findings and Questioned Costs (continued)

Section I – Summary of Auditor's Results (continued)

Identification of major federal programs

Assistance Listing number(s)	Name of federal program or cluster	
Various ALN Numbers	Research and Development Cluster	
Various Listing number(s)	Student Financial Aid Cluster	
21.027	Covid-19 Coronavirus State and Local Fiscal	
	Recovery Funds	
Identification of major state programs		
Assistance Listing number(s)	Name of state program or cluster	
No AL Number	Graduate Medical Education Resident support	
No AL Number	Undergraduate Medical Education Program	
No AL Number	UT System - TCMHCC	
Dollar threshold used to distinguish between Type A and Type B federal programs:	\$ 3,000,000	
Dollar threshold used to distinguish between Type A and Type B state programs:	\$ 2,436,790	
Auditee qualified as low-risk auditee?	X Yes No	

Schedule of Findings and Questioned Costs (continued)

Section II – Financial Statement Findings

Finding 2024-001 Preparation of the Financial Statements and Related Disclosures

Criteria or specific requirement (including statutory, regulatory or other citation):

Management is responsible for the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of the financial statements that are free of material misstatement, for properly recording transactions in the accounting records, and for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America.

Context:

In connection with the preparation and review of the College's FY24 financial statements and comparison to the related Schedule of Expenditures of Federal Awards ("SEFA"), and Schedule of Expenditures of State Awards ("SESA") as required by Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards and State Awards of Texas Singular Audit Circular, management identified differences in the presentation of grant-related expenses between the SAP general ledger and the SEFA/SESA statements. While expenditures on the SEFA/SESA were deemed to be complete and accurate, general ledger balances were concluded to be overstated with respect to indirect costs. Upon further investigation with the College's Mosaic IT partners, a design error was identified within the automated grant revenue journal entries put in place effective January 1, 2024 as part of the SAP S4 ERP implementation wherein ultimately indirect cost revenue for the six-month period ended June 30th was being double counted within direct grant and contract revenue as well as within expenses on the general ledger.

Effect or potential effect:

Lack of appropriate internal controls over the financial statement close process could lead to the material misstatement to the financial statements or omission of a material disclosure.

Cause:

Management did not have the appropriate internal controls in place to prevent or detect errors in the financial statement close process.

Identification as a repeat finding, if applicable:

This is not a repeat finding

Schedule of Findings and Questioned Costs (continued)

Section II – Financial Statement Findings (continued)

Recommendation:

Management should enhance controls surrounding the financial statement close process.

Views of responsible officials and planned corrective actions:

Management agrees with the finding and has developed a plan to ensure proper review of the financial statements and reconciliation to the SEFA.

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs

Finding 2024-002 Procurement

Information on the federal/state program:

Federal Programs:

Research and Development Cluster (R&D)

ALN: 93.855

Criteria or specific requirement (including statutory, regulatory or other citation):

Federal Program

2 CFR 200.303(a) requires that a non-federal entity must "(a) establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in "Standards for Internal Control in the Federal Government" issued by the Comptroller General of the United States and the "Internal Control Integrated Framework", issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO)."

2 CFR 200.318 (i) General Procurement Standards states, "the non-Federal entity must maintain records sufficient to detail the history of procurement. These records will include, but are not necessarily limited to, the following: Rationale for the method of procurement, selection of contract type, contractor selection or rejection, and the basis for the contract price."

Condition:

The College did not maintain records for procurements sufficient to detail the history of procurement, including the rationale for the method of procurement, selection of contract type, contractor selection or rejection, and the basis for the contract price.

Questioned costs:

\$65,815

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Context:

EY selected and tested 8 procurements over \$50,000 with expenditures totaling, \$1,779,434 from a population of \$8,490,052 procurements over \$50,000 during the year ended June 30, 2024. Of the 8 expenditures selected for testing 1 procurement totaling \$65,815 did not have evidence of sole source justification.

Effect or potential effect:

The College did not comply with the general procurement standards and methods of procurement to be followed per the Uniform Guidance to maintain sufficient detail of the history of the procurement, including the rationale of the method of procurement.

Cause:

The College did not have effective internal controls and procedures in place to ensure the College maintained records for procurements sufficient to detail the history of procurement, including the rationale for the method of procurement and other required elements.

Identification as a repeat finding, if applicable:

This is not a repeat finding.

Recommendation:

The College should retain written documentation for procurements, documenting the history of the procurement prior to the procurement of goods or services including, but not limited to, the rationale for the method of procurement, selection of contract type, contractor selection or rejection, and the basis for the contract price.

Views of responsible officials and planned corrective actions:

Management agrees with the finding and has developed a plan to ensure that documentation is retained for sole source procurements.

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Finding 2024-003 Indirect Cost

Information on the federal/state program:

Federal Award agency;

Research and Development Cluster

COVID-19 Coronavirus State and Local Fiscal Recovery Funds (CSLFRF)

ALN:

Various

21.027

Criteria or specific requirement (including statutory, regulatory or other citation):

Internal Controls

Federal Awards

2 CFR Section 200.303 of the Uniform Guidance states the following regarding internal control:

"The non-Federal entity must:

(a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in "Standards for Internal Control in the Federal Government" issued by the Comptroller General of the United States or the "Internal Control Integrated Framework", issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO)."

Condition:

The College did not retain documentation and evidence of review of the indirect cost amounts being charged to the R&D and CSLFRF programs. Management performed a monthly control that included reviewing a sample of indirect costs charged to grants on a sample basis. The College had a new ERP implementation that went into effect on January 1, 2024. Management did not perform the monthly control subsequent to the ERP implementation for the last 6 months of year.

Questioned costs:

None

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Context:

During our testing over indirect cost, we selected 2 months during FY24 to test managements control. We observed that during FY24, BCM had a mid year ERP implementation in January 2024. After the ERP implementation, management no longer performed the monthly control for the remainder of FY24. As such for 6 months during FY24, the control was not in place.

Effect or potential effect:

The incorrect indirect cost rate could be applied to a grant.

Cause:

Management's internal control over the review and approval of indirect cost expenditures for compliance was not consistently documented.

Identification as a repeat finding, if applicable:

This is not a repeat finding

Recommendation:

The College should reassess its internal controls over the review and approval of indirect cost expenditures post ERP implementation and ensure documentation is retained to evidence review and approval to support the allowability of the expenditure.

Views of responsible officials and planned corrective actions:

Management agrees with the finding and has developed a plan to ensure indirect costs are reviewed.

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Finding 2024-004 Reporting

Information on the federal/state programs:

Federal Program:

COVID-19 Coronavirus State and Local Fiscal Recovery Funds (CSLFRF)

ALN:

21.027

State Awarding Agency:

Texas Higher Education Coordinating Board

State Program:

Texas Child Mental Health Care Consortium (TCMHCC)

Criteria or specific requirement (including statutory, regulatory or other citation): Federal Program

2 CFR 200.303(a) requires that a non-federal entity must "(a) establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in "Standards for Internal Control in the Federal Government" issued by the Comptroller General of the United States and the "Internal Control Integrated Framework", issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO)."

Pursuant to 47 C.F.R 302.9 and in accordance with the grant agreement, the award recipient was to submit monthly technical progress reports within 15 days of the end of the month.

Per the CSLFRF and TCHMCC agreements with UT Austin: A monthly progress report is due to UT System by the 15th of the month for the previous month.

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Condition:

The College did not submit monthly reports for the CSLFRF or TCMHCC grants by the 15th of the each month.

Questioned costs:

None

Context:

Federal and State:

The College submitted monthly reports for the 4 health initiatives created under the TCMHCC grant.

CPAN 6 out of 12 reports were not submitted by the 15th deadline.

CPWE 7 out of 12 reports were not submitted by the 15th deadline.

CAP 7 out of 12 reports were not submitted by the 15th deadline.

Effect or potential effect:

The College did not comply with the timing of the CSLFRF and TCMHC reporting requirements.

Cause:

The College did not have effective internal controls in place to ensure the monthly reports were submitted by the required dates, resulting in noncompliance.

Identification as a repeat finding, if applicable:

This is not a repeat finding.

Recommendation:

The College should develop and implement effective internal controls to ensure the required reports are submitted by the required due dates.

Views of responsible officials and planned corrective actions:

Management agrees with the finding and has developed a plan to ensure all reports are filed timely.

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Finding 2024-005

Information on the federal/state program:

Federal Programs:

Student Financial Assistance Cluster

ALN:

84.268

Criteria or specific requirement (including statutory, regulatory or other citation): Federal Program

2 CFR 200.303(a) requires that a non-federal entity must "(a) establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in "Standards for Internal Control in the Federal Government" issued by the Comptroller General of the United States and the "Internal Control Integrated Framework", issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO)."

Cash Management Program Requirements for Direct Lonas- Monthly Reconciliations Schools participating in the Direct Loan program are required to perform monthly Direct Loan Reconciliations (34 CFR 685.300(b)(5)). Electronic Announcements DL-22-07 and General -22-86 explain that a school must reconcile the funds it received from G5 with actual disbursement records the school submitted to Common Origination and Disbursement (COD). Each month COD sends the school a School Account Statement, which is Department of Education (ED's) official record of the school's cash and disbursement records and identifies the difference between net draws from G5 and the actual disbursement information reported to COD by the school. The School is required to account for any differences by reconciling ED's records (School Account Statement) with the school's financial and business records.

Condition:

The College did not submit the required monthly reconciliation for the direct loan program timely.

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Questioned costs:

None

Context:

As part of our testing, EY selected 4 months to test the monthly reconciliation between the funds received from G5 to the actual disbursement submitted to the COD. During our testing we determined that the College did not perform the monthly reconciliation timely for 3 of the 4 months selected for testing.

Effect or potential effect:

The College did not comply with the cash management reporting requirements, which could result in unreconciled differences between the funds the College received to what was actually disbursed to students.

Cause:

As part of our testing, EY selected 4 months to test the monthly reconciliation between the funds received from G5 to the actual disbursement submitted to the COD. During our testing we determined that the College did not perform the monthly reconciliation timely for 3 of the 4 months selected for testing. There was turnover by management and management was working with the IT department to ensure information was accurately obtained from the system to perform the reconciliation. After the data could be appropriately downloaded, management reconciled all transactions to date. Ultimately, management missed the monthly reconciliation deadline for 4 months during FY24. However the College did perform a year to date reconciliation in order to ensure all months during FY24 were reconciled from G5 to COD.

Identification as a repeat finding, if applicable:

This is not a repeat finding.

Recommendation:

The College should perform and submit the required monthly reconciliation between the G5 and the COD timely.

Views of responsible officials and planned corrective actions:

Management agrees with the finding and has developed a plan to ensure that the reconciliation is performed on a monthly basis.



Corrective Action Plan – Audit Findings

Year Ended June 30, 2024

Finding 2024-001 Preparation of the Financial Statements and Related Disclosures

Financial Statement Findings

Finding: Management did not have the appropriate internal controls in place to prevent or detect errors in the financial statement close process.

Corrective Action Plan: The College identified a design error within the automated grant revenue journal entries put in place January 1, 2024, as part of the SAP S4 ERP implementation. The system application design failed to carry over certain revenue and expense elimination entries that were embedded within the automated processes in the legacy SAP ECC system, resulting in an offsetting overstatement of revenues and expenses during the six-month period ending June 30, 2024. This design issue was not appropriately resolved prior to go-live as part of the College's IT implementation controls. While there was no impact on the College's operating income in total, this error required the correction of an overstatement of \$65M of grant revenues and expenses presented in the first draft of the FY24 financial statements shared with the Audit Compliance and Risk Committee. Management subsequently remediated this deficiency with the redesign of its monthly grant revenue journal entry processes during FY25.

Person Responsible: Don Turilli, Vice President, Finance, Baylor College of Medicine

Expected Completion: December 2024

Finding 2024-002 Procurement

ALN: 93.855

Finding: The College did not have effective internal controls and procedures in place to ensure the College maintained records for procurements sufficient to detail the history of procurement, including the rationale for the method of procurement and other required elements.

Corrective Action Plan: BCM management agrees that a sole source documentation form was not completed for this procurement. We do believe that this would have been easily justified as a sole source procurement as this vendor had unique capabilities required by the grant. The master service agreement for this procurement was effective September 1, 2019, and the related PO for this scope of work was issued on June 15, 2023. Since this time period, BCM has implemented a new procure to pay system with improved internal controls and approval routings. With this new

system, we believe we have already put in place the appropriate corrective actions necessary to prevent this from happening going forward.

Person Responsible: Rob Falivene, Vice President, Supply Chain Services, Baylor College of

Medicine

Expected Completion: March 2025

2024-003 Indirect Costs

ALN: Research and Development Cluster (R&D), 21.027

Finding: The College did not retain documentation and evidence of review of the indirect cost amounts being charged to the R&D and CSLFRF programs. Management performed a monthly control that included reviewing a sample of indirect costs charged to grants on a sample basis. The College had a new ERP implementation that went into effect on January 1, 2024. Management did not perform the monthly control subsequent to the ERP implementation for the last 6 months of year.

Corrective Action Plan: With the implementation of the new ERP system, BCM went from an on-premises solution to a software-as-a-service solution. Since we no longer have access to modify the code that calculates the F&A expense on awards, management concluded that previous random testing control was no longer necessary. Management also believes that there are numerous compensating reporting controls that would alert us if the F&A calculations were not accurate. Notably, management's compensating controls and the testing the audit firm conducted identified no instances where the F&A calculations were inaccurate. However, to satisfy this audit finding we will be resuming the manual control procedure used with the legacy system.

Person Responsible: Chryll Batiste, Director, Research Administration, Baylor College of Medicine

Expected Completion: April 2025

Finding 2024-004 Reporting

ALN: 21.027

Finding: The College did not submit monthly reports for the CSLFRF or TCMHCC grants by the 15th of each month.

Corrective Action Plan: BCM agrees that these reports were not submitted by the 15th deadline. Going forward, BCM will require the department to attest that the programmatic reports were submitted when the monthly financial reports are submitted on the TCMHCC grant.

Person Responsible: Chryll Batiste, Director, Research Administration, Baylor College of Medicine

Expected Completion: April 2025

Finding 2024-005 Student Financial Assistance Cluster

ALN: 84.268

Finding: The College did not submit the required monthly reconciliation for the direct loan program

Corrective Action Plan: To address the issue of not submitting the required monthly reconciliation for the Direct Loan Program, the Financial Aid office has implemented a process to ensure Direct Loan reconciliation is completed monthly. An outlook calendar reminder entry will serve as a reminder to begin the reconciliation process on the 15th of each month. The Senior Financial Aid Counselor requests a YTD SAS report from COD, which contains loan data from the central processor, the report is delivered to our electronic mailbox within 24 hours. The Senior Financial Aid Counselor runs a second report from the SIS System to generate YTD loan disbursement information. The files are reformatted and compared by the Senior Financial Aid Counselor. Any discrepancies are reviewed and resolved in the appropriate system (COD or SIS), dependent on the discrepancy. The Senior Counselor notifies the Senior Manager of Financial Aid that the comparison and updates are complete. The Senior Manager of Financial Aid then reviews delta from the compared data and verifies that corrections are made in the correct system. The Senior Manager ensures that resolved amount is within the COD delta found on the summary page in COD and a screenshot is maintained in the reconciliation file. Senior Manager marks "Sr Manager Reviewed" column on the loan reconciliation spreadsheet with a date of review as evidence. The completed reconciliation is maintained in the Financial Aid Shared Directory.

Person Responsible: Scott Moore, Senior Manager, Financial Aid, Baylor College of Medicine

Expected Completion: April 2024

EY | Building a better working world

EY is building a better working world by creating new value for clients, people, society and the planet, while building trust in capital markets.

Enabled by data, AI and advanced technology, EY teams help clients shape the future with confidence and develop answers for the most pressing issues of today and tomorrow.

EY teams work across a full spectrum of services in assurance, consulting, tax, strategy and transactions. Fueled by sector insights, a globally connected, multidisciplinary network and diverse ecosystem partners, EY teams can provide services in more than 150 countries and territories.

All in to shape the future with confidence.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

© 2025 Ernst & Young LLP. All Rights Reserved.

ey.com